<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.opportunitymonitor.v1.DrugRecordOutput xmlns:ns2="local" id="6850"><DrugName>infliximab</DrugName><DrugNamesKey><Name id="42758126">Avakine</Name><Name id="42986951">Remicade</Name><Name id="42758127">infliximab</Name></DrugNamesKey><DrugSynonyms><Name><Value>Avakine</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>infliximab</Value><Types><Type>INN</Type></Types></Name><Name><Value>Remicad</Value></Name><Name><Value>CenTNF</Value></Name><Name><Value>TA-650</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>cA2 antibody</Value></Name><Name><Value>anti-TNF-alpha MAb, Tanabe</Value></Name><Name><Value>anti-TNF-alpha MAb, Centocor</Value></Name><Name><Value>SCH-215596</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>Remicade</Value><Types><Type>Trade Name</Type></Types></Name></DrugSynonyms><CompanyOriginator id="1112040">Centocor Ortho Biotech Services</CompanyOriginator><CompaniesPrimary><Company id="26997">Janssen Biotech Inc</Company><Company id="18077">Merck &amp; Co Inc</Company><Company id="1035060">Mitsubishi Tanabe Pharma Corp</Company><Company id="1062953">Janssen Biologics BV</Company><Company id="17332">Johnson &amp; Johnson</Company><Company id="17608">Xian-Janssen Pharmaceutical Ltd</Company><Company id="19711">Schering-Plough Corp</Company></CompaniesPrimary><CompaniesSecondary><Company id="20315">Tanabe Seiyaku Co Ltd</Company></CompaniesSecondary><CrossReferences><SourceEntity id="6850" type="Drug"><TargetEntity id="198460" type="siDrug">Infliximab</TargetEntity></SourceEntity><SourceEntity id="1035060" type="Company"><TargetEntity id="4295878022" type="organizationId">Mitsubishi Tanabe Pharma Corp</TargetEntity></SourceEntity><SourceEntity id="1062953" type="Company"><TargetEntity id="4298326925" type="organizationId">Janssen Biologics BV</TargetEntity></SourceEntity><SourceEntity id="1112040" type="Company"><TargetEntity id="5000136206" type="organizationId">Centocor Ortho Biotech Services LLC</TargetEntity></SourceEntity><SourceEntity id="17332" type="Company"><TargetEntity id="4295904341" type="organizationId">Johnson &amp; Johnson</TargetEntity></SourceEntity><SourceEntity id="17608" type="Company"><TargetEntity id="5000173488" type="organizationId">Xian-Janssen Pharmaceutical Ltd</TargetEntity></SourceEntity><SourceEntity id="18077" type="Company"><TargetEntity id="4295904886" type="organizationId">Merck &amp; Co Inc</TargetEntity></SourceEntity><SourceEntity id="20315" type="Company"><TargetEntity id="4298123051" type="organizationId">Nipro ES Pharma Co Ltd</TargetEntity></SourceEntity><SourceEntity id="26997" type="Company"><TargetEntity id="4295909367" type="organizationId">Janssen Biotech Inc</TargetEntity></SourceEntity><SourceEntity id="1036" type="ciIndication"><TargetEntity id="D86" type="ICD10"></TargetEntity><TargetEntity id="135" type="ICD9"></TargetEntity><TargetEntity id="10039486" type="MEDDRA"></TargetEntity><TargetEntity id="D012507" type="MeSH"></TargetEntity><TargetEntity id="797" type="ORPHANET"></TargetEntity><TargetEntity id="-554430548" type="omicsDisease"></TargetEntity><TargetEntity id="1232" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1185" type="ciIndication"><TargetEntity id="10009033" type="MEDDRA"></TargetEntity><TargetEntity id="D029424" type="MeSH"></TargetEntity><TargetEntity id="-459670493" type="omicsDisease"></TargetEntity><TargetEntity id="277" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="153" type="ciIndication"><TargetEntity id="10019744" type="MEDDRA"></TargetEntity><TargetEntity id="D019698" type="MeSH"></TargetEntity><TargetEntity id="-776640207" type="omicsDisease"></TargetEntity><TargetEntity id="430" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1781" type="ciIndication"><TargetEntity id="10037162" type="MEDDRA"></TargetEntity><TargetEntity id="D015535" type="MeSH"></TargetEntity><TargetEntity id="-689721545" type="omicsDisease"></TargetEntity><TargetEntity id="724" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1828" type="ciIndication"><TargetEntity id="C90.0" type="ICD10"></TargetEntity><TargetEntity id="10028228" type="MEDDRA"></TargetEntity><TargetEntity id="D009101" type="MeSH"></TargetEntity><TargetEntity id="29073" type="ORPHANET"></TargetEntity><TargetEntity id="-18870694" type="omicsDisease"></TargetEntity><TargetEntity id="710" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="245" type="ciIndication"><TargetEntity id="10031161" type="MEDDRA"></TargetEntity><TargetEntity id="D010003" type="MeSH"></TargetEntity><TargetEntity id="-478836143" type="omicsDisease"></TargetEntity><TargetEntity id="747" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="281" type="ciIndication"><TargetEntity id="L40" type="ICD10"></TargetEntity><TargetEntity id="10037153" type="MEDDRA"></TargetEntity><TargetEntity id="D011565" type="MeSH"></TargetEntity><TargetEntity id="-1735788310" type="omicsDisease"></TargetEntity><TargetEntity id="490" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2887" type="ciIndication"><TargetEntity id="M35.3" type="ICD10"></TargetEntity><TargetEntity id="10036099" type="MEDDRA"></TargetEntity><TargetEntity id="D011111" type="MeSH"></TargetEntity><TargetEntity id="-120965901" type="omicsDisease"></TargetEntity><TargetEntity id="3634" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="291" type="ciIndication"><TargetEntity id="10039073" type="MEDDRA"></TargetEntity><TargetEntity id="D001172" type="MeSH"></TargetEntity><TargetEntity id="-1391695545" type="omicsDisease"></TargetEntity><TargetEntity id="749" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="31" type="ciIndication"><TargetEntity id="J45" type="ICD10"></TargetEntity><TargetEntity id="493" type="ICD9"></TargetEntity><TargetEntity id="10003553" type="MEDDRA"></TargetEntity><TargetEntity id="D001249" type="MeSH"></TargetEntity><TargetEntity id="-1473716268" type="omicsDisease"></TargetEntity><TargetEntity id="270" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="337" type="ciIndication"><TargetEntity id="K51" type="ICD10"></TargetEntity><TargetEntity id="10009900" type="MEDDRA"></TargetEntity><TargetEntity id="D003093" type="MeSH"></TargetEntity><TargetEntity id="-1993209976" type="omicsDisease"></TargetEntity><TargetEntity id="396" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="398" type="ciIndication"><TargetEntity id="M45" type="ICD10"></TargetEntity><TargetEntity id="720.0" type="ICD9"></TargetEntity><TargetEntity id="10002556" type="MEDDRA"></TargetEntity><TargetEntity id="D013167" type="MeSH"></TargetEntity><TargetEntity id="-605402220" type="omicsDisease"></TargetEntity><TargetEntity id="752" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="425" type="ciIndication"><TargetEntity id="R64" type="ICD10"></TargetEntity><TargetEntity id="10006895" type="MEDDRA"></TargetEntity><TargetEntity id="D002100" type="MeSH"></TargetEntity><TargetEntity id="-1500634021" type="omicsDisease"></TargetEntity><TargetEntity id="1127" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="55" type="ciIndication"><TargetEntity id="I50" type="ICD10"></TargetEntity><TargetEntity id="10007554" type="MEDDRA"></TargetEntity><TargetEntity id="D006333" type="MeSH"></TargetEntity><TargetEntity id="-1323949873" type="omicsDisease"></TargetEntity><TargetEntity id="237" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="616" type="ciIndication"><TargetEntity id="D89.81" type="ICD10"></TargetEntity><TargetEntity id="10018651" type="MEDDRA"></TargetEntity><TargetEntity id="D006086" type="MeSH"></TargetEntity><TargetEntity id="39812" type="ORPHANET"></TargetEntity><TargetEntity id="-1437372564" type="omicsDisease"></TargetEntity><TargetEntity id="1129" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="651" type="ciIndication"><TargetEntity id="576" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="768" type="ciIndication"><TargetEntity id="M35.2" type="ICD10"></TargetEntity><TargetEntity id="136.1" type="ICD9"></TargetEntity><TargetEntity id="10004213" type="MEDDRA"></TargetEntity><TargetEntity id="D001528" type="MeSH"></TargetEntity><TargetEntity id="117" type="ORPHANET"></TargetEntity><TargetEntity id="-1672179307" type="omicsDisease"></TargetEntity><TargetEntity id="730" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="780" type="ciIndication"><TargetEntity id="M30.3" type="ICD10"></TargetEntity><TargetEntity id="10023320" type="MEDDRA"></TargetEntity><TargetEntity id="D009080" type="MeSH"></TargetEntity><TargetEntity id="2331" type="ORPHANET"></TargetEntity><TargetEntity id="-1954143291" type="omicsDisease"></TargetEntity><TargetEntity id="1571" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="84" type="ciIndication"><TargetEntity id="K50" type="ICD10"></TargetEntity><TargetEntity id="10011401" type="MEDDRA"></TargetEntity><TargetEntity id="D003424" type="MeSH"></TargetEntity><TargetEntity id="-248155260" type="omicsDisease"></TargetEntity><TargetEntity id="395" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="991" type="Action"><TargetEntity id="5287" type="Mechanism">Drugs Targeting Influenza Virus Proteins</TargetEntity><TargetEntity id="3482" type="Mechanism">UL37 Expression Inhibitors</TargetEntity><TargetEntity id="2893" type="Mechanism">Human T-Cell Leukemia Virus Type I (HTLV-I) Protease Inhibitors</TargetEntity><TargetEntity id="4128" type="Mechanism">Flavivirus Guanylyl Transferase (NS5) Inhibitors</TargetEntity><TargetEntity id="4476" type="Mechanism">Anti-JC Polyomavirus Capsid Protein</TargetEntity><TargetEntity id="4612" type="Mechanism">Drugs Targeting Human Immunodeficiency Virus 1 (HIV-1) Proteins</TargetEntity><TargetEntity id="2436" type="Mechanism">Viral Maturation Inhibitors</TargetEntity><TargetEntity id="4886" type="Mechanism">Drugs Targeting Hepatitis C Virus (HCV) Proteins</TargetEntity><TargetEntity id="3371" type="Mechanism">Drugs Acting on Influenza Virus Proton Channels</TargetEntity><TargetEntity id="3575" type="Mechanism">Orthopoxvirus Egress Inhibitors</TargetEntity><TargetEntity id="3051" type="Mechanism">Viral Attachment Inhibitors</TargetEntity><TargetEntity id="3759" type="Mechanism">L Expression Inhibitors</TargetEntity><TargetEntity id="3235" type="Mechanism">UL29 Expression Inhibitors</TargetEntity><TargetEntity id="5304" type="Mechanism">Drugs Targeting Rabies Virus Proteins</TargetEntity><TargetEntity id="4479" type="Mechanism">Drugs Targeting JC Polyomavirus Proteins</TargetEntity><TargetEntity id="1307" type="Mechanism">Viral Fusion Inhibitors</TargetEntity><TargetEntity id="3481" type="Mechanism">UL36 Expression Inhibitors</TargetEntity><TargetEntity id="1376" type="Mechanism">BR1 Expression Inhibitors</TargetEntity></SourceEntity><SourceEntity id="2953" type="Action"><TargetEntity id="802" type="Mechanism">Mediator Release Inhibitors</TargetEntity><TargetEntity id="775" type="Mechanism">Antiinflammatory Drugs</TargetEntity></SourceEntity><SourceEntity id="381" type="Action"><TargetEntity id="663" type="Mechanism">TNF-alpha Antagonists</TargetEntity><TargetEntity id="1551" type="Mechanism">Anti-TNF-alpha</TargetEntity></SourceEntity><SourceEntity id="PTGT-07179" type="ciTarget"><TargetEntity id="202005724971243" type="siTarget">Tumor necrosis factor</TargetEntity><TargetEntity id="4487" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="L">Launched</PhaseHighest><PhaseHighestDetailed><FirstLaunched>Crohns disease - US - Oct-1998</FirstLaunched></PhaseHighestDetailed><RegulatoryDesignations><RegulatoryDesignation id="5">Accelerated Approval</RegulatoryDesignation><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication id="1781">Psoriatic arthritis</Indication><Indication id="281">Psoriasis</Indication><Indication id="291">Rheumatoid arthritis</Indication><Indication id="337">Ulcerative colitis</Indication><Indication id="398">Ankylosing spondylitis</Indication><Indication id="768">Behcets disease</Indication><Indication id="780">Kawasaki disease</Indication><Indication id="84">Crohns disease</Indication></IndicationsPrimary><IndicationsSecondary><Indication id="1036">Sarcoidosis</Indication><Indication id="1185">Chronic obstructive pulmonary disease</Indication><Indication id="153">Hepatitis C virus infection</Indication><Indication id="1828">Multiple myeloma</Indication><Indication id="245">Osteoarthritis</Indication><Indication id="2887">Polymyalgia rheumatica</Indication><Indication id="31">Asthma</Indication><Indication id="425">Cachexia</Indication><Indication id="55">Cardiac failure</Indication><Indication id="616">Graft versus host disease</Indication><Indication id="651">Cancer</Indication></IndicationsSecondary><ActionsPrimary><Action id="721">TNF binding agent</Action><Action id="381">TNF alpha ligand inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="15184">Systemic antipsoriatic product</Action><Action id="2946">Analgesic</Action><Action id="2953">Anti-inflammatory</Action><Action id="55685">Anticancer monoclonal antibody</Action><Action id="991">Antiviral</Action></ActionsSecondary><Technologies><Technology id="128">Cell culture technique</Technology><Technology id="166">Chimeric monoclonal antibody</Technology><Technology id="573">Immunoglobulin-G</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="898">Formulation powder</Technology><Technology id="740">Infusion</Technology><Technology id="750">Freeze drying</Technology><Technology id="761">Biological therapeutic</Technology><Technology id="652">Intra-articular formulation</Technology></Technologies><EphmraCodes><Ephmra><Code>D5B</Code><Name>SYSTEMIC ANTIPSORIASIS PRODUCTS</Name></Ephmra><Ephmra><Code>N2</Code><Name>ANALGESICS</Name></Ephmra><Ephmra><Code>J5</Code><Name>ANTIVIRALS FOR SYSTEMIC USE</Name></Ephmra></EphmraCodes><LastModificationDate>2019-07-02T13:00:46.000Z</LastModificationDate><ChangeDateLast>2019-07-03T00:00:00.000Z</ChangeDateLast><AddedDate>1996-02-16T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="26997" linkType="Company"&gt;Janssen Biotech&lt;/ulink&gt; (formerly known as Centocor Ortho Biotech and a subsidiary of &lt;ulink linkID="17332" linkType="Company"&gt;Johnson &amp;amp; Johnson&lt;/ulink&gt;; J&amp;amp;J), &lt;ulink linkID="19711" linkType="Company"&gt;Schering-Plough&lt;/ulink&gt; (now &lt;ulink linkID="18077" linkType="Company"&gt;Merck &amp;amp; Co&lt;/ulink&gt;) and &lt;ulink linkID="20315" linkType="Company"&gt;Tanabe Seiyaku&lt;/ulink&gt; (now &lt;ulink linkID="1035060" linkType="Company"&gt;Mitsubishi Tanabe Pharma&lt;/ulink&gt;) have developed and launched  infliximab (Remicade; TA-650; cA2; CenTNF; SCH-215596), a chimeric human-murine IgG1 anti-TNF alpha monoclonal antibody [&lt;ulink linkID="1199858" linkType="Reference"&gt;1199858&lt;/ulink&gt;]. The drug is indicated for  reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in patients with moderately-to-severely active rheumatoid arthritis (RA) when used in combination with methotrexate (MTX). It is also indicated for reducing signs and symptoms, and inducing and maintaining clinical remission in patients with  moderately-to-severely active Crohn's disease (CD) who have had an inadequate response to conventional therapy, and for reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in  patients with fistulizing CD. It is further indicated for reducing signs and symptoms in patients with active ankylosing spondylitis (AS), reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage, and improving physical function in patients with psoriatic arthritis (PsA), for the treatment of adults with chronic severe plaque psoriasis who are candidates for systemic therapy and when other systemic therapies are medically less appropriate, and for reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in patients (including pediatrics) with moderately-to-severely active ulcerative colitis (UC) who have had an inadequate response to conventional therapy [&lt;ulink linkID="585004" linkType="Reference"&gt;585004&lt;/ulink&gt;], [&lt;ulink linkID="999807" linkType="Reference"&gt;999807&lt;/ulink&gt;], [&lt;ulink linkID="1003057" linkType="Reference"&gt;1003057&lt;/ulink&gt;], [&lt;ulink linkID="1225326" linkType="Reference"&gt;1225326&lt;/ulink&gt;]. In Japan, the drug is also indicated for the treatment of patients with Behcet's disease with refractory uveoretinitis, entero-Behcet's disease, neuro-Behcet's disease and vasculo-Behcet's disease, following unsuccessful treatment with conventional therapies; and for the treatment of acute stage Kawasaki disease [&lt;ulink linkID="1688784" linkType="Reference"&gt;1688784&lt;/ulink&gt;], [&lt;ulink linkID="1722916" linkType="Reference"&gt;1722916&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The drug was first launched in the US in October 1998 for non-responsive, moderately-to-severely active CD [&lt;ulink linkID="301111" linkType="Reference"&gt;301111&lt;/ulink&gt;]. In August 1999, the drug was approved in Denmark and subsequently launched [&lt;ulink linkID="1427364" linkType="Reference"&gt;1427364&lt;/ulink&gt;]. In January 2000, the drug was launched  by &lt;ulink linkID="17332" linkType="Company"&gt;Janssen Biologics&lt;/ulink&gt; in France [&lt;ulink linkID="1351880" linkType="Reference"&gt;1351880&lt;/ulink&gt;]; launch had occurred in other EU countries by  2000 [&lt;ulink linkID="376121" linkType="Reference"&gt;376121&lt;/ulink&gt;]. The FDA expanded the approved CD indications in 2002, and again in April 2004, in relation to fistulizing CD [&lt;ulink linkID="584595" linkType="Reference"&gt;584595&lt;/ulink&gt;]. EU approval for expanded use in maintenance dosing in patients with severe, active CD and fistulizing CD was granted in May and October 2003, respectively [&lt;ulink linkID="516210" linkType="Reference"&gt;516210&lt;/ulink&gt;]. Japanese launch for CD took place in May 2002 [&lt;ulink linkID="485413" linkType="Reference"&gt;485413&lt;/ulink&gt;]; in November 2007, infliximab was granted Japanese approval for the additional indication of CD maintenance therapy  [&lt;ulink linkID="855285" linkType="Reference"&gt;855285&lt;/ulink&gt;].  In March 2011, the EMA's CHMP recommended extension of the CD indication in the EU to include patients with moderately to severely active CD [&lt;ulink linkID="1177608" linkType="Reference"&gt;1177608&lt;/ulink&gt;].  In May 2013, filings for post-operative CD were expected between 2013 and 2017 [&lt;ulink linkID="1440862" linkType="Reference"&gt;1440862&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;Infliximab was launched for RA in Europe by July 2000 [&lt;ulink linkID="376121" linkType="Reference"&gt;376121&lt;/ulink&gt;]; in the US by August 2003 [&lt;ulink linkID="500103" linkType="Reference"&gt;500103&lt;/ulink&gt;]; and in Japan  in July 2003 [&lt;ulink linkID="500704" linkType="Reference"&gt;500704&lt;/ulink&gt;]. Japanese approval for RA  including prevention of structural joint damage was granted in July 2009 [&lt;ulink linkID="1024161" linkType="Reference"&gt;1024161&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The drug was approved in the US for active AS in December 2004 [&lt;ulink linkID="577869" linkType="Reference"&gt;577869&lt;/ulink&gt;]. By July 2004, infliximab had been launched in the EU for AS [&lt;ulink linkID="550199" linkType="Reference"&gt;550199&lt;/ulink&gt;].  In April 2010, Japanese approval was granted for AS [&lt;ulink linkID="1163897" linkType="Reference"&gt;1163897&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2004, infliximab received EC approval for active and progressive PsA [&lt;ulink linkID="564519" linkType="Reference"&gt;564519&lt;/ulink&gt;]. By October 2005, the drug had been launched for PsA in the US [&lt;ulink linkID="629282" linkType="Reference"&gt;629282&lt;/ulink&gt;]. In October 2005, infliximab was approved for moderate-to-severe plaque psoriasis in the EU and launched in the UK in December 2005 [&lt;ulink linkID="627104" linkType="Reference"&gt;627104&lt;/ulink&gt;], [&lt;ulink linkID="642831" linkType="Reference"&gt;642831&lt;/ulink&gt;]. In September 2006, the FDA approved infliximab for the treatment of chronic severe plaque psoriasis [&lt;ulink linkID="694230" linkType="Reference"&gt;694230&lt;/ulink&gt;].     Japanese approval was granted for psoriasis, including PsA, in January 2010 [&lt;ulink linkID="1069817" linkType="Reference"&gt;1069817&lt;/ulink&gt;]; in May 2016, the use of an increased dosage and shorter dosing intervals of iv infliximab  infusion 100 in patients with psoriasis was approved in Japan [&lt;ulink linkID="1770455" linkType="Reference"&gt;1770455&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By January 2006, infliximab had been launched for UC in the US [&lt;ulink linkID="647339" linkType="Reference"&gt;647339&lt;/ulink&gt;]; the EC granted approval for the treatment of moderate-to-severe active UC in March 2006 [&lt;ulink linkID="654634" linkType="Reference"&gt;654634&lt;/ulink&gt;]. Mitsubishi Tanabe  was granted approval for UC in Japan  in June 2010  [&lt;ulink linkID="1121601" linkType="Reference"&gt;1121601&lt;/ulink&gt;], [&lt;ulink linkID="1119862" linkType="Reference"&gt;1119862&lt;/ulink&gt;]. In December 2010, Centocor Ortho Biotech filed for US  and EU approval for the use of infliximab in pediatric patients with UC [&lt;ulink linkID="1158054" linkType="Reference"&gt;1158054&lt;/ulink&gt;], [&lt;ulink linkID="1163855" linkType="Reference"&gt;1163855&lt;/ulink&gt;]. In September 2011, the FDA additionally approved infliximab for the treatment of moderately to severely active UC in pediatric patients (older than 6 years old) who have had an inadequate response to conventional therapy [&lt;ulink linkID="1225326" linkType="Reference"&gt;1225326&lt;/ulink&gt;], [&lt;ulink linkID="1225323" linkType="Reference"&gt;1225323&lt;/ulink&gt;]. In February 2012, the EMA approved infliximab for UC in pediatric patients aged 6 to 17 years [&lt;ulink linkID="1281407" linkType="Reference"&gt;1281407&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;Mitsubishi Tanabe has also developed and launched infliximab for Behcet's disease with refractory uveoretinitis in Japan by August 2009 [&lt;ulink linkID="1047222" linkType="Reference"&gt;1047222&lt;/ulink&gt;]; in August 2015, the drug was additionally approved for entero-Behcet's disease, neuro-Behcet's disease and vasculo-Behcet's disease in Japan [&lt;ulink linkID="1688784" linkType="Reference"&gt;1688784&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2015, infliximab was approved in Japan for the treatment of acute stage Kawasaki disease [&lt;ulink linkID="1722916" linkType="Reference"&gt;1722916&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Infliximab was previously  being developed for a number of  other indications.  In August 2000, a phase II trial  for congestive heart failure (CHF) began [&lt;ulink linkID="2051301" linkType="Reference"&gt;2051301&lt;/ulink&gt;]; however, in October 2001, following evaluation of preliminary results from this phase II trial, development of infliximab for the treatment of CHF was put on hold [&lt;ulink linkID="428095" linkType="Reference"&gt;428095&lt;/ulink&gt;]; no further development was report. By September 2004, infliximab was being investigated for the potential treatment of cancer [&lt;ulink linkID="564755" linkType="Reference"&gt;564755&lt;/ulink&gt;]; however, no development has been reported since December 2007 [&lt;ulink linkID="857767" linkType="Reference"&gt;857767&lt;/ulink&gt;]. In July 2005, a phase III trial began in patients with hepatitis C virus (HCV) infection [&lt;ulink linkID="1163901" linkType="Reference"&gt;1163901&lt;/ulink&gt;]; however, no development has been reported since November 2012, when negative clinical data from the phase III trial were presented  [&lt;ulink linkID="1340422" linkType="Reference"&gt;1340422&lt;/ulink&gt;]. In August 2005, Tanabe was in protocol discussions with the Japanese regulatory body to expand the range of indications to include sarcoidosis, giant cell arteritis and cachexia [&lt;ulink linkID="619481" linkType="Reference"&gt;619481&lt;/ulink&gt;]; however, no development has since been reported. In April 2006, data from a phase II dose-finding study to assess the safety and efficacy of infliximab with moderate-to-severe COPD were presented, which showed that no treatment benefit was observed with infliximab treatment [&lt;ulink linkID="665081" linkType="Reference"&gt;665081&lt;/ulink&gt;]; no development has since been reported for this indication and development is assumed to be discontinued. In June 2007, a   phase III trial  was 	initiated in patients   with refractory polymyalgia rheumatica; in August 2011, the trial was ongoing  [&lt;ulink linkID="1458337" linkType="Reference"&gt;1458337&lt;/ulink&gt;]; however; no further development was reported. In the US, a phase I trial was completed in October 2006 for KD; however, no development has been reported [&lt;ulink linkID="1163663" linkType="Reference"&gt;1163663&lt;/ulink&gt;]. In February 2015, infliximab was in phase III development for pediatric CD in Japan [&lt;ulink linkID="1630728" linkType="Reference"&gt;1630728&lt;/ulink&gt;]; however, in November 2016, the indication of pediatric CD was listed as 'deleted' on the company pipeline [&lt;ulink linkID="1868643" linkType="Reference"&gt;1868643&lt;/ulink&gt;].  A phase IV trial investigating infliximab for the intra-articular treatment of osteoarthritis began in July 2007 and was completed in January 2011 [&lt;ulink linkID="1163688" linkType="Reference"&gt;1163688&lt;/ulink&gt;];  results were reported in June 2012  [&lt;ulink linkID="1163688" linkType="Reference"&gt;&lt;/ulink&gt;&lt;ulink linkID="1299787" linkType="Reference"&gt;1299787&lt;/ulink&gt;]; however, since that time, no development has been reported. In May  2016, infliximab was listed as in phase III development for pediatric UC in Japan [&lt;ulink linkID="1630728" linkType="Reference"&gt;1630728&lt;/ulink&gt;]; however, in November 2016, the indication of pediatric UC was listed as 'deleted' on the company pipeline [&lt;ulink linkID="1868643" linkType="Reference"&gt;1868643&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><PatentsAndGenerics><displayLabel>Patents and Generics</displayLabel><value>&lt;PatentsAndGenerics&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;In June 2011, it was reported that US patent coverage was due to expire in 2018 [&lt;ulink linkID="1270018" linkType="Reference"&gt;1270018&lt;/ulink&gt;]. In February 2014,   it  was stated  that the patents granted to the Kennedy Institute of Rheumatology in the US were reported to expire in 2018 in the US; Janssen Biotech had an exclusive license to these patents. By February 2014, J&amp;amp;J expected no further extensions for these patents [&lt;ulink linkID="1528425" linkType="Reference"&gt;1528425&lt;/ulink&gt;]. In September 2013, Janssen Biotech and &lt;ulink linkID="20646" linkType="Company"&gt;New York University&lt;/ulink&gt; (NYU), co-owners of &lt;ulink linkID="PA3118187" linkType="Patent"&gt;US-06284471&lt;/ulink&gt;, received an Office Action from the US Patent and Trademark Office (USPTO) rejecting the claims in the '471 patent as part of a re-examination instituted by a third party. In December 2013, Janssen responded to that rejection and in August 2014, the patent was further rejected; Janssen responded by filing a further amendment  which was granted in November 2014 [&lt;ulink linkID="1642124" linkType="Reference"&gt;1642124&lt;/ulink&gt;]; in February 2015, the PTO took further action against the re-examination of the '471 patent set to expire in September 2018, and issued a final rejection of the patent.  At that time, J&amp;amp;J had 60 days to respond to the action. The company stated that it believed the patent to be valid and planned to  appeal [&lt;ulink linkID="1633688" linkType="Reference"&gt;1633688&lt;/ulink&gt;]. Later that month, J&amp;amp;J stated that certain challenged claims from the set of patents granted to the   Kennedy Institute of Rheumatology were invalidated and others were under review in several countries [&lt;ulink linkID="1642124" linkType="Reference"&gt;1642124&lt;/ulink&gt;]; that was still the case in February 2016. In March 2015, Janssen filed a motion to stay all proceedings  in the District Court with respect to the ‘471 patent, pending the USPTO re-examination proceeding [&lt;ulink linkID="1738240" linkType="Reference"&gt;1738240&lt;/ulink&gt;]. In April 2015, the USPTO maintained its rejection of the '471 patent for infliximab following a re-examination of the patent. At that time, the company planned to file an appeal to USPTO's Patent Trial and Appeal Board before June 12, 2015 [&lt;ulink linkID="1655543" linkType="Reference"&gt;1655543&lt;/ulink&gt;]; in May 2015, the company filed a notice of appeal to the USPTO's Patent Trial and Appeal Board; in February 2016, the appeal was still pending. At that time, J&amp;amp;J stated that the '471 patent remained valid and enforceable while it was subject to ongoing re-examination proceedings instituted by the third party in the USPTO [&lt;ulink linkID="1738240" linkType="Reference"&gt;1738240&lt;/ulink&gt;]. In November 2016, the Patent Trial and Appeal Board issued a decision upholding the examiner's rejection. By February 2017, Janssen had  filed an appeal to the US Court of Appeals for the Federal Circuit. At that time, the appeals regarding the decisions by the USPTO and the Federal District Court on the '471 patent were still pending [&lt;ulink linkID="1903902" linkType="Reference"&gt;1903902&lt;/ulink&gt;]. In January 2018, the US Court of Appeals for the Federal Circuit affirmed the Board's decision. In February 2018, J&amp;amp;J noted that the  set of patents  granted to The Kennedy Institute of Rheumatology in the US are to expire in August 2018  [&lt;ulink linkID="2008068" linkType="Reference"&gt;2008068&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In April 2017, the US FDA accepted for review a BLA for &lt;ulink linkID="18767" linkType="Company"&gt;Pfizer&lt;/ulink&gt;'s infliximab biosimilar, &lt;ulink linkID="85115" linkType="Drug"&gt;IXIFI&lt;/ulink&gt;; in December 2017, the FDA approved the biosimilar [&lt;ulink linkID="1991464" linkType="Reference"&gt;1991464&lt;/ulink&gt;]. In February 2018, Pfizer stated it was not planning to launch   IXIFI in the US [&lt;ulink linkID="2001350" linkType="Reference"&gt;2001350&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2016, the US FDA accepted &lt;ulink linkID="1071703" linkType="Company"&gt;Samsung Bioepis&lt;/ulink&gt;'   (joint venture of &lt;ulink linkID="28039" linkType="Company"&gt;Samsung&lt;/ulink&gt; and &lt;ulink linkID="1005244" linkType="Company"&gt;Biogen&lt;/ulink&gt;; previously Biogen Idec) BLA for its infliximab biosimilar, &lt;ulink linkID="87510" linkType="Drug"&gt;infliximab-abda&lt;/ulink&gt; (Renflexis), for review [&lt;ulink linkID="1765125" linkType="Reference"&gt;1765125&lt;/ulink&gt;]. In April 2017, the  FDA granted marketing approval in the US for the treatment of adult and pediatric crohn’s disease, adult ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and adult plaque psoriasis. At that time,   the company revealed that  marketing and  distribution would be done by  Merck in the  US [&lt;ulink linkID="1919916" linkType="Reference"&gt;1919916&lt;/ulink&gt;]. In May 2017, Janssen filed a US lawsuit against Samsung Bioepis alleging patent infringement of three patents covering the manufacturing process of infliximab, and seeking a preliminary or permanent injunction to block the sale of  Samsung Bioepis' biosimilar of infliximab  [&lt;ulink linkID="1929138" linkType="Reference"&gt;1929138&lt;/ulink&gt;]. In July 2017, the drug was launched in the US (commercialized by Merck) [&lt;ulink linkID="1947538" linkType="Reference"&gt;1947538&lt;/ulink&gt;], [&lt;ulink linkID="2008068" linkType="Reference"&gt;2008068&lt;/ulink&gt;]. In November 2017, Janssen voluntarily dismissed its suit against Samsung Bioepis filed to prevent the company from selling its biosimilar [&lt;ulink linkID="1981735" linkType="Reference"&gt;1981735&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2014, &lt;ulink linkID="1105372" linkType="Company"&gt;Celltrion&lt;/ulink&gt; filed for US approval of its &lt;ulink linkID="78759" linkType="Drug"&gt;infliximab biosimilar, Remsima&lt;/ulink&gt; [&lt;ulink linkID="1584918" linkType="Reference"&gt;1584918&lt;/ulink&gt;]. By March 2015, &lt;ulink linkID="1010293" linkType="Company"&gt;Hospira&lt;/ulink&gt; had also filed for US approval for its &lt;ulink linkID="78759" linkType="Drug"&gt;infliximab biosimilar,  Inflectra&lt;/ulink&gt;. At that time, a lawsuit was filed in a US District Court against Celltrion and Hospira seeking a declaratory judgment that their biosimilar products, for which both companies sought FDA approval under the new Biologics Price Competition and Innovation Act (BPCIA),  infringed or potentially infringed six  patents from Janssen Biotech. Additionally, Janssen also sought a declaratory judgment that Celltrion and Hospira had failed to comply with certain procedural requirements of the BPCIA; and it also filed motion for a preliminary and permanent injunction to prohibit both Celltrion and Hospira from launching the biosimilar products until 180 days after a Notice Commercial Marketing would have been given to Janssen, and such notice not to be given before FDA approval of Celltrion's product. In August 2015, Janssen also filed a motion seeking the District Court's   permission to file a patent infringement lawsuit asserting the &lt;ulink linkID="PA3194845" linkType="Patent"&gt;US-07598083&lt;/ulink&gt; patent against Celltrion and the manufacturer of the cell culture media that Celltrion used to make its biosimilar product. By February 2016, the '083 patent had been already asserted in the ongoing lawsuit; at that time, Celltrion and Hospira agreed not to launch their biosimilar product before June 30, 2016, and the '471 and '083 patents would be the two remaining patents in the lawsuit; consequently, the Court denied Janssen's motion for preliminary injunction, but it noted that Janssen might renew its motion following the Court of Appeals decision, if necessary, or if the Court of Appeals failed to decide the  issue by June 29, 2016. Additionally, at that time, Celltrion and Hospira filed a motion for summary judgment of invalidity of the '471 patent; and a positive opinion from the FDA's Arthritis Advisory Committee was issued recommending by a vote of 21-3 to approve Celltrion's investigational biosimilar version of infliximab across all eligible indications in the US. At that time, J&amp;amp;J noted that a biosimilar could be launched by a competitor subject to enforcement of patent rights and  FDA approval (subject to compliance with the 180-day notice provisions of the BPCIA) even though one or more valid patents were in place [&lt;ulink linkID="1738240" linkType="Reference"&gt;1738240&lt;/ulink&gt;]. In April 2016, the FDA approved Celltrion's biosimilar infliximab, as Inflectra, for RA, adult UC, plaque psoriasis, PsA, AS and adult and pediatric CD [&lt;ulink linkID="1733768" linkType="Reference"&gt;1733768&lt;/ulink&gt;], [&lt;ulink linkID="1749069" linkType="Reference"&gt;1749069&lt;/ulink&gt;]. In June 2016, Janssen filed a further patent infringement lawsuit asserting the '083 patent, one against Celltrion  in a US District Court expanding the claims to include any use of the cell culture media made in the US to manufacture Celltrion's biosimilar, which was consolidated with the existing lawsuit [&lt;ulink linkID="1903902" linkType="Reference"&gt;1903902&lt;/ulink&gt;]. In August 2016, a District Court ruled in favor of Celltrion and Hospira, holding that the patent '471 was invalid; at that time, Janssen was to appeal the decision. Janssen was also continuing the appeal process before the USPTO; at that time, a date for the oral hearing was still to be set [&lt;ulink linkID="1789009" linkType="Reference"&gt;1789009&lt;/ulink&gt;], [&lt;ulink linkID="1789183" linkType="Reference"&gt;1789183&lt;/ulink&gt;]. In November 2016, Celltrion's biosimilar infliximab was launched by Hospira's parent company, &lt;ulink linkID="18767" linkType="Company"&gt;Pfizer&lt;/ulink&gt;, which began shipment of the biosimilar at risk in the US; at that time, J&amp;amp;J stated that it had not observed any significant impact from the launch and stated it would continue to vigorously defend its patents [&lt;ulink linkID="1895152" linkType="Reference"&gt;1895152&lt;/ulink&gt;], [&lt;ulink linkID="1896874" linkType="Reference"&gt;1896874&lt;/ulink&gt;], [&lt;ulink linkID="1903902" linkType="Reference"&gt;1903902&lt;/ulink&gt;]. By February 2017, Hospira had moved to dismiss all counts of the lawsuit related to the '083 patent as to it and Celltrion had moved to dismiss all counts of the lawsuit related to the '083 patent without prejudice for failure to join all the co-owners of the '083 patent as plaintiffs. The trial had been postponed pending resolution of these motions [&lt;ulink linkID="1903902" linkType="Reference"&gt;1903902&lt;/ulink&gt;]. In January 2018, the Federal Circuit dismissed Janssen's appeal as moot based on its affirmance of the Board's reexamination decision. In February 2018, J&amp;amp;J noted that trial regarding the additional patent infringement lawsuit asserting the '083 patent was scheduled to begin in July 2018 [&lt;ulink linkID="2008068" linkType="Reference"&gt;2008068&lt;/ulink&gt;]. In July  2018, the district court granted Celltrion's motion for summary judgment of non-infringement and entered an order dismissing the '083 lawsuit against Celltrion and Hospira. By February 2019,  Janssen had appealed to the United States Court of Appeals for the Federal Circuit [&lt;ulink linkID="2121710" linkType="Reference"&gt;2121710&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;By February 2009, Centocor and NYU had filed a patent infringement lawsuit against &lt;ulink linkID="13601" linkType="Company"&gt;Abbott Laboratories&lt;/ulink&gt;. The complaint alleged that &lt;ulink linkID="14163" linkType="Drug"&gt;adalimumab&lt;/ulink&gt; infringed the US product patent for infliximab &lt;ulink linkID="PA3130830" linkType="Patent"&gt;US-07070775&lt;/ulink&gt; (due to expire in April 2013), co-owned by NYU and Centocor and exclusively licensed to Centocor. A March 2008 arbitration ruled that Abbott had license to the patents at issue for a portion of adalimumab sales, however, the non-licensed sales had not been resolved [&lt;ulink linkID="996115" linkType="Reference"&gt;996115&lt;/ulink&gt;].  In June 2009, the US Federal Jury ruled in favor of NYU and Centocor, stating that the patent was infringed, ordering Abbott to pay damages [&lt;ulink linkID="1022145" linkType="Reference"&gt;1022145&lt;/ulink&gt;]. In October 2009, the District Court overturned the jury's finding that Abbott’s infringement was willful, but denied Abbott's request to overturn the verdict on validity, infringement and damages. In December 2009, the court issued its final judgment; Abbott appealed against the verdict [&lt;ulink linkID="1085332" linkType="Reference"&gt;1085332&lt;/ulink&gt;]. In February 2011, the US Court of Appeals overturned the verdict on infringement and damages. The Court stated that J&amp;amp;J had failed to show that the patent's claims provided adequate written description of claimed human variable regions and therefore did not cover a fully human antibody [&lt;ulink linkID="1237893" linkType="Reference"&gt;1237893&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In May 2008, Centocor filed a lawsuit against &lt;ulink linkID="19453" linkType="Company"&gt;Genentech&lt;/ulink&gt;, alleging that the Cabilly II patent (&lt;ulink linkID="PA2910853" linkType="Patent"&gt;US-06331415&lt;/ulink&gt;) was invalid. Genentech filed a counter claim alleging that infliximab infringed the Cabilly II patent. In August 2010, a Summary Judgment Motions hearing was conducted. Subsequent to the hearing, the case was settled, with the Cabilly II patent being licensed to Centocor [&lt;ulink linkID="1172278" linkType="Reference"&gt;1172278&lt;/ulink&gt;]. Genentech also dropped its claims that the manufacture of infliximab infringed a patent relating to the purification of antibodies made through recombinant DNA techniques [&lt;ulink linkID="1169150" linkType="Reference"&gt;1169150&lt;/ulink&gt;]. In January 2011, Genentech initiated arbitration against &lt;ulink linkID="15336" linkType="Company"&gt;UCB Celltech&lt;/ulink&gt; seeking damages for allegedly cooperating with Centocor to improperly terminate the agreement under which  Centocor   sub-licensed the rights  to market infliximab under the Cabilly patents.  Celltech asserted that  its indemnity agreement with Centocor meant that Centocor would be liable for any damages that the arbitration might require Celltech to pay. Following an arbitration hearing in June 2012, a finding of no liability   for Celltech was issued and  Janssen (formerly Centocor) was  thus not liable for any potential indemnity claim [&lt;ulink linkID="1393266" linkType="Reference"&gt;1393266&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;In June 2011, it was reported that European patent coverage was due to expire in 2015 [&lt;ulink linkID="1270018" linkType="Reference"&gt;1270018&lt;/ulink&gt;]. In February 2014,   it  was stated  that the patent coverage of the set of patents co-owned by Janssen Biotech and  &lt;ulink linkID="20646" linkType="Company"&gt;&lt;/ulink&gt;NYU  in certain countries in Europe (Germany, Spain, UK, Sweden, Austria, Belgium, Switzerland, Denmark, France, Greece, Italy, Luxembourg and the Netherlands) had been extended to February 2015.   The patents granted to the Kennedy Institute of Rheumatology in the UK in Europe were reported to expire in 2017; Janssen Biotech had an exclusive licence to these patents, and in May 2012 the validity of European Patent (UK) had been disputed and was in litigation. By February 2014, J&amp;amp;J expected no further extensions for these patents [&lt;ulink linkID="1528425" linkType="Reference"&gt;1528425&lt;/ulink&gt;]. In February 2015, J&amp;amp;J stated that certain challenged claims from the set of patents granted to the   Kennedy Institute of Rheumatology were invalidated and others were under review in several countries [&lt;ulink linkID="1642124" linkType="Reference"&gt;1642124&lt;/ulink&gt;]; at that time, the patents for infliximab in certain European countries expired  [&lt;ulink linkID="1738240" linkType="Reference"&gt;1738240&lt;/ulink&gt;]. In July 2015, Merck stated that infliximab had lost marketing exclusivity in Europe [&lt;ulink linkID="1681188" linkType="Reference"&gt;1681188&lt;/ulink&gt;]. In February 2018, J&amp;amp;J confirmed that the patents granted to the Kennedy Institute of Rheumatology expired in Europe in 2017 [&lt;ulink linkID="2008068" linkType="Reference"&gt;2008068&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2019, a Amgen filed for approval for its biosimilar ABP-710 in the EU [&lt;ulink linkID="2114847" linkType="Reference"&gt;2114847&lt;/ulink&gt;]; however, in May 2019, Amgen withdrew the filing due to a change in the company's strategy [&lt;ulink linkID="2169516" linkType="Reference"&gt;2169516&lt;/ulink&gt;]&lt;/para&gt;&lt;para&gt;In March 2015, Samsung Bioepis submitted an MAA for its biosimilar version of infliximab,   &lt;ulink linkID="87510" linkType="Drug"&gt;infliximab-abda&lt;/ulink&gt;, for the treatment of RA [&lt;ulink linkID="1641379" linkType="Reference"&gt;1641379&lt;/ulink&gt;]; later that month, the MAA was validated for review by the EMA [&lt;ulink linkID="1645730" linkType="Reference"&gt;1645730&lt;/ulink&gt;]. In May 2016, the EC  approved the biosimilar, as Flixabi, in the EU for the treatment of   RA, CD, UC, ankylosing spondylitis, PsA and psoriasis [&lt;ulink linkID="1767040" linkType="Reference"&gt;1767040&lt;/ulink&gt;]. By January 2017, Flixabi had been launched [&lt;ulink linkID="1896425" linkType="Reference"&gt;1896425&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2015, Merck reported that a biosimilar product had been launched in Norway in October 2013 [&lt;ulink linkID="1640015" linkType="Reference"&gt;1640015&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In September 2013, the European Commission approved Hospira's  infliximab biosimilar, &lt;ulink linkID="78759" linkType="Drug"&gt;Inflectra&lt;/ulink&gt; [&lt;ulink linkID="1475229" linkType="Reference"&gt;1475229&lt;/ulink&gt;]. In February 2014, Inflectra was launched in Europe by Hospira and &lt;ulink linkID="1051273" linkType="Company"&gt;Alvogen&lt;/ulink&gt; [&lt;ulink linkID="1524510" linkType="Reference"&gt;1524510&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2012, Celltrion filed its infliximab biosimilar,  &lt;ulink linkID="78759" linkType="Drug"&gt;Remsima&lt;/ulink&gt;, for EU approval [&lt;ulink linkID="1304082" linkType="Reference"&gt;1304082&lt;/ulink&gt;], and in September 2013, Remsima was approved by the EMA for the treatment of RA, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and psoriasis [&lt;ulink linkID="1484891" linkType="Reference"&gt;1484891&lt;/ulink&gt;]. In February 2015,  Celltrion launched the drug in 12 European countries including Austria, Belgium, Denmark, France, Germany, Greece, Italy, Luxembourg, the Netherlands, Spain, Sweden and the UK, for the treatment of adult and pediatric Crohn’s disease (CD), adult and pediatric ulcerative colitis, RA, ankylosing spondylitis, psoriasis, and psoriatic arthritis [&lt;ulink linkID="1636361" linkType="Reference"&gt;1636361&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Japan&lt;/subtitle&gt;In September 2018, Mitsubishi noted that the third biosimilar was expected to be launched in Japan in fiscal 2018 [&lt;ulink linkID="2076570" linkType="Reference"&gt;2076570&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2017,  &lt;ulink linkID="18511" linkType="Company"&gt;Nichi-Iko&lt;/ulink&gt; and &lt;ulink linkID="1009547" linkType="Company"&gt;Sanofi&lt;/ulink&gt;'s infliximab biosimilar, &lt;ulink linkID="77726" linkType="Drug"&gt;GS-071&lt;/ulink&gt; (NS-071) was approved in Japan  [&lt;ulink linkID="1965998" linkType="Reference"&gt;1965998&lt;/ulink&gt;]. By September 2018, launch had presumably occurred [&lt;ulink linkID="2076570" linkType="Reference"&gt;2076570&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2013,  &lt;ulink linkID="18535" linkType="Company"&gt;Nippon Kayaku&lt;/ulink&gt; submitted a marketing authorization application in Japan for its infliximab biosimilar, &lt;ulink linkID="78759" linkType="Drug"&gt;CT-P13&lt;/ulink&gt;, for the treatment of RA,  Crohn's disease and ulcerative colitis  [&lt;ulink linkID="1475881" linkType="Reference"&gt;1475881&lt;/ulink&gt;], [&lt;ulink linkID="1479066" linkType="Reference"&gt;1479066&lt;/ulink&gt;].  In July 2014, the company received marketing approval for the treatment of RA, Crohn's disease and ulcerative colitis [&lt;ulink linkID="1574928" linkType="Reference"&gt;1574928&lt;/ulink&gt;]. In November 2014, the drug was launched  in Japan for RA [&lt;ulink linkID="1616481" linkType="Reference"&gt;1616481&lt;/ulink&gt;]. In February 2015, Nippon Kayaku filed for Japanese approval  for psoriasis vulgaris, psoriasis arthropica, pustular psoriasis and erythrodermic psoriasis [&lt;ulink linkID="1631996" linkType="Reference"&gt;1631996&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Rest of the world&lt;/subtitle&gt;In February 2014,   it  was stated  that the set of patents co-owned by Janssen Biotech and  &lt;ulink linkID="20646" linkType="Company"&gt;&lt;/ulink&gt;NYU  were  slated to expire in March 2017 in Australia.  The patents granted to the Kennedy Institute of Rheumatology in Canada and Australia were reported to expire in 2017; Janssen Biotech had an exclusive licence to these patents; by February 2014, J&amp;amp;J expected no further extensions for these patents. In March 2012, certain patents expired in Canada [&lt;ulink linkID="1528425" linkType="Reference"&gt;1528425&lt;/ulink&gt;]. In February 2015, J&amp;amp;J stated that the Australian patent from the set  of patents co-owned by Janssen Biotech and NYU is to expire in August 2015. Additionally, certain challenged claims from the set of patents granted to the   Kennedy Institute of Rheumatology were invalidated and others were under review in several countries and also subject to litigation in Canada [&lt;ulink linkID="1642124" linkType="Reference"&gt;1642124&lt;/ulink&gt;];  in February 2016, that was still the case regarding the Kennedy Institute of Rheumatology set of patents. At that time, it was stated that the set of patents co-owned by Janssen Biotech and NYU had expired in all countries outside the US [&lt;ulink linkID="1738240" linkType="Reference"&gt;1738240&lt;/ulink&gt;]. In February 2017, that was still the case regarding the Kennedy Institute of Rheumatology set of patents [&lt;ulink linkID="1903902" linkType="Reference"&gt;1903902&lt;/ulink&gt;]. In February 2018, J&amp;amp;J confirmed that the patents granted to the Kennedy Institute of Rheumatology expired in Canada in 2017 [&lt;ulink linkID="2008068" linkType="Reference"&gt;2008068&lt;/ulink&gt;]&lt;/para&gt;&lt;para&gt;In April 2016, Merck, under license from  Samsung Bioepis,   launched its biosimilar infliximab, infliximab-abda, as &lt;ulink linkID="87510" linkType="Drug"&gt;Renflexis&lt;/ulink&gt;, in South Korea [&lt;ulink linkID="1804793" linkType="Reference"&gt;1804793&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In October 2013, The Kennedy Institute of Rheumatology along with Janssen Biotech filed a counterclaim against Celltrion alleging that Celltrion's filing  to the Health Canada would infringe the Feldman patents owned by Kennedy [&lt;ulink linkID="1642124" linkType="Reference"&gt;1642124&lt;/ulink&gt;]. In January 2014, Health Canada issued a Notice of Compliance to Celltrion for the product (&lt;ulink linkID="78759" linkType="Drug"&gt;Inflectra&lt;/ulink&gt;) for the treatment of RA (in combination with &lt;ulink linkID="69847" linkType="Drug"&gt;methotrexate&lt;/ulink&gt;),  ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis [&lt;ulink linkID="1546177" linkType="Reference"&gt;1546177&lt;/ulink&gt;]. In March 2014, Celltrion also filed suits against Kennedy seeking to invalidate the 3 Feldman patents, but Kennedy moved to dismiss the case for lack of jurisdiction and in December 2014, the US Court granted the motion. In January 2014,  a subsequent entry biologics to infliximab was approved by Health Canada regardless of the pending Feldman patent action. In February 2015, J&amp;amp;J stated that discovery in the Canadian Kennedy's patent action was ongoing and a trial was scheduled for September 2016 [&lt;ulink linkID="1642124" linkType="Reference"&gt;1642124&lt;/ulink&gt;]; in February 2016, that was still the case [&lt;ulink linkID="1738240" linkType="Reference"&gt;1738240&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In March 2013, Hospira filed against The Kennedy Institute of Rheumatology challenging the validity of a Feldman patent from Canada. In October 2013, The Kennedy Institute of Rheumatology along with Janssen Biotech filed a counterclaim against Hospira alleging that Hospira's filing  to the Health Canada would infringe the Feldman patents. In June 2014, the subsequent entry biologics to infliximab was approved by Health Canada regardless of the pending Feldman patent action. In July 2014, Janssen filed a lawsuit to compel the withdrawal of the Notice of Compliance for Hospira's infliximab biosimilar due to lack of a Notice of Allegation on Janssen to address the challenged patent. In February 2015, J&amp;amp;J stated that discovery in the Canadian Kennedy's patent action was ongoing and a trial was scheduled for September 2016. Additionally, a hearing regarding the Notice of Allegation lawsuit was scheduled for March 2015 [&lt;ulink linkID="1642124" linkType="Reference"&gt;1642124&lt;/ulink&gt;]. In March 2015, the parties entered into a settlement agreement whereby Health Canada agreed to a Consent Judgment setting aside Hospira’s Notice of Compliance, subject to Health Canada's right to appeal, which appeal was filed in June 2015 [&lt;ulink linkID="1738240" linkType="Reference"&gt;1738240&lt;/ulink&gt;]; however, already in March 2015, Inflectra was launched in Canada by Hospira as a distributor under Celltrion's Notice of Compliance [&lt;ulink linkID="1645957" linkType="Reference"&gt;1645957&lt;/ulink&gt;], [&lt;ulink linkID="1738240" linkType="Reference"&gt;1738240&lt;/ulink&gt;]. In February 2016, discovery in the patent action was ongoing [&lt;ulink linkID="1738240" linkType="Reference"&gt;1738240&lt;/ulink&gt;]. In October 2016, the appeals court reversed the Consent Judgment and Janssen had filed an application for leave to appeal with the Supreme Court of Canada. At that time, a trial in this patent action concluded, and in January 2017, closing arguments took place. In February 2017, the parties were awaiting a decision and Hospira continued to market and sell Celltrion's infliximab biosimilar in Canada [&lt;ulink linkID="1903902" linkType="Reference"&gt;1903902&lt;/ulink&gt;].&lt;/para&gt;&lt;/PatentsAndGenerics&gt;</value></PatentsAndGenerics><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;&lt;subtitle&gt;Ulcerative colitis&lt;/subtitle&gt;In December 2004, infliximab was granted Fast Track designation for the treatment of active UC [&lt;ulink linkID="576598" linkType="Reference"&gt;576598&lt;/ulink&gt;]. In April 2005, infliximab was filed with the FDA [&lt;ulink linkID="596330" linkType="Reference"&gt;596330&lt;/ulink&gt;], [&lt;ulink linkID="596042" linkType="Reference"&gt;596042&lt;/ulink&gt;]. The drug was approved in September 2005 [&lt;ulink linkID="623536" linkType="Reference"&gt;623536&lt;/ulink&gt;] and had been launched for this indication by January 2006 [&lt;ulink linkID="604950" linkType="Reference"&gt;604950&lt;/ulink&gt;], [&lt;ulink linkID="623536" linkType="Reference"&gt;623536&lt;/ulink&gt;], [&lt;ulink linkID="647339" linkType="Reference"&gt;647339&lt;/ulink&gt;]. The US label was expanded to include maintenance therapy of UC in October 2006 [&lt;ulink linkID="732940" linkType="Reference"&gt;732940&lt;/ulink&gt;]. In August 2007, a filing for colectomy avoidance took place [&lt;ulink linkID="900649" linkType="Reference"&gt;900649&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2003, infliximab was granted Orphan Drug status in the US for pediatric UC. In December 2010, Centocor Ortho Biotech submitted an sBLA to the FDA for infliximab in the treatment of moderately to severely active UC in pediatric patients [&lt;ulink linkID="1158054" linkType="Reference"&gt;1158054&lt;/ulink&gt;], [&lt;ulink linkID="1205487" linkType="Reference"&gt;1205487&lt;/ulink&gt;]. In July 2011, the FDA's Gastrointestinal Drugs Advisory Committee (GIDAC)  voted in favor of approval [&lt;ulink linkID="1209304" linkType="Reference"&gt;1209304&lt;/ulink&gt;]. In September 2011, the FDA approved infliximab for the treatment of moderately to severely active UC in pediatric patients (older than 6 years old) who have had an inadequate response to conventional therapy [&lt;ulink linkID="1225326" linkType="Reference"&gt;1225326&lt;/ulink&gt;], [&lt;ulink linkID="1225323" linkType="Reference"&gt;1225323&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Psoriasis&lt;/subtitle&gt;In September 2005, Centocor Ortho Biotech submitted an sBLA to the FDA for treatment of moderate-to-severe plaque psoriasis and, in November 2005, the filing was accepted [&lt;ulink linkID="629052" linkType="Reference"&gt;629052&lt;/ulink&gt;], [&lt;ulink linkID="632863" linkType="Reference"&gt;632863&lt;/ulink&gt;]. In September 2006, the FDA approved infliximab for the treatment of adult patients with chronic severe plaque psoriasis who are candidates for systemic therapy and when other systemic therapies are medically less appropriate [&lt;ulink linkID="694230" linkType="Reference"&gt;694230&lt;/ulink&gt;].&lt;br&gt;&lt;/br&gt;&lt;br&gt;&lt;/br&gt;&lt;subtitle&gt;Rheumatoid arthritis&lt;/subtitle&gt;Infliximab, in combination with MTX, was approved in the US for the treatment of RA in November 1999 [&lt;ulink linkID="347168" linkType="Reference"&gt;347168&lt;/ulink&gt;]. An FDA advisory committee meeting on the use of infliximab in the prevention of radiographic progression and physical disability in RA was scheduled for July 12, 2000 [&lt;ulink linkID="371708" linkType="Reference"&gt;371708&lt;/ulink&gt;], [&lt;ulink linkID="373280" linkType="Reference"&gt;373280&lt;/ulink&gt;]; the committee recommended approval of infliximab with MTX for reduction of structural damage in patients with RA though it opted not to vote on the claim of prevention of RA progression [&lt;ulink linkID="374366" linkType="Reference"&gt;374366&lt;/ulink&gt;], [&lt;ulink linkID="375966" linkType="Reference"&gt;375966&lt;/ulink&gt;]. The FDA Advisory Committee on Arthritis discussed safety issues for cytokine inhibitors in August 2001 [&lt;ulink linkID="421435" linkType="Reference"&gt;421435&lt;/ulink&gt;]. By August 2003, the drug had been launched for RA [&lt;ulink linkID="500103" linkType="Reference"&gt;500103&lt;/ulink&gt;]. In November 2003, Centocor Ortho Biotech filed for FDA approval for infliximab in RA prior to MTX treatment failure [&lt;ulink linkID="519679" linkType="Reference"&gt;519679&lt;/ulink&gt;]; approval as a first-line regimen was granted in September 2004 [&lt;ulink linkID="574797" linkType="Reference"&gt;574797&lt;/ulink&gt;], [&lt;ulink linkID="575526" linkType="Reference"&gt;575526&lt;/ulink&gt;]. By July 2005, the company had submitted to the FDA an sBLA for use in juvenile RA [&lt;ulink linkID="612962" linkType="Reference"&gt;612962&lt;/ulink&gt;]. An sNDA containing a shortened infusion time for RA treatment was filed in the US in June 2006 [&lt;ulink linkID="732038" linkType="Reference"&gt;732038&lt;/ulink&gt;]; in April 2007, a complete response letter was sent for this indication [&lt;ulink linkID="900649" linkType="Reference"&gt;900649&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Crohn's disease&lt;/subtitle&gt;Infliximab was launched in the US for the treatment of CD in October 1998 [&lt;ulink linkID="301111" linkType="Reference"&gt;301111&lt;/ulink&gt;]. The FDA expanded the approved CD indications in 2002, and again in April 2004, in relation to fistulizing CD [&lt;ulink linkID="584595" linkType="Reference"&gt;584595&lt;/ulink&gt;]. A BLA in pediatric CD was accepted in April 2006 [&lt;ulink linkID="659983" linkType="Reference"&gt;659983&lt;/ulink&gt;]; approval was granted in May 2006 [&lt;ulink linkID="668524" linkType="Reference"&gt;668524&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Ankylosing spondylitis&lt;/subtitle&gt;In February 2004, the drug was filed in the US for the treatment of AS and in April 2004, Centocor Ortho Biotech's sBLA was accepted by the FDA  [&lt;ulink linkID="533368" linkType="Reference"&gt;533368&lt;/ulink&gt;], [&lt;ulink linkID="533440" linkType="Reference"&gt;533440&lt;/ulink&gt;]. In December 2004, the FDA approved infliximab for this indication [&lt;ulink linkID="577869" linkType="Reference"&gt;577869&lt;/ulink&gt;], [&lt;ulink linkID="582791" linkType="Reference"&gt;582791&lt;/ulink&gt;]; by April 2005, infliximab had been launched in the US [&lt;ulink linkID="596330" linkType="Reference"&gt;596330&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Psoriatic arthritis&lt;/subtitle&gt;In December 2004, the FDA accepted Centocor Ortho Biotech's sBLA [&lt;ulink linkID="573924" linkType="Reference"&gt;573924&lt;/ulink&gt;]. In May 2005, infliximab was approved by the FDA for PsA and by October 2005, the drug had been launched in the US [&lt;ulink linkID="601834" linkType="Reference"&gt;601834&lt;/ulink&gt;], [&lt;ulink linkID="629282" linkType="Reference"&gt;629282&lt;/ulink&gt;]. In June 2005, Centocor Ortho Biotech planned to submit an infliximab sBLA to the FDA for inhibiting the progression of structural damage of active arthritis in patients with PsA [&lt;ulink linkID="606767" linkType="Reference"&gt;606767&lt;/ulink&gt;]. The FDA accepted Centocor Ortho Biotech's sBLA for this indication in June 2006 and approval was granted in August 2006 [&lt;ulink linkID="674824" linkType="Reference"&gt;674824&lt;/ulink&gt;], [&lt;ulink linkID="683901" linkType="Reference"&gt;683901&lt;/ulink&gt;]. The FDA approved an sBLA extending the PsA label to include inhibition of progression of structural damage and improving physical function in August 2006 [&lt;ulink linkID="674824" linkType="Reference"&gt;674824&lt;/ulink&gt;], [&lt;ulink linkID="683901" linkType="Reference"&gt;683901&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Behcet's disease&lt;/subtitle&gt;In May 2003, Tanabe reported that Centocor Ortho Biotech was preparing to file an NDA for infliximab in Behcet's disease [&lt;ulink linkID="492580" linkType="Reference"&gt;492580&lt;/ulink&gt;]; however, no further US development was reported by Centocor Ortho Biotech for this indication.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;In 2011, a label extension was approved for a shorter infusion time in all approved indications [&lt;ulink linkID="1288556" linkType="Reference"&gt;1288556&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Ulcerative colitis&lt;/subtitle&gt;In September 1999, the drug was approved and by January 2013, it had been launched in Spain [&lt;ulink linkID="1362545" linkType="Reference"&gt;1362545&lt;/ulink&gt;]. In October 2004, the drug was launched in Norway [&lt;ulink linkID="1458649" linkType="Reference"&gt;1458649&lt;/ulink&gt;]. In March 2006, infliximab was approved in Europe for UC [&lt;ulink linkID="654634" linkType="Reference"&gt;654634&lt;/ulink&gt;]. In January 2006, the CHMP adopted a positive opinion, recommending the approval of infliximab for moderately-to-severely active UC [&lt;ulink linkID="647468" linkType="Reference"&gt;647468&lt;/ulink&gt;]. In March 2006, infliximab was approved in Europe for moderately-to-severely active UC in patients who had an inadequate response to, or who could not take, conventional therapy, including corticosteroids and 6-MP or AZA [&lt;ulink linkID="654634" linkType="Reference"&gt;654634&lt;/ulink&gt;]. In April 2008, a filing for colectomy avoidance was approved [&lt;ulink linkID="900649" linkType="Reference"&gt;900649&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2010, Centocor Ortho Biotech filed for EU approval for the use of infliximab in pediatric patients with UC [&lt;ulink linkID="1163855" linkType="Reference"&gt;1163855&lt;/ulink&gt;]. In January 2012, the CHMP recommended the approval of infliximab for the treatment of severely active UC in pediatric patients aged 6 to 17 years, who had an inadequate response to conventional therapy (including corticosteroids and 6-mercaptopurine or azathioprine), or who were intolerant to or had medical contraindications for such therapies. At that time, a final EC decision was expected in 1Q12 [&lt;ulink linkID="1256468" linkType="Reference"&gt;1256468&lt;/ulink&gt;], [&lt;ulink linkID="1256625" linkType="Reference"&gt;1256625&lt;/ulink&gt;], [&lt;ulink linkID="1257693" linkType="Reference"&gt;1257693&lt;/ulink&gt;]. In February 2012, approval was obtained [&lt;ulink linkID="1281407" linkType="Reference"&gt;1281407&lt;/ulink&gt;]. By May 2013, the drug had been launched in Sweden [&lt;ulink linkID="1414388" linkType="Reference"&gt;1414388&lt;/ulink&gt;]. By March 2012, the drug had been approved in Cyprus, and subsequently launched [&lt;ulink linkID="1501609" linkType="Reference"&gt;1501609&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Psoriasis&lt;/subtitle&gt;In September 1999, the drug was approved and by January 2013, it had been launched in Spain [&lt;ulink linkID="1362545" linkType="Reference"&gt;1362545&lt;/ulink&gt;]. In October 2004, the drug was launched in Norway [&lt;ulink linkID="1458649" linkType="Reference"&gt;1458649&lt;/ulink&gt;]. In July 2005 the EU CHMP recommended approval of infliximab for the expanded indication of moderate-to-severe plaque psoriasis in patients refractory or intolerant to other systemic therapy [&lt;ulink linkID="615044" linkType="Reference"&gt;615044&lt;/ulink&gt;]; European approval was gained for this indication in October 2005 [&lt;ulink linkID="627104" linkType="Reference"&gt;627104&lt;/ulink&gt;], and the drug was launched in the UK in December 2005 [&lt;ulink linkID="642831" linkType="Reference"&gt;642831&lt;/ulink&gt;]. In October 2006, the EC approved infliximab for the treatment of moderate-to-severe plaque psoriasis in adults who failed to respond to, or were unable to take other systemic therapies including cyclosporine, MTX or psoralen plus ultraviolet A light (PUVA); the approval followed the positive opinion issued by the EU's CHMP in July 2006 [&lt;ulink linkID="728788" linkType="Reference"&gt;728788&lt;/ulink&gt;]. By May 2013, the drug had been launched in Sweden [&lt;ulink linkID="1414388" linkType="Reference"&gt;1414388&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Rheumatoid arthritis&lt;/subtitle&gt;In August 1999, the drug was approved in Denmark and subsequently launched [&lt;ulink linkID="1427364" linkType="Reference"&gt;1427364&lt;/ulink&gt;]; at that time, the drug was approved in Slovak Republic [&lt;ulink linkID="1466864" linkType="Reference"&gt;1466864&lt;/ulink&gt;]  and subsequently launched [&lt;ulink linkID="1466334" linkType="Reference"&gt;1466334&lt;/ulink&gt;].In September 1999, the drug was approved and by January 2013, it had been launched in Spain [&lt;ulink linkID="1362545" linkType="Reference"&gt;1362545&lt;/ulink&gt;]. In February 2000, the European CPMP recommended its approval for RA in patients with active disease who have had an inadequate response to  disease-modifying antirheumatic drugs (DMARDs), and approval was granted in June 2000 [&lt;ulink linkID="356925" linkType="Reference"&gt;356925&lt;/ulink&gt;], [&lt;ulink linkID="372577" linkType="Reference"&gt;372577&lt;/ulink&gt;]. By July 2000, infliximab had been launched for the treatment of RA in Europe [&lt;ulink linkID="376121" linkType="Reference"&gt;376121&lt;/ulink&gt;]. In October 2000, the CPMP of the EMEA issued a positive opinion recommending approval of infliximab with MTX for the improvement in physical function of patients with RA and a reduction in the rate of the progression of joint damage when the response to disease-modifying drugs, including MTX, has been inadequate. The EMEA's approval would result in one single marketing authorization with unified labeling that would be valid in all 15 EU-member states [&lt;ulink linkID="385255" linkType="Reference"&gt;385255&lt;/ulink&gt;].   In October 2000, the drug was approved in Iceland [&lt;ulink linkID="1451739" linkType="Reference"&gt;1451739&lt;/ulink&gt;] and subsequently launched [&lt;ulink linkID="1450511" linkType="Reference"&gt;1450511&lt;/ulink&gt;]. In January 2003, the drug was launched in Sweden [&lt;ulink linkID="1414388" linkType="Reference"&gt;1414388&lt;/ulink&gt;]. In April 2004, the drug was approved in Latvia [&lt;ulink linkID="1457075" linkType="Reference"&gt;1457075&lt;/ulink&gt;]. In June 2004, a label expansion for infliximab in RA prior to MTX treatment failure was granted in the EU [&lt;ulink linkID="555719" linkType="Reference"&gt;555719&lt;/ulink&gt;]. In October 2004, the drug was launched in Norway [&lt;ulink linkID="1458649" linkType="Reference"&gt;1458649&lt;/ulink&gt;]. In December 2006, EU approval was granted for shortened infusion time in RA patients [&lt;ulink linkID="751723" linkType="Reference"&gt;751723&lt;/ulink&gt;], and in March 2007, the label in the EU was extended to permit dose titration from 3 mg/kg to 7.5 mg/kg every 8 weeks, or to treat patients with 3 mg/kg as often as every 4 weeks [&lt;ulink linkID="770163" linkType="Reference"&gt;770163&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Crohn's disease&lt;/subtitle&gt;Infliximab was approved for CD in the EU in August 1999 [&lt;ulink linkID="336911" linkType="Reference"&gt;336911&lt;/ulink&gt;]; and had been  launched  by October 2000 [&lt;ulink linkID="385255" linkType="Reference"&gt;385255&lt;/ulink&gt;]; at that time, the drug was approved in Denmark and subsequently launched [&lt;ulink linkID="1427364" linkType="Reference"&gt;1427364&lt;/ulink&gt;]; at the same time, the drug was approved in the Netherlands [&lt;ulink linkID="1437443" linkType="Reference"&gt;1437443&lt;/ulink&gt;], and subsequently launched [&lt;ulink linkID="1437445" linkType="Reference"&gt;1437445&lt;/ulink&gt;]. In September 1999, the drug was approved and by January 2013, it had been launched in Spain [&lt;ulink linkID="1362545" linkType="Reference"&gt;1362545&lt;/ulink&gt;].    In October 2000, the drug was approved in Iceland [&lt;ulink linkID="1451739" linkType="Reference"&gt;1451739&lt;/ulink&gt;] and subsequently launched [&lt;ulink linkID="1450511" linkType="Reference"&gt;1450511&lt;/ulink&gt;]. EU approval for expanded use in maintenance dosing in patients with severe, active CD and fistulizing CD was granted in May and October 2003, respectively [&lt;ulink linkID="516210" linkType="Reference"&gt;516210&lt;/ulink&gt;]. In April 2004, the drug was approved in Latvia [&lt;ulink linkID="1457075" linkType="Reference"&gt;1457075&lt;/ulink&gt;]. In October 2004, the drug was launched in Norway [&lt;ulink linkID="1458649" linkType="Reference"&gt;1458649&lt;/ulink&gt;]. In July 2006, the EU CHMP recommended changing the indication from third to second-line therapy in patients with severe, active CD [&lt;ulink linkID="682617" linkType="Reference"&gt;682617&lt;/ulink&gt;]. In October 2006, the EC approved a label change for second-line therapy for the treatment of severe CD in patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant, or who are intolerant to or have medical contraindications for such therapies [&lt;ulink linkID="729313" linkType="Reference"&gt;729313&lt;/ulink&gt;]. In September 2008, the drug was launched in Portugal [&lt;ulink linkID="1387614" linkType="Reference"&gt;1387614&lt;/ulink&gt;]. In March 2011, the CHMP recommended extension of the CD indication to include patients with moderately-to-severely active CD [&lt;ulink linkID="1177608" linkType="Reference"&gt;1177608&lt;/ulink&gt;]. By May 2013, the drug had been launched in Sweden [&lt;ulink linkID="1414388" linkType="Reference"&gt;1414388&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2007, the CHMP adopted a positive option for the use of the drug in children aged 6 to 17 years who were unresponsive to conventional therapies [&lt;ulink linkID="777714" linkType="Reference"&gt;777714&lt;/ulink&gt;]; approval was granted in June 2007 [&lt;ulink linkID="802845" linkType="Reference"&gt;802845&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Ankylosing spondylitis&lt;/subtitle&gt;In September 1999, the drug was approved and by January 2013, it had been launched in Spain [&lt;ulink linkID="1362545" linkType="Reference"&gt;1362545&lt;/ulink&gt;]. In May 2003, the EU granted centralized marketing authorization to infliximab for the treatment of AS patients who had severe axial symptoms, elevated serological markers of inflammatory activity and who had responded inadequately to conventional therapy [&lt;ulink linkID="533721" linkType="Reference"&gt;533721&lt;/ulink&gt;]. In April 2004, the drug was approved in Latvia [&lt;ulink linkID="1457075" linkType="Reference"&gt;1457075&lt;/ulink&gt;]. By July 2004, infliximab had been launched for this indication in Europe [&lt;ulink linkID="550199" linkType="Reference"&gt;550199&lt;/ulink&gt;]. In October 2004, the drug was launched in Norway [&lt;ulink linkID="1458649" linkType="Reference"&gt;1458649&lt;/ulink&gt;]. By May 2013, the drug had been launched in Sweden [&lt;ulink linkID="1414388" linkType="Reference"&gt;1414388&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Psoriatic arthritis&lt;/subtitle&gt;In September 1999, the drug was approved and by January 2013, it had been launched in Spain [&lt;ulink linkID="1362545" linkType="Reference"&gt;1362545&lt;/ulink&gt;]. In July 2004, the EU CHMP recommended approval of infliximab in combination with MTX for treatment of active and progressive PsA in patients who had responded inadequately to DMARDs [&lt;ulink linkID="551851" linkType="Reference"&gt;551851&lt;/ulink&gt;].  In October 2004, infliximab was approved for this indication [&lt;ulink linkID="564519" linkType="Reference"&gt;564519&lt;/ulink&gt;]; at that time, the drug was launched in Norway [&lt;ulink linkID="1458649" linkType="Reference"&gt;1458649&lt;/ulink&gt;]. By January 2005, it had been launched for PsA in the UK [&lt;ulink linkID="657689" linkType="Reference"&gt;657689&lt;/ulink&gt;] and Germany [&lt;ulink linkID="657893" linkType="Reference"&gt;657893&lt;/ulink&gt;]. By May 2013, the drug had been launched in Sweden [&lt;ulink linkID="1414388" linkType="Reference"&gt;1414388&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The label was extended in July 2006 to include monotherapy use in patients intolerant to MTX [&lt;ulink linkID="680284" linkType="Reference"&gt;680284&lt;/ulink&gt;]. European phase III trials to extend the PsA label to include inhibition of progression of structural damage were ongoing in October 2006 [&lt;ulink linkID="732038" linkType="Reference"&gt;732038&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Japan&lt;/subtitle&gt;In May 2012, a label extension was approved for a shorter infusion time, in selected patients who had tolerated three previous infusions [&lt;ulink linkID="1288556" linkType="Reference"&gt;1288556&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Rheumatoid arthritis&lt;/subtitle&gt;In June 2001, Tanabe filed an NDA for RA in Japan and in July 2003, infliximab was approved and launched [&lt;ulink linkID="500704" linkType="Reference"&gt;500704&lt;/ulink&gt;], [&lt;ulink linkID="492580" linkType="Reference"&gt;492580&lt;/ulink&gt;]. By November 2007, a Japanese sNDA  had been filed  for RA (dose escalation) [&lt;ulink linkID="853099" linkType="Reference"&gt;853099&lt;/ulink&gt;]. In July 2009, the Japanese authorities granted approval for RA, including prevention of structural joint damage; in addition a new administration and dosage regimen for infliximab use in RA was approved [&lt;ulink linkID="1024161" linkType="Reference"&gt;1024161&lt;/ulink&gt;], [&lt;ulink linkID="1029779" linkType="Reference"&gt;1029779&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Crohn's disease&lt;/subtitle&gt;in Japan, infliximab was designated an Orphan Drug and an NDA was filed for CD by December 2001 [&lt;ulink linkID="422782" linkType="Reference"&gt;422782&lt;/ulink&gt;]; in January 2002, the drug was approved for CD  [&lt;ulink linkID="1660434" linkType="Reference"&gt;1660434&lt;/ulink&gt;], and the Japanese launch for CD took place in May 2002 [&lt;ulink linkID="485413" linkType="Reference"&gt;485413&lt;/ulink&gt;]. An sNDA for CD maintenance therapy was filed in November 2006 and approval was granted in November 2007 [&lt;ulink linkID="801369" linkType="Reference"&gt;801369&lt;/ulink&gt;], [&lt;ulink linkID="810874" linkType="Reference"&gt;810874&lt;/ulink&gt;], [&lt;ulink linkID="855285" linkType="Reference"&gt;855285&lt;/ulink&gt;]. In December 2010,  an sNDA was filed in Japan for dose-escalation in CD [&lt;ulink linkID="1164273" linkType="Reference"&gt;1164273&lt;/ulink&gt;]; in August 2011, Japanese approval was granted to partially change the dosage of infliximab from 5 mg/kg to 10 mg/kg (both at 8-week administration interval) for CD [&lt;ulink linkID="1215739" linkType="Reference"&gt;1215739&lt;/ulink&gt;]. In May 2017, Japanese approval was granted to partially change the dosage of infliximab from 10 mg/kg 8-week administration interval to 5 mg/kg 4-week administration interval for CD [&lt;ulink linkID="1929055" linkType="Reference"&gt;1929055&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2016, Mitsubishi Tanabe filed an application for a partial change of dosage of infliximab from 10 mg/kg, 8- week administration interval to 5 mg/kg, 4- week administration interval; at that time, the company also planned to revise the precautions for use with pediatric patients [&lt;ulink linkID="1794097" linkType="Reference"&gt;1794097&lt;/ulink&gt;]. In April 2017, the first committee of the PAFSC  recommended the approval of the new dosage regimen of 5mg/kg every 4 weeks for  CD [&lt;ulink linkID="1923454" linkType="Reference"&gt;1923454&lt;/ulink&gt;]. In May 2017, approval of the new dosage regimen was granted [&lt;ulink linkID="1949558" linkType="Reference"&gt;1949558&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Behcet's disease&lt;/subtitle&gt;In March 2002, infliximab was granted Japanese Orphan Drug status for Behcet's disease [&lt;ulink linkID="492580" linkType="Reference"&gt;492580&lt;/ulink&gt;]; filing took place in July 2003 [&lt;ulink linkID="514105" linkType="Reference"&gt;514105&lt;/ulink&gt;]. Approval was granted in January 2007, for the treatment of patients with refractory uveoretinitis in Behcet's disease, following unsuccessful treatment with conventional therapies [&lt;ulink linkID="760918" linkType="Reference"&gt;760918&lt;/ulink&gt;], [&lt;ulink linkID="901809" linkType="Reference"&gt;901809&lt;/ulink&gt;], [&lt;ulink linkID="1125005" linkType="Reference"&gt;1125005&lt;/ulink&gt;]. In August 2009, it appeared that the drug was available for this indication [&lt;ulink linkID="1047222" linkType="Reference"&gt;1047222&lt;/ulink&gt;]. In September 2012, the Second Committee on Drugs of the Pharmaceutical Affairs and Food Sanitation Council granted the drug Orphan status for Behcet's disease with intestinal form, neural form, or vascular form [&lt;ulink linkID="1322796" linkType="Reference"&gt;1322796&lt;/ulink&gt;], [&lt;ulink linkID="1330320" linkType="Reference"&gt;1330320&lt;/ulink&gt;]. In October 2014, Mitsubishi filed an sNDA for approval for entero-Behcet's disease, neuro-Behcet's disease and vasculo-Behcet's disease [&lt;ulink linkID="1606862" linkType="Reference"&gt;1606862&lt;/ulink&gt;]; [&lt;ulink linkID="1630728" linkType="Reference"&gt;1630728&lt;/ulink&gt;]. In August 2015, the drug was approved for those additional indications in Japan [&lt;ulink linkID="1688784" linkType="Reference"&gt;1688784&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2005, Tanabe was in protocol discussions with the Japanese regulatory body to expand the range of indications to include sarcoidosis, giant cell arteritis and cachexia [&lt;ulink linkID="619481" linkType="Reference"&gt;619481&lt;/ulink&gt;]; however, no development has since been reported. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Ankylosing spondylitis&lt;/subtitle&gt;In June 2008, infliximab was designated an Orphan Drug. In September 2008, an sNDA was filed for the treatment of AS [&lt;ulink linkID="957748" linkType="Reference"&gt;957748&lt;/ulink&gt;]; in April 2010,  approval was granted  [&lt;ulink linkID="1163897" linkType="Reference"&gt;1163897&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Ulcerative colitis&lt;/subtitle&gt;In June 2009, an sNDA for UC was filed in Japan [&lt;ulink linkID="1029779" linkType="Reference"&gt;1029779&lt;/ulink&gt;]. This was approved in June 2010 [&lt;ulink linkID="1121601" linkType="Reference"&gt;1121601&lt;/ulink&gt;], [&lt;ulink linkID="1119862" linkType="Reference"&gt;1119862&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Psoriasis&lt;/subtitle&gt;In February 2008, an sNDA was filed in Japan for psoriasis [ &lt;ulink linkID="957748" linkType="Reference"&gt;957748&lt;/ulink&gt;]. In January 2010, infliximab was granted Japanese approval for plaque psoriasis, psoriatic arthritis, pustular psoriasis and erthrodermic psoriasis [&lt;ulink linkID="1069817" linkType="Reference"&gt;1069817&lt;/ulink&gt;]. In May 2012, the conditions on approval of the drug for psoriasis were lifted, after post-marketing surveillance data confirmed the safety of the drug for that indication [&lt;ulink linkID="1288555" linkType="Reference"&gt;1288555&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2015, Mitsubishi Tanabe filed for approval in Japan to partially change to a higher dosage of infliximab for psoriasis [&lt;ulink linkID="1676830" linkType="Reference"&gt;1676830&lt;/ulink&gt;]; in May 2016, the use of an increased dosage and shorter dosing intervals of iv infliximab  infusion 100 in patients with psoriasis was approved in Japan [&lt;ulink linkID="1770455" linkType="Reference"&gt;1770455&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Kawasaki disease&lt;/subtitle&gt;In September 2012, the Second Committee on Drugs of the Pharmaceutical Affairs and Food Sanitation Council granted the drug Orphan status for refractory Kawasaki disease [&lt;ulink linkID="1322796" linkType="Reference"&gt;1322796&lt;/ulink&gt;], [&lt;ulink linkID="1330320" linkType="Reference"&gt;1330320&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2015, infliximab was filed for Japanese approval in the treatment of Kawasaki disease [&lt;ulink linkID="1660434" linkType="Reference"&gt;1660434&lt;/ulink&gt;]. In November 2015, the Ministry of Health, Labour and Welfare's Second Committee on New Drugs, Pharmaceutical Affairs and Food Sanitation Council recommended approval [&lt;ulink linkID="1717217" linkType="Reference"&gt;1717217&lt;/ulink&gt;]; in December 2015, approval was granted in Japan for that indication [&lt;ulink linkID="1722916" linkType="Reference"&gt;1722916&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;China&lt;/subtitle&gt;In September 2009, infliximab was launched in China for the treatment of rheumatoid arthtitis, ankylosing spondylitis and Crohns disease [&lt;ulink linkID="1268046" linkType="Reference"&gt;1268046&lt;/ulink&gt;]. In December 2018, the drug was approved in China for the treatment of moderate to severe active Crohn's disease in children aged 6 to 17 years who experienced an inadequate response to conventional therapy [&lt;ulink linkID="2104864" linkType="Reference"&gt;2104864&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By May 2013, a filing for psoriasis had been submitted in China   [&lt;ulink linkID="1440862" linkType="Reference"&gt;1440862&lt;/ulink&gt;]; in October  2013, approval was granted [&lt;ulink linkID="1615066" linkType="Reference"&gt;1615066&lt;/ulink&gt;]. The product was assumed to be launched shortly after the approval in 2013 [&lt;ulink linkID="2066111" linkType="Reference"&gt;2066111&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2014, a filing, presumed to be for UC, was submitted in China [&lt;ulink linkID="1608951" linkType="Reference"&gt;1608951&lt;/ulink&gt;], [&lt;ulink linkID="1615054" linkType="Reference"&gt;1615054&lt;/ulink&gt;]; in  May 2015, it was assumed that supplemental materials were requested by the CFDA for the further review [&lt;ulink linkID="1715639" linkType="Reference"&gt;1715639&lt;/ulink&gt;]. In November 2015, another launch application, presumably for UC, was filed in China [&lt;ulink linkID="1710021" linkType="Reference"&gt;1710021&lt;/ulink&gt;], [&lt;ulink linkID="1715640" linkType="Reference"&gt;1715640&lt;/ulink&gt;]. In January 2019, the drug was approved in China by the National Medical Product Administration (NMPA) for the treatment of adults with severe active UC [&lt;ulink linkID="2110322" linkType="Reference"&gt;2110322&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Rest of the world&lt;/subtitle&gt;&lt;subtitle&gt;Canada&lt;/subtitle&gt;&lt;subtitle&gt;Ulcerative colitis&lt;/subtitle&gt;In September 2011, Health Canada approved infliximab for the treatment of pediatric patients (age 6 to 17 years) with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy [&lt;ulink linkID="1225323" linkType="Reference"&gt;1225323&lt;/ulink&gt;]; by January 2014, the product had been launched in Canada [&lt;ulink linkID="1517902" linkType="Reference"&gt;1517902&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Latin America&lt;/subtitle&gt;&lt;subtitle&gt;Ulcerative colitis&lt;/subtitle&gt;In December 2000, the drug was approved in Brazil [&lt;ulink linkID="1737842" linkType="Reference"&gt;1737842&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;By January 2014, the product had been launched in Latin America presumably for the treatment of UC [&lt;ulink linkID="1517902" linkType="Reference"&gt;1517902&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Middle East and Africa&lt;/subtitle&gt;&lt;subtitle&gt;Ulcerative colitis&lt;/subtitle&gt;By February 2017, the product had presumably been launched in Turkey for the treatment of UC [&lt;ulink linkID="1904530" linkType="Reference"&gt;1904530&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Psoriatic arthritis&lt;/subtitle&gt;By February 2017, the product had presumably been launched in Turkey for the treatment of PsA [&lt;ulink linkID="1904530" linkType="Reference"&gt;1904530&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Rheumatoid arthritis&lt;/subtitle&gt;By February 2017, the product had presumably been launched in Turkey for the treatment of RA [&lt;ulink linkID="1904530" linkType="Reference"&gt;1904530&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Crohn's disease&lt;/subtitle&gt;By February 2017, the product had presumably been launched in Turkey for the treatment of CD [&lt;ulink linkID="1904530" linkType="Reference"&gt;1904530&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Commonwealth of Independent States&lt;/subtitle&gt;&lt;subtitle&gt;Ulcerative colitis&lt;/subtitle&gt;By February 2017, the product had presumably been launched in Russia for the treatment of UC [&lt;ulink linkID="1904530" linkType="Reference"&gt;1904530&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Psoriatic arthritis&lt;/subtitle&gt;By February 2017, the product had presumably been launched in Russia for the treatment of PsA [&lt;ulink linkID="1904530" linkType="Reference"&gt;1904530&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Rheumatoid arthritis&lt;/subtitle&gt;By February 2017, the product had  presumably been launched in Russia for the treatment of RA [&lt;ulink linkID="1904530" linkType="Reference"&gt;1904530&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Crohn's disease&lt;/subtitle&gt;By February 2017, the product had presumably been launched in Russia for the treatment of CD [&lt;ulink linkID="1904530" linkType="Reference"&gt;1904530&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Asia Pacific&lt;/subtitle&gt;&lt;subtitle&gt;Ulcerative colitis&lt;/subtitle&gt;In September 2013, the product was filed for approval in Taiwan for UC in adults and children [&lt;ulink linkID="1658315" linkType="Reference"&gt;1658315&lt;/ulink&gt;]; by  September 2015, the drug was approved in Taiwan [&lt;ulink linkID="1732119" linkType="Reference"&gt;1732119&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2012, the product was approved in  Australia for the treatment of moderately severe to severe active UC in adults or in children and adolescent (6 to 17 years) patients who experienced an inadequate response to conventional therapy [&lt;ulink linkID="1354304" linkType="Reference"&gt;1354304&lt;/ulink&gt;]. By Janaury 2018, the drug had been launched in Australia for the treatment of UC [&lt;ulink linkID="2124671" linkType="Reference"&gt;2124671&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Psoriatic arthritis&lt;/subtitle&gt;In March 2006, infliximab was approved in Australia for PsA patients who had an inadequate response to DMARDs [&lt;ulink linkID="657452" linkType="Reference"&gt;657452&lt;/ulink&gt;]. By Janaury 2018, the drug had been launched in Australia for the treatment of PsA [&lt;ulink linkID="2124671" linkType="Reference"&gt;2124671&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Rheumatoid arthritis&lt;/subtitle&gt;In August 2005, the agent was approved in Korea as Remicade; it was presumed that the product was launched shortly after [&lt;ulink linkID="962951" linkType="Reference"&gt;962951&lt;/ulink&gt;], [&lt;ulink linkID="1782302" linkType="Reference"&gt;1782302&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Crohn's disease&lt;/subtitle&gt;By Janaury 2018, the drug had been approved and launched in Australia for the treatment of CD [&lt;ulink linkID="2124671" linkType="Reference"&gt;2124671&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2013, the product was filed for approval in Taiwan for CD in adults and children [&lt;ulink linkID="1658315" linkType="Reference"&gt;1658315&lt;/ulink&gt;]; by  September 2015, the drug was approved in Taiwan [&lt;ulink linkID="1732119" linkType="Reference"&gt;1732119&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Ankylosing spondylitis&lt;/subtitle&gt;By Janaury 2018, the drug had been approved and launched in Australia for the treatment of ankylosing spondylitis [&lt;ulink linkID="2124671" linkType="Reference"&gt;2124671&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;SAFETY INFORMATION&lt;/subtitle&gt;By August 2004, hematological events including leukopenia, neutropenia, thrombocytopenia and pancytopenia, some with fatal outcome, had been reported in patients receiving infliximab. Accordingly, Centocor Ortho Biotech added a warning to the labeling [&lt;ulink linkID="556128" linkType="Reference"&gt;556128&lt;/ulink&gt;], [&lt;ulink linkID="556131" linkType="Reference"&gt;556131&lt;/ulink&gt;]. In October 2004, revisions were made to the prescribing information due to cases of lymphoma [&lt;ulink linkID="564745" linkType="Reference"&gt;564745&lt;/ulink&gt;]. The Japanese label also reports the possibility of interstitial pneumonia when used with MTX [&lt;ulink linkID="560567" linkType="Reference"&gt;560567&lt;/ulink&gt;]. In June 2007, the FDA updated the infliximab label to reflect the occurrence of severe cutaneous adverse reactions [&lt;ulink linkID="998751" linkType="Reference"&gt;998751&lt;/ulink&gt;]. In September 2008, the FDA requested that manufacturers of TNF-alpha blockers  strengthen warnings and precaution sections of  prescribing information and medication guides advising of the risk of developing opportunistic fungal infections, as cases of histoplasmosis infection were not being consistently recognized in patients taking these medications [&lt;ulink linkID="940909" linkType="Reference"&gt;940909&lt;/ulink&gt;]. In August 2009, the FDA also requested that labeling for anti-TNF drugs be updated to highlight the increased risk of cancer in pediatric patients; the agency added that the prescribing information should include reports of psoriasis associated with the use of the drug class [&lt;ulink linkID="1031449" linkType="Reference"&gt;1031449&lt;/ulink&gt;]. By October 2015, the changes had been applied to the label and the black-boxed warning highlighted the increased risk of serious infections and malignancy [&lt;ulink linkID="585004" linkType="Reference"&gt;585004&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Postmarketing><displayLabel>Postmarketing</displayLabel><value>&lt;Postmarketing&gt;&lt;para&gt;&lt;subtitle&gt;Chronic obstructive pulmonary disease&lt;/subtitle&gt;In September 2006, a prospective, multicenter, phase IV trial (&lt;ulink linkID="84984" linkType="Protocol"&gt;NCT00380796&lt;/ulink&gt;; CR012292; C0168T70) began in patients (expected n = 88) with COPD in the US to evaluate the long-term safety of infliximab. At that time, the trial was estimated to complete in December 2009. In November 2012, the trial was completed [&lt;ulink linkID="1437466" linkType="Reference"&gt;1437466&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Rheumatoid arthritis&lt;/subtitle&gt;In June 2017, interim data were presented from the prospective, non-interventional and non-randomized US-based study (AWARE), a comparative and pragmatic study of intravenous golimumab versus infliximab in adults with RA were presented at the 18th EULAR Annual European Congress of Rheumatology, Madrid, Spain. Patients (n = 1200) received treatment with golimumab or infliximab.  A total of 363 patients were analyzed in the interim analysis. When compared to patients with CDAI &amp;lt;/= 22, patients with CDAI &amp;gt; 22 exhibited significantly worse T-scores for all PROMIS-29 Profile v2.0 domains, PROMIS Short Form Fatigue-7a and PROMIS Pain Interference Short Form-6b. When compared to CDAI disease activity, except the sleep disturbance domain, the PROMIS T-scores across all domains exhibited correlation, with significantly higher T-scores in HDA patients when compared to patients with moderate and low disease activity and patients in remission (p &amp;lt; 0.05) [&lt;ulink linkID="1935764" linkType="Reference"&gt;1935764&lt;/ulink&gt;].  In November 2017, further interim analysis data of the differences in dosing and administration efficiencies between intravenous golimumab and infliximab (n = 421 and 326, respectively) were presented at the 81st ACR Annual Meeting in San Diego, CA. The dose of golimumab did not change over the course of the first 7 infusions. A significant (p &amp;lt; 0.0001) difference in the percent of patients with a reported dose increase from baseline between golimumab and infliximab was observed; between the first and seventh dose among patients with seven infusions, the mean dose of infliximab increased by approximately 152%.  The mean infusion time of golimumab was consistently shorter (0.65 h) compared to infliximab (2.0 h) [&lt;ulink linkID="1978217" linkType="Reference"&gt;1978217&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In October 2013,  data from an ongoing multicenter, prospective, non-interventional, observational study (BioTRAC)  in 838 Canadian RA patients  were presented at the 77th ACR/ARHP Annual Meeting in San Diego CA. No significant positive effect of corticosteroid use was observed on sustainability of remission  [&lt;ulink linkID="1493977" linkType="Reference"&gt;1493977&lt;/ulink&gt;]. In October 2013, further data were presented from 790 patients at the same conference.  Infliximab along with methotrexate was found to associate with improved outcomes as indicated by higher rates of remission in disease activity score 28 (DAS-28) based on CRP, SDAI and clinical disease activity index [&lt;ulink linkID="1493603" linkType="Reference"&gt;1493603&lt;/ulink&gt;]. In October 2013, further data from 628 patients were presented at the same conference. Infliximab treatment for five years was well tolerated and safe. Infliximab was associated with significant decreases in mean disease activity, number of swollen and tender joints, mean morning stiffness and physician and patient global assessment of disease activity scores. A high proportion of patients achieved DAS28-CRP remission; the mean health assessment disability index scores were significantly improved [&lt;ulink linkID="1493599" linkType="Reference"&gt;1493599&lt;/ulink&gt;]. In June 2014, further data from 303 patients were presented at EULAR 2014 Annual Meeting in Paris, France. After 6 months of therapy, infliximab was effective in reducing disease activity regardless of the enrolment period [&lt;ulink linkID="1567143" linkType="Reference"&gt;1567143&lt;/ulink&gt;]. In June 2014, further data from 230 patients who were enrolled between 2005 and 2012 were presented at the same meeting. Over 6 months of therapy, significant improvements were observed in CRP, ESR, morning stiffness, health assessment questionnaire disability index, physician global assessment of disease activity, bath AS disease activity index, AS disease activity score and bath AS functional index; these effects were sustained or further enhanced over 48 months of therapy [&lt;ulink linkID="1567172" linkType="Reference"&gt;1567172&lt;/ulink&gt;]. In June 2014, further data from 832 RA and 92 PsA patients were presented at the same meeting. Over 6 months of infliximab therapy, significant improvements in swelling/tenderness in all the most commonly affected joints were observed in both RA and PsA; treatment resistance was observed mostly in metacarpophalangeal joints [&lt;ulink linkID="1563863" linkType="Reference"&gt;1563863&lt;/ulink&gt;]. In June 2014, treatment durability data from 830 RA and 92 PsA patients were presented at the same meeting. In both the patient populations, an association between longer treatment duration and significantly greater improvements in pain, patient global and health assessment questionnaire disability index were observed. In PsA patients, treatment duration was significantly associated with disease duration, prior biological therapy, baseline 28-tender joint count, baseline psoriasis area and severity index and concomitant disease modifying anti-rheumatoid drugs or NSAID use. Infliximab dose optimization and concomitant use of steroids were identified as significant predictors of treatment durability in RA patients [&lt;ulink linkID="1566882" linkType="Reference"&gt;1566882&lt;/ulink&gt;]. In June 2015, further results were presented at the 16th EULAR Annual European Congress in Rome, Italy. Overall, an additional 10.1, 10.6 and 17.8% of non-remission cases for DAS28, clinical disease activity index  and SDAI, respectively, were classified as remission with the modified definition [&lt;ulink linkID="1668687" linkType="Reference"&gt;1668687&lt;/ulink&gt;]. In November 2015, further data were presented at the 79th ACR Annual Meeting in San Francisco, CA. , Infliximab + methotrexate was significantly associated with higher treatment durability compared with infliximab + leflunomide in RA patients with increased risk for adverse events (AEs) but not for serious AEs [&lt;ulink linkID="1709739" linkType="Reference"&gt;1709739&lt;/ulink&gt;]. Further clinical data were presented at the same conference. The number of infections per 100 person-years (PY) was 37.4 and 2.8 of non-serious and serious infections, respectively. The mean adjusted incidence density ratio (IDR) for infections was 23.9, 30.2 and 30.5 events/100 PY for monotherapy, methotrexate low moderate dose and methotrexate high dose, respectively [&lt;ulink linkID="1873853" linkType="Reference"&gt;1873853&lt;/ulink&gt;]. In June 2017, further clinical data were presented at the 18th EULAR Annual European Congress of Rheumatology, Madrid, Spain. At baseline, 12 and 24 months, Ankylosing Spondylitis Disease Activity Score  was 2.17, 2.02 and 2.02, respectively. In rheumatoid arthritis patients, the Disease Activity Score 28 (DAS28) Erythrocyte Sedimentation Rate was 3.37, 3.26 and 3.11 at baseline, 12 and 24 months, respectively, whereas DAS28 C reactive protein observed in rheumatoid arthritis patients was 3, 2.87 and 2.61 at baseline, 12 and 24 months, respectively [&lt;ulink linkID="1935763" linkType="Reference"&gt;1935763&lt;/ulink&gt;].  In November 2017, further clinical data were presented at the 81st ACR Annual Meeting in San Diego, CA. After 12 and 24 months of treatment, the proportion of AS patients with disease worsening (increase in ASDAS &amp;gt;/= 1.1 from baseline and a minimum score of 2.1) was 11.4 and 10.2%, 4.8 and 2.7%, and 4 and 11.1%, respectively, at two, four and six years  [&lt;ulink linkID="1978291" linkType="Reference"&gt;1978291&lt;/ulink&gt;]. In June 2018, further long-term safety data of infliximab were presented at the 19th EULAR Annual European Congress of Rheumatology in Amsterdam, Netherlands. Treatment with infliximab was generally safe, with AEs and SAEs being reported for 64.3 and 19.5% of patients, respectively. The incidence rate of AEs and SAEs was 116.0 and 11.2 events per 100 patient-years, respectively [&lt;ulink linkID="2045133" linkType="Reference"&gt;2045133&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2013, results from a multicenter Japanese study were reported showing that 33 of 114 patients who had achieved low disease activity with infliximab continued to show low disease activity three years after discontinuing treatment [&lt;ulink linkID="1464139" linkType="Reference"&gt;1464139&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2010, data from a multicenter, open-label, active switch phase IV study (&lt;ulink linkID="20269" linkType="Protocol"&gt;NCT00714493&lt;/ulink&gt;; RESTART) were announced. The trial evaluated 197 patients with moderate to severe RA who had an inadequate response to &lt;ulink linkID="4567" linkType="Drug"&gt;etanercept&lt;/ulink&gt; or &lt;ulink linkID="14163" linkType="Drug"&gt;adalimumab&lt;/ulink&gt;, who were switched to infliximab. Patients who switched to infliximab demonstrated significant improvement from baseline at week 10, and sustained response until week 26. Improvements of 51.8% were seen with infliximab maintenance dosing. Improvements in ACR20, ACR50 and ACR70 scores were demonstrated at week 10 and were sustained until week 26. Moreover, by week 26, more than half of patients demonstrated a clinical improvement, as evaluated by the EULAR response criteria; 48.3% of patients previously treated with etanercept and 57.1%  of patients previously treated with adalimumab achieved a EULAR response [&lt;ulink linkID="1146002" linkType="Reference"&gt;1146002&lt;/ulink&gt;]. In May 2011, clinical data were presented at EULAR 2011 in London, UK. Significant and clinically important improvements in quality of life, health status and productivity was demonstrated by patients who switched to infliximab from adalimumab or etanercept without a washout period [&lt;ulink linkID="1197317" linkType="Reference"&gt;1197317&lt;/ulink&gt;].  In November 2012, data were presented at the ACR/ARHP Annual Meeting in Washington DC. Of the 195 patients from whom the samples were available, detectable levels of antibodies to infliximab were noted in 24 patients, including 23 patients who had evidence of prior antibodies to etanercept or adalimumab [&lt;ulink linkID="1342991" linkType="Reference"&gt;1342991&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2006, results from a 12-month study in adults with moderate-to-severe RA, who have had an inadequate response to  MTX, showed the efficacy of &lt;ulink linkID="2888" linkType="Drug"&gt;abatacept&lt;/ulink&gt; (Orencia) or infliximab  was superior to placebo. At baseline, clinical characteristics and demographics for abatacept, infliximab and placebo patients were similar, with mean scores of approximately 1.7 for the Health Assessment Questionnaire Disability Index (HAQ-DI) and 6.8 for the DAS28. At 6 months,  DAS28 score changes compared to baseline were -2.53, -2.25 and -1.48 for abatacept, infliximab and placebo, respectively. At 12 months, the changes from baseline in DAS28 were -2.88 and -2.25 for abatacept and infliximab, respectively. A total of 86% of abatacept patients and 75% infliximab patients  had a DAS28 improvement of greater than or equal to 1.2;  35.3% of  abatacept and 22.4% of infliximab patients had  28 scores &amp;lt;= 3.2. At 12 months, 72.4, 45.5 and 26.3% of abatacept patients and 55.8, 36.4 and 20.6% of infliximab patients achieved  ACR 20, 50 and 70 scores, respectively [&lt;ulink linkID="742422" linkType="Reference"&gt;742422&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2015, clinical data were presented from a phase I, single-blind, 3-arm, parallel, single-dose study (&lt;ulink linkID="150612" linkType="Protocol"&gt;NCT01922336&lt;/ulink&gt;), at the 16th EULAR Annual European Congress in Rome, Italy. AUC infinity, AUC last, Cmax, Vd and t1/2 were 39360 microg.h/ml, 37022 microg.h/ml, 126.2 microg/ml, 4846 ml and 339.5 h, respectively in EU-infliximab group and 39270 microg.h/ml, 37368 microg.h/ml, 129.2 microg/ml, 4806 ml and 339.7 h, respectively in US-infliximab group. Incidence of anti-drug antibodies was observed in 53 patients in EU-infliximab and US-infliximab groups [&lt;ulink linkID="1668731" linkType="Reference"&gt;1668731&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Crohn's disease&lt;/subtitle&gt;In November 2008, Schering-Plough initiated an open-label, randomized, parallel, phase IV trial (&lt;ulink linkID="27572" linkType="Protocol"&gt;NCT00752622&lt;/ulink&gt;, P05587; OPTIMIST) investigating the efficacy of increased dosing with infliximab in patients (expected n = 120) with Crohn's disease not responding to standard of care treatment. Patients received induction therapy with 3 infusions of infliximab at weeks 0, 2 and 6. Those with clinical response at week 10 entered an observational phase and received standard of care treatment with infliximab. Patients with clinical failure were then randomised to receive infliximab 7 mg/kg q8w or infliximab 5 mg/kg q6w. The primary endpoint was clinical response. In April 2009, the expected completion date for this trial was June 2011 [&lt;ulink linkID="1001802" linkType="Reference"&gt;1001802&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2004, Centocor Ortho Biotech and Schering-Plough initiated the phase III SONIC  trial (&lt;ulink linkID="17690" linkType="Protocol"&gt;NCT00094458&lt;/ulink&gt;; CR004804; C0168T67), to evaluate the efficacy of infliximab versus azathioprine in CD,  either alone or in combination for the treatment of patients with CD (n = 508). SONIC was the first trial to compare a biological agent with a conventional therapy in CD. The multicenter, randomized, double-blind, parallel-assignment trial was to involve immunomodulator-naive, biological-naive patients with moderately-to-severely active CD. The primary endpoint of SONIC was steroid-free remission. Secondary endpoints included mucosal healing and aggregate steroid use. The study completed in December 2009 [&lt;ulink linkID="584603" linkType="Reference"&gt;584603&lt;/ulink&gt;], [&lt;ulink linkID="1091031" linkType="Reference"&gt;1091031&lt;/ulink&gt;]. In October 2008, data were presented at the Annual Meeting of the American College of Gastroenterology in Orlando, FL, showing that  at week 26, 57% of patients on infliximab combination therapy and 44% on infliximab monotherapy achieved steroid-free remission, compared with 31% of those on azathioprine alone. A greater proportion of patients also achieved  mucosal healing and the safety profile was similar in each of the groups [&lt;ulink linkID="949035" linkType="Reference"&gt;949035&lt;/ulink&gt;]. In April 2010, similar data were published.  In addition, patients who completed the study were given the option of continuing in a blinded study extension up to 50 weeks; at week 50, infliximab showed similar significant therapeutic benefits over azathioprine monotherapy to those observed at 26 weeks    [&lt;ulink linkID="1090818" linkType="Reference"&gt;1090818&lt;/ulink&gt;], [&lt;ulink linkID="1091077" linkType="Reference"&gt;1091077&lt;/ulink&gt;]. In February 2017, post hoc analysis results were presented from 206 patients at the 12th Congress of ECCO IBD in Barcelona, Spain. At week-30, the proportion of patients who achieved corticosteroid-free remission at week-26 (CSFR26)  in quartile-1, 2, 3 and 4 were 61.54, 65.2, 66.7 and 78.6% (monotherapy), 33.3, 86.2, 73.3 and 71.1% (combination group), respectively. In a subgroup of patients (n = 126), numerically higher proportions achieved mucosal healing at week-26 (MH26 ) in the combination group relative to monotherapy particularly in lower two serum infliximab concentration quartiles and the differences were statistically significant [&lt;ulink linkID="1903303" linkType="Reference"&gt;1903303&lt;/ulink&gt;]. In May 2017, further post-hoc analysis data were presented DDW 2017 in Chicago, IL. While patients on combination therapy were enriched in higher serum infliximab concentration (SIC) quartiles, the proportions of patients achieving CSFR26 were found to be not significantly greater among those receiving combination therapy versus monotherapy within the same quartile (p = 0.11, 0.10, 0.76 and 0.73 in quartile -1, -2, -3 and -4, respectively) [&lt;ulink linkID="1924232" linkType="Reference"&gt;1924232&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Results from the ACCENT II trial, the largest study ever conducted in patients with fistulizing CD, were published in February 2004. In the 54-week study, 36% of patients who received infliximab as a maintenance therapy every eight weeks had complete and durable fistula closure compared with 19% of patients who received placebo maintenance [&lt;ulink linkID="584595" linkType="Reference"&gt;584595&lt;/ulink&gt;]. In March 2019, clinical data were presented at the 14th ECCO Congress on Inflammatory Bowel Diseases in Copenhagen, Denmark. Median infliximab concentrations were significantly higher at week-6 (18.4 versus 15.2 microg/ml, p = 0.038) and week-14 (6.4 versus 3.7 microg/ml, p = 0.001) in patients who achieved complete fistula response at week 14 (CFR14) versus those who did not. Infliximab cut-point concentrations of 13.9 and 4.8 microg/ml at weeks-6 and 14, respectively, were found to be associated with CFR14 [&lt;ulink linkID="2127847" linkType="Reference"&gt;2127847&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2000, a randomized, double-blind, parallel-group, phase III study (&lt;ulink linkID="18035" linkType="Protocol"&gt;NCT00207662&lt;/ulink&gt;; CR004771; ACCENT I) began in the US to assess the safety and efficacy of infliximab in patients with moderately-to-severely active CD (n = 580). The primary endpoint was reduction in signs and symptoms of CD. The study completed in November 2005  [&lt;ulink linkID="1163700" linkType="Reference"&gt;1163700&lt;/ulink&gt;]. In November 2004, data from a meta-analysis of the 54-week ACCENT I  trial demonstrated that patients who received a 3-dose induction regimen of infliximab experienced a significantly greater reduction in pain after 10 weeks, compared with patients who received a single dose of the drug [&lt;ulink linkID="584644" linkType="Reference"&gt;584644&lt;/ulink&gt;]. At week 30, significantly more patients treated with infliximab achieved clinical remission compared with placebo-treated patients, and significantly more infliximab-treated patients were able to discontinue corticosteroid use compared with  patients treated with placebo. In addition, significant improvement from baseline was seen in the  infliximab groups compared with the placebo group in the disease-specific inflammatory bowel disease questionnaire and  the physical component summary score of the general health-related quality of life questionnaire SF-36 at weeks 30 and 54 [&lt;ulink linkID="585004" linkType="Reference"&gt;585004&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 1999, a phase IV, multicenter, long-term, observational study (&lt;ulink linkID="66669" linkType="Protocol"&gt;NCT00553176&lt;/ulink&gt;; CR014140; TREAT) began to assess the clinical, economic and humanistic outcomes of various treatment regimens, including infliximab, in patients with CD (estimated n = 5000) [&lt;ulink linkID="1101397" linkType="Reference"&gt;1101397&lt;/ulink&gt;]. In November 2004, safety data from a subanalysis of the TREAT registry indicated that while severity and duration of disease were associated with the development or exacerbation of intestinal strictures, stenosis or obstruction, the use of infliximab and other CD medications did not appear to contribute to this risk [&lt;ulink linkID="584642" linkType="Reference"&gt;584642&lt;/ulink&gt;]. In May 2010, an analysis of patients treated with either infliximab or other CD therapies was presented at the DDW meeting in New Orleans, LA. The incidence of mortality, malignancies and lymphomas in patients treated with infliximab plus methotrexate was comparable to the incidence observed in patients treated with other therapies. The unadjusted rate of serious infections was significantly increased in infliximab plus methotrexate-treated patients compared with  patients receiving other treatments, and infliximab was defined as a significant predictor of serious infection [&lt;ulink linkID="1091270" linkType="Reference"&gt;1091270&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Behcet's disease&lt;/subtitle&gt;In August 2010, Mitsubishi Tanabe completed a postmarketing surveillance study on patients with refractory uveoretinitis in Behcet's disease. The study confirmed that infliximab was safe for use in patients with refractory uveoretinitis in Behcet's disease following unsuccessful treatment with conventional therapies. The safety profile was very similar to other indications of the drug with serious side effects observed in 4.5% of patients. In addition it was reconfirmed that infliximab controlled ocular attacks and augmented the retention of visual function [&lt;ulink linkID="1125005" linkType="Reference"&gt;1125005&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Ankylosing spondylitis&lt;/subtitle&gt;In October 2013,  data from an ongoing multicenter, prospective, non-interventional, observational study (BioTRAC)  in 230 Canadian AS patients  were presented at the 77th ACR/ARHP Annual Meeting in San Diego CA. Significant improvements in CRP, erythrocyte sedimentation rate (ESR), morning stiffness, HAQ-DI, physician global assessment, bath AS disease activity index, bath spondylitis functional index  and AS disease activity score  were observed  at 6 months of treament and were sustained or further enhanced over 48 months of treatment  [&lt;ulink linkID="1494073" linkType="Reference"&gt;1494073&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Psoriatic arthritis&lt;/subtitle&gt;In October 2013,  data from an ongoing multicenter, prospective, non-interventional, longitudinal, real-world,  observational study (BioTRAC)  in 103 Canadian patients with PsA   were presented at the 77th ACR/ARHP Annual Meeting in San Diego CA. Statistically significant improvements in DAS-28-CRP were observed and were sustained through 12 months of treatment when compared with baseline.  Infliximab treatment effectively reduced the symptom severity and improved outcomes in PsA patients [&lt;ulink linkID="1494077" linkType="Reference"&gt;1494077&lt;/ulink&gt;].  In November 2016, further data from 223 patients were presented at the 80th ACR Annual Meeting in Washington DC. At 6 and 12 months of treatment, 43.5 and 44.8% of patients achieved MDA, respectively. At 6 and 12 months of treatment, the proportion of patients who achieved modified MDA upon eliminating pain increased to 54.3 and 57.1%, respectively;  PtGA to 52.2 and 55.2%, respectively; HAQ to 50.7 and 58.1%, respectively. However, at 6 and 12 months, the removal of objective measures did not increase in substantial manner in the percentage of patients achieving modified MDA: for TJC removal was 46.4 and 50.5%, respectively; for PASI removal was 44.9 and 46.7%, respectively; for SJC removal was 44.2 and 48.6%, respectively; for enthesitis removal was 44.2 and 45.7%, respectively [&lt;ulink linkID="1873887" linkType="Reference"&gt;1873887&lt;/ulink&gt;]. Further data were presented at the same conference. Between regions a statistical trend was observed with respect to MDA achievement at 6 or 12 months of treatment. A total of 55.9 and 52.1% of patients in Ontario and Quebec had the highest MDA rates, while 44.4 and 18.2% of patients in Maritime and Western provinces achieved MDA, respectively [&lt;ulink linkID="1873850" linkType="Reference"&gt;1873850&lt;/ulink&gt;]. Further data were presented at the same conference. The most commonly unmet MDA criteria in patients who achieved 5/7 criteria was patient-reported pain, ptga and HAQ (69.2, 48.4 and 20.5%, respectively); and the mean value was 3.2 and 3.9 cm, and 0.95, respectively. Furthermore, in these patients, pain + PtGA (38.5%) followed by PASI + pain (12.8%) was the most prevalent combination in unmet criteria. The most commonly unmet MDA criteria in patients who achieved 6/7 criteria was PASI, pain and HAQ (21.9, 18.8 and18.8%, respectively); with mean value of 3.7, 2.3 mm and 0.75, respectively [&lt;ulink linkID="1874069" linkType="Reference"&gt;1874069&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Psoriasis&lt;/subtitle&gt;In November 2014, data were presented from a multi-center, longitudinal, prospective, observational study (&lt;ulink linkID="75562" linkType="Protocol"&gt;PSOLAR&lt;/ulink&gt;) which evaluated the long-term safety and efficacy in 12095 patients at the 78th ACR Annual Meeting in Boston, MA. Unadjusted cumulative rates of malignancies (excluding non-melanoma skin cancer)  were in the range of 0.00 to 0.17 per 100 patient years  in &lt;ulink linkID="42858" linkType="Drug"&gt;ustekinumab&lt;/ulink&gt;, infliximab, &lt;ulink linkID="42857" linkType="Drug"&gt;golimumab&lt;/ulink&gt;, other biologicals (&lt;ulink linkID="14163" linkType="Drug"&gt;adalimumab&lt;/ulink&gt; or &lt;ulink linkID="4567" linkType="Drug"&gt;etanercept&lt;/ulink&gt;) and non-biologicals treatment groups [&lt;ulink linkID="1611819" linkType="Reference"&gt;1611819&lt;/ulink&gt;]. In March 2015, further clinical data were presented at the 73rd AAD Annual Meeting in San Francisco, CA. Numerically lower rates of serious infections  were observed in the ustekinumab, etanercept and non-biological groups when compared with those in the infliximab and adalimumab groups. Pneumonia and cellulitis were the most frequently reported infections [&lt;ulink linkID="1644418" linkType="Reference"&gt;1644418&lt;/ulink&gt;]. Further clinical data were also presented at the same conference showing that age and gender adjusted cumulative rates of malignancies (excluding  non-melanoma skin cancer) were 0.51, 0.81, 0.73 and 0.75  events per 100 patient-years for ustekinumab, infliximab, other biologicals and non-biologicals, respectively [&lt;ulink linkID="1644417" linkType="Reference"&gt;1644417&lt;/ulink&gt;]. At the same conference, further clinical data were presented. Age and gender adjusted cumulative rates of major adverse cardiovascular events were 0.35, 0.34, 0.29 and 0.39/100 patient-years for ustekinumab, infliximab/golimumab, other biologicals and non-biologicals groups, respectively [&lt;ulink linkID="1644468" linkType="Reference"&gt;1644468&lt;/ulink&gt;]. Further clinical data were also presented at the same conference showing that ustekinumab exhibited significantly better persistence and lower rates of discontinuation when compared with infliximab, adalimumab and etanercept among bio-naive and biological experienced patients [&lt;ulink linkID="1644443" linkType="Reference"&gt;1644443&lt;/ulink&gt;].   In June 2015, further results were presented at the 16th EULAR Annual European Congress in Rome, Italy. Excluding NMSC, cumulative rates (&amp;gt;/= 10 reported malignancies across treatment groups) of breast, prostate, lung, melanoma, lymphoma, colorectal and thyroid malignancies were 0.03, 0.03, 0.02, 0.07, 0.05, 0.02 and 0.02 with ustekinumab (12,472 patient-years) and were 0.12, 0.04, 0.14, 0.06, 0.04, 0.08 and 0.00 with infliximab (5176 patient-years), respectively [&lt;ulink linkID="1668387" linkType="Reference"&gt;1668387&lt;/ulink&gt;].  Further results were presented at the same conference. Cumulative incidence rate (total n = 11,466) of serious infections was 1.45/100 patient-years. Numerically lower serious infection rates were observed with ustekinumab (0.83/100 patient-years), etanercept (1.47/100 patient-years), methotrexate non-biologic (1.28/100 patient-years), non-methotrexate non-biologic (1.05/100 patient-years) when compared to infliximab (2.49/100 patient-years) and adalimumab (1.97/100 patient-years) [&lt;ulink linkID="1668386" linkType="Reference"&gt;1668386&lt;/ulink&gt;].  Further results were presented at the same conference. Of the 12,095 patients enrolled, majority of patients initiated ustekinumab (n = 1833) and adalimumab (n = 1303) on registry when compared to etanercept (n = 537) and infliximab (n = 327). Patients who received infliximab, adalimumab and etanercept had decreased treatment persistence [&lt;ulink linkID="1668410" linkType="Reference"&gt;1668410&lt;/ulink&gt;]. In March 2016, further clinical data from 2076 patients were presented at the 74th AAD Annual Meeting in Washington DC. At month 6, significantly better responses for PGA score of 0/1 and BSA were observed for ustekinumab when compared with adalimumab and etanercept, and for infliximab for PGA only. At month 12, ustekinumab had numerically better responses for PGA and BSA but statistical significance was not consistently reached when compared with adalimumab, etanercept and infliximab [&lt;ulink linkID="1742563" linkType="Reference"&gt;1742563&lt;/ulink&gt;]. Further results were presented at the same conference. At 6/12 months, the overall mean Dermatology Life Quality Index (DLQI) improvement for ustekinumab, infliximab, adalimumab and etanercept was 6.9/7.5, 6.5/6.9, 4.5/4.9 and 6.2/5.4, respectively [&lt;ulink linkID="1742373" linkType="Reference"&gt;1742373&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2014, data from 50-week analysis of a multicenter, prospective, open-label, observational, phase IV study (REALITY) were presented at the 72nd AAD Annual Meeting in Denver, CO. Patients (n = 521) received infliximab (5 mg/kg) infusion. At week 50, Psoriasis Area and Severity Index 75 (PASI 75) response was achieved by 56.8% of patients, respectively. In biological-naive and –exposed patients, PASI 75 response was achieved by 66.9 and 42.9% of patients, respectively.  At week 50, the proportions of patients who maintained response were 70.4, 64.7 and 56.8% of patients, respectively [&lt;ulink linkID="1537019" linkType="Reference"&gt;1537019&lt;/ulink&gt;]. In October 2014, further data from the trial in 516 patients were presented at the 23rd EADV Congress in Amsterdam, the Netherlands. Patients (n = 114) with PASI 25 entered the extended treatment phase which involved 98 weeks if treatment. Improvement in dermatology life quality index (DLQI) from 12.7 at baseline was 4.7, 3.6, 2.9, and 2.8 at weeks 50, 62, 78, and 98, respectively. From baseline to week 98, 68.6% of patients had &amp;gt;5 DLQI points improvement [&lt;ulink linkID="1600847" linkType="Reference"&gt;1600847&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Other&lt;/subtitle&gt;In June 2017, descriptive analysis data from a retrospective database study which evaluated the real-world treatment patterns of innovator infliximab (Remicade) and biosimilar infliximab (CT-P13) in treatment naive Turkish patients with rheumatologic diseases were presented at the 18th EULAR Annual European Congress of Rheumatology, Madrid, Spain. A total of 1044 patients who were treated with either Remicade (n = 831) or CT-P13 (n = 213) were included. In Remicade and CT-P13 groups, discontinuation of index therapy was observed in 27 and 44%, respectively, at 6-month follow-up and 55 and 63%, respectively, at entire follow-up period. The proportion of patients who switched to another biologic therapy during the entire observation period was 24 and 31%, respectively, in Remicade and CT-P13 groups [&lt;ulink linkID="1935646" linkType="Reference"&gt;1935646&lt;/ulink&gt;].In November 2017, further data were presented at the 81st ACR Annual Meeting in San Diego, CA. Of 19% of patients in continuous cohort who switched to another biologic, 7% switched back to Remicade. Of 82% of patients in switched cohort who switched to another biologic, 72% switched back to Remicade [&lt;ulink linkID="1978364" linkType="Reference"&gt;1978364&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In June 2014, pregnancy outcomes were presented from Nordic REMICADE Pregnancy registry at EULAR 2014 Annual Meeting in Paris, France. Patients who were exposed to infliximab (n = 27), other anti-TNF (n = 281) or non-biological systemic therapy (n = 1903) during or 3 months prior to pregnancy and had live births were included in this analysis. In infants born to infliximab-treated patients, higher incidence of premature births, small for gestational age and low birth weight were reported (22.2, 15.4 and 30.8%, respectively) than those born to mothers treated with other anti-TNF therapies or non-biological systemic therapy [&lt;ulink linkID="1566933" linkType="Reference"&gt;1566933&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2013, data from a prospective, multicenter, observational study (RemiTRAC infusion registry) in 1632 patients with various inflammatory diseases were presented at the 77th ACR/ARHP Annual Meeting in San Diego CA. Infliximab was safe in a real-world setting with a very low incidence rate of infusion reactions. Pre-medication with acetaminophen was associated with low incidence of infusion reactions while histamines and steroids were found to be ineffective [&lt;ulink linkID="1493587" linkType="Reference"&gt;1493587&lt;/ulink&gt;]. In June 2014, further data were presented at EULAR 2014 Annual Meeting in Paris, France. In a multivariate analysis, pre-treatment with antihistamines, number prior infusion reactions, female gender and prior corticosteroid use were significantly associated with increased incidence of infusion reactions (primary endpoint) [&lt;ulink linkID="1563869" linkType="Reference"&gt;1563869&lt;/ulink&gt;].&lt;/para&gt;&lt;/Postmarketing&gt;</value></Postmarketing><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Spondyloarthritis&lt;/subtitle&gt;In November 2012, data from double-blind, randomized controlled trial (&lt;ulink linkID="46137" linkType="Protocol"&gt;INFAST&lt;/ulink&gt;) of infliximab plus naproxen in spondyloarthritis patients (n = 158) were presented at the ACR/ARHP Annual Meeting in Washington DC. There was a steady increase in the partial remission rates with time (weeks 2, 6, 16 and 26) in the infliximab arm (28.6, 41, 51.4 and 61.9%, respectively) as well as in the placebo arm (11.8, 15.7, 25.5 and 35.3%, respectively), and these rates were higher in the infliximab arm at each visit [&lt;ulink linkID="1343258" linkType="Reference"&gt;1343258&lt;/ulink&gt;]. In October 2013,  further data from 156 patients were presented at the 77th ACR/ARHP Annual Meeting in San Diego CA. In the infliximab and placebo groups, the partial remission rate (primary endpoint) in patients with high C-reactive protein (CRP) was higher (71.4 and 40.7%, respectively) than patients with low CRP (59.1 and 38.5%, respectively) [&lt;ulink linkID="1493608" linkType="Reference"&gt;1493608&lt;/ulink&gt;]. In June 2015, further clinical data were presented from part II of this study at the 16th EULAR Annual European Congress in Rome, Italy.​											At week 52, 39.2 and 28.7% of sacroiliac joints quadrents and 8.1 and 14% of vertebral units were reported in the naproxen and no treatment groups, respectively,  affected by inflammation. Overall, treatment with naproxen did not prevent occurrence of new inflammatory lesions which occurred more likely in areas already affected by inflammation in the past [&lt;ulink linkID="1668374" linkType="Reference"&gt;1668374&lt;/ulink&gt;].&lt;br&gt;&lt;/br&gt;&lt;br&gt;&lt;/br&gt;&lt;subtitle&gt;Ulcerative colitis&lt;/subtitle&gt;In 2012, a phase III trial in Japan was initiated in pediatric patients with UC [&lt;ulink linkID="1461753" linkType="Reference"&gt;1461753&lt;/ulink&gt;]. In May 2016, the drug was listed as being under phase III development for pediatric UC in Japan [&lt;ulink linkID="1761876" linkType="Reference"&gt;1761876&lt;/ulink&gt;]. In September 2016, this was still the case [&lt;ulink linkID="1797626" linkType="Reference"&gt;1797626&lt;/ulink&gt;]; however, in November 2016, the indication of pediatric UC was listed as 'deleted' on the company pipeline [&lt;ulink linkID="1868643" linkType="Reference"&gt;1868643&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2012, a multicenter, randomized, double-blind, placebo-controlled, phase III trial (&lt;ulink linkID="85574" linkType="Protocol"&gt;NCT01551290&lt;/ulink&gt;; CTR20132140; REMICADEUCO3001) was initiated in China to evaluate the efficacy and safety of infliximab in Chinese patients (n = 99) with active ulcerative colitis [&lt;ulink linkID="1401782" linkType="Reference"&gt;1401782&lt;/ulink&gt;], [&lt;ulink linkID="1646944" linkType="Reference"&gt;1646944&lt;/ulink&gt;]. In October 2014, the trial was completed [&lt;ulink linkID="1715638" linkType="Reference"&gt;1715638&lt;/ulink&gt;], [&lt;ulink linkID="1401782" linkType="Reference"&gt;1401782&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By November 2007, Japanese phase III trials in UC were underway [&lt;ulink linkID="853099" linkType="Reference"&gt;853099&lt;/ulink&gt;]; in January  2008, Mitsubishi listed infliximab  as being in Japanese phase III trials for UC  [&lt;ulink linkID="901809" linkType="Reference"&gt;901809&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;By October 2006, phase III trials in pediatric UC had been initiated in the US [&lt;ulink linkID="732038" linkType="Reference"&gt;732038&lt;/ulink&gt;]; these trials were ongoing in October 2009 [&lt;ulink linkID="1049480" linkType="Reference"&gt;1049480&lt;/ulink&gt;]. In May 2012, phase III trials began in Japan [&lt;ulink linkID="1312178" linkType="Reference"&gt;1312178&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In September 2006, a multicenter, randomized, open-label, parallel-group, phase III trial (&lt;ulink linkID="17729" linkType="Protocol"&gt;NCT00336492&lt;/ulink&gt;; CR012388; C0168T72) began in North America and Europe to assess the safety and efficacy of infliximab  in pediatric patients aged 6 to 17 years (n = 60) with moderate to severe UC. The primary endpoint was clinical efficacy at week 8, defined as decrease from baseline in Mayo score &amp;gt;/=30% and &amp;gt;/= 3 points, and decrease in rectal bleeding subscore &amp;gt;/=1 or rectal bleeding subscore 0/1.   The study completed in April 2010. In May 2011, data were presented at the Digestive Disease Week (DDW) meeting in Chicago, IL. The trial  reached its primary endpoint, with clinical response observed in 73.3% of patients at week 8;  at that time, 40% of patients were in clinical remission as defined by Mayo score, with 33.3% defined as in remission according to the Pediatric UC Activity Index (PUCAI). In addition, 68.3% of patients achieved mucosal healing at week 8. Patients who achieved clinical response at week 8  were then randomized to receive infliximab every 8 weeks up to week 46,   or every 12 weeks to week 42. At week 54, twice as many patients in the 8-week maintenance group achieved remission (as defined by PUCAI) compared with the 12-week maintenance group  [&lt;ulink linkID="1190210" linkType="Reference"&gt;1190210&lt;/ulink&gt;], [&lt;ulink linkID="1190359" linkType="Reference"&gt;1190359&lt;/ulink&gt;]. In May 2012, pharmacokinetic data were presented at DDW 2012, in San Diego, CA. Half-life and peak serum concentration values for infliximab were mainly consistent for pediatric patients with UC or CD and adult patients with UC, but median steady-state trough serum infliximab concentration was lower in pediatric patients with UC compared with adult patients with UC. These data were reported to support a dosing regimen of 5mg/kg at weeks 0, 2 and 6, followed by maintenance doses of 5mg/kg q8w in pediatric patients aged 6 to 17 years [&lt;ulink linkID="1291769" linkType="Reference"&gt;1291769&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In August 2006, phase III multi-center, randomized, double-blind, parallel-group trial (&lt;ulink linkID="97311" linkType="Protocol"&gt;JapicCTI-060298&lt;/ulink&gt;) began in Japan  to  assess the efficacy and safety of infliximab  in adult patients  with active ulcerative colitis. The primary endpoint was efficacy (clinical response). Other outcomes included safety and pharmacokinetics. The study completed  in  June 2011[&lt;ulink linkID="1338541" linkType="Reference"&gt;1338541&lt;/ulink&gt;]. In February 2015,  results were presented at the 10th Annual ECCO Congress on Inflammatory Bowel Diseases in Barcelona, Spain, that showed, clinical response rate was higher in infliximab-treated patients at week 8 and week 30 (54.8 and 46.2%, respectively) compared to placebo (35.6 and 31.7%, respectively). Clinical remission rate and mucosal healing rates significantly improved  by 20.2 versus 10.6% and  46.2 versus 27.9%, respectively. Early response to the drug was associated with serum levels [&lt;ulink linkID="1641887" linkType="Reference"&gt;1641887&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By January 2004, phase III trials were underway [&lt;ulink linkID="519679" linkType="Reference"&gt;519679&lt;/ulink&gt;]. In December 2004, top-line data from these studies were expected to be presented in May 2005  [&lt;ulink linkID="576598" linkType="Reference"&gt;576598&lt;/ulink&gt;]. In May 2005, results from two phase III trials were presented at the DDW meeting in Chicago, IL. Infliximab resulted in 70% of UC patients experiencing improvement in their symptoms after 8 weeks of therapy. Data from the ACT 1 and ACT 2 studies also revealed that infliximab met primary and secondary endpoints of clinical response, clinical remission and mucosal healing [&lt;ulink linkID="601474" linkType="Reference"&gt;601474&lt;/ulink&gt;].  In October 2005, similar data were presented at the 13th United European Gastroenterology Week meeting in Copenhagen, Denmark. Additional results of an extension of the ACT I trial showed that at 54 weeks, infliximab was associated with maintenance of clinical response, clinical remission and mucosal healing, in addition to remission off steroids [&lt;ulink linkID="629407" linkType="Reference"&gt;629407&lt;/ulink&gt;]. In December 2005, similar data were published [&lt;ulink linkID="639252" linkType="Reference"&gt;639252&lt;/ulink&gt;], [&lt;ulink linkID="639409" linkType="Reference"&gt;639409&lt;/ulink&gt;]. In October 2006, results from an analysis of long-term data from the ACT 1 study showed infliximab-treated patients with UC had an approximate 50% reduction in mean number of hospitalizations per year, compared with placebo [&lt;ulink linkID="733729" linkType="Reference"&gt;733729&lt;/ulink&gt;]. In October 2007, additional data from a primary analysis of long-term extension data from the ACT 1 and 2 trials demonstrated a 41% reduction in colectomy incidence in moderately-to-severely active UC patients taking infliximab through 54 weeks compared with placebo [&lt;ulink linkID="840657" linkType="Reference"&gt;840657&lt;/ulink&gt;]. Further results from ACT 1 and 2 were reported in May 2008 at the DDW meeting in San Diego, CA. Disease duration before infliximab therapy and baseline disease severity had no influence on the efficacy of the drug. An incremental response to the drug was seen after the second and third infusions [&lt;ulink linkID="908275" linkType="Reference"&gt;908275&lt;/ulink&gt;], [&lt;ulink linkID="908303" linkType="Reference"&gt;908303&lt;/ulink&gt;], [&lt;ulink linkID="908271" linkType="Reference"&gt;908271&lt;/ulink&gt;]. In May 2012, further data on the association between serum infliximab concentration and clinical outcomes were presented at DDW 2012, in San Diego, CA. At weeks 8, 30 and 54, with increasing quartiles of infliximab concentrations, the proportion of patients achieving clinical remission, clinical response and mucosal healing increased [&lt;ulink linkID="1292163" linkType="Reference"&gt;1292163&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By September 2000, infliximab was reported to be undergoing phase II trials for UC [&lt;ulink linkID="384704" linkType="Reference"&gt;384704&lt;/ulink&gt;]; in June 2001, trials were reported to be ongoing  [&lt;ulink linkID="412607" linkType="Reference"&gt;412607&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2014, a single-centre, observational, pilot, retrospective, cohort clinical trial (&lt;ulink linkID="171862" linkType="Protocol"&gt;NCT02057016&lt;/ulink&gt;; LTIT-090114) was initiated in Italy in patients (expected n = 258) with inflammatory bowel disease including ulcerative colitis. At that time, the trial was expected to complete in December 2014. In February 2015, the trial was completed [&lt;ulink linkID="1634184" linkType="Reference"&gt;1634184&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Psoriasis&lt;/subtitle&gt;By October 2012, a phase III trial of an increased dose of the drug was underway in Japan [&lt;ulink linkID="1335413" linkType="Reference"&gt;1335413&lt;/ulink&gt;]; in February 2015, the drug was listed as being under phase III development [&lt;ulink linkID="1630728" linkType="Reference"&gt;1630728&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In May 2006, a randomized, parallel-assignment, open-label, phase III extension trial (&lt;ulink linkID="36635" linkType="Protocol"&gt;NCT00358670&lt;/ulink&gt;; P04563; EUDRACT NUMBER: 2005-005367-28; RESTORE 2) to evaluate the long-term efficacy and safety of infliximab began in patients (expected n = 441) with moderate-to-severe plaque-type psoriasis. The primary endpoint was the number of participants who achieved psoriasis area and severity index (PASI) 75  response at week 128. At that time, the trial was estimated to complete in January 2009. However, in February 2009, the study was terminated early because serious infusion reactions were observed in some intermittent therapy patients [&lt;ulink linkID="1225724" linkType="Reference"&gt;1225724&lt;/ulink&gt;]. In February 2011, clinical data were presented at the 69th American Academy of Dermatology Annual Meeting in New Orleans, LA. Patients that had been randomized to infliximab in RESTORE 1 and had achieved  PASI 75 response by the end of the study received 5 mg/kg infliximab as a maintenance (infusions every 8 weeks; n = 222) or intermittent therapy (initiated upon relapse; n = 219). PASI 50, PASI 75 and PASI 90 values showed that greater response rates were achieved by maintenance therapy at most times compared with intermittent therapy [&lt;ulink linkID="1169827" linkType="Reference"&gt;1169827&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2005, a randomized, parallel-assignment, open-label, phase III trial (&lt;ulink linkID="36634" linkType="Protocol"&gt;NCT00251641&lt;/ulink&gt;; P04271; P04271AM2; RESTORE 1) evaluating infliximab versus methotrexate began in patients (expected n = 868) with moderate-to-severe psoriasis. The primary endpoint was  PASI 75 response at week 16. The trial completed in July 2008 [&lt;ulink linkID="1225838" linkType="Reference"&gt;1225838&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2004, clinical data on infliximab were presented at the American Academy of Dermatology Summer meeting in New York, NY. In the phase II, randomized SPIRIT trial, infliximab improved psoriasis of the scalp and lower extremities and provided a significant objective improvement in difficult-to-treat areas. Across all subgroups, infliximab was significantly more effective than placebo. The percentage of patients receiving a PASI score of 75% or above ranged from 69% to 87% in all subgroups at week 14 [&lt;ulink linkID="553857" linkType="Reference"&gt;553857&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2003, data were presented from a trial in patients with severe plaque psoriasis, in which 88% of patients treated with 5 mg/kg infliximab showed a 75% or more improvement in PASI score, compared to 5.9% of patients treated with placebo [&lt;ulink linkID="500260" linkType="Reference"&gt;500260&lt;/ulink&gt;]. In February 2004, an analysis of the double blind, phase II study data was presented. Significantly more patients treated with infliximab achieved PASI 75, compared to placebo-treated patients. The median percentage change from baseline in DLQI at week 10 was a reduction of 84% and 91% respectively for the 3 mg/kg and 5 mg/kg infliximab groups compared with 0% reduction in the placebo group. 33 and 40% of patients receiving infliximab 3 or 5 mg/kg, respectively, had a DLQI score of 0 at week 10. No patients in the placebo group recorded a DLQI score of 0 [&lt;ulink linkID="522130" linkType="Reference"&gt;522130&lt;/ulink&gt;], [&lt;ulink linkID="522646" linkType="Reference"&gt;522646&lt;/ulink&gt;]. Similar data were presented in February 2003 at the 62nd American Academy of Dermatology meeting in Washington, DC [&lt;ulink linkID="524648" linkType="Reference"&gt;524648&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By September 2000, infliximab was reported to be undergoing phase III trials in psoriasis and psoriatic arthritis [&lt;ulink linkID="384704" linkType="Reference"&gt;384704&lt;/ulink&gt;]. These were ongoing in July 2005 [&lt;ulink linkID="614046" linkType="Reference"&gt;614046&lt;/ulink&gt;]. In March 2006, data from the phase III EXPRESS and EXPRESS II studies were presented at the 64th annual American Academy of Dermatology meeting in San Francisco, CA. EXPRESS enrolled 378 patients to receive 5 mg/kg infliximab or placebo at weeks 0, 2 and 6, followed by maintenance treatment every 8 weeks. At week 10, 80% of patients receiving infliximab achieved PASI 75, compared to 3% of placebo patients; 57% of treated patients achieved PASI 90. The drug was well tolerated. EXPRESS II tested induction doses of 3 or 5 mg/kg infliximab at weeks 0, 2 and 6 in 835 patients with moderate-to-severe plaque psoriasis. Patients were then randomized again at week 14 to receive either scheduled or as-needed maintenance treatment. After 10 weeks, 70% of patients on the 3 mg/kg dose and 75% receiving 5 mg/kg had at least 75% improvement in PASI score, compared to 2% of placebo patients. Patients receiving 5 mg/kg every 8 weeks had the highest sustained PASI improvement at 50 weeks. A total of 63% of patients at 3 mg/kg and 69% of 5 mg/kg patients reported adverse events by week 14, compared to 56% in the placebo arm. Serious adverse events occurred in 2% of placebo patients, 3% of 5 mg/kg patients and 1% of the 3 mg/kg group [&lt;ulink linkID="653757" linkType="Reference"&gt;653757&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Rheumatoid arthritis&lt;/subtitle&gt;In June 2013, data were presented from a post-hoc analysis of randomized, double-blind study (RISING; &lt;ulink linkID="16611" linkType="Protocol"&gt;NCT00691028&lt;/ulink&gt;) in 307 Japanese patients at the EULAR 2013 Annual Meeting in Madrid, Spain. At 3, 6 and 10 mg/kg dose levels, simplified disease activity index (SDAI)-remission scores were achieved by 21.2, 33.7 and 32.7% of patients, respectively, and SDAI-low disease activity scores were achieved by 56.6, 64.4 and 69.2% of patients, respectively [&lt;ulink linkID="1439064" linkType="Reference"&gt;1439064&lt;/ulink&gt;]. In June 2016, further data evaluating the influence of baseline rheumatoid factor (RF) and antibodies to citrullinated protein antigens (ACPA) titers on the efficacy of infliximab were presented at the 17th EULAR Annual European Congress of Rheumatology in London, UK. Low, high and intermediate TNF level (median 0.73, 1.15, and 0.91 pg/ml, respectively) was observed in low/low, high/high and middle class, respectively, which correlated with low serum infliximab level and low clinical response. At week 14, high, low and intermediate serum infliximab levels (median 1.5, 0.7, and 0.4 microg/ml, respectively), and low, high and intermediate disease activity score 28-C-reactive protein (median 3.17, 3.53, and 3.82, respectively) was observed in low/low, high/high and middle class, respectively [&lt;ulink linkID="1768042" linkType="Reference"&gt;&lt;/ulink&gt;&lt;ulink linkID="1768071" linkType="Reference"&gt;1768071&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By September 2000, infliximab was reported to be undergoing phase III trials in early RA and juvenile RA [&lt;ulink linkID="384704" linkType="Reference"&gt;384704&lt;/ulink&gt;]. In July 2000, phase III studies in RA were ongoing in Japan, and further trials in other inflammatory diseases were being carried out in the US.&lt;/para&gt;&lt;para&gt;During 1999 and 2000, infliximab was in phase II/III bridging trials for RA [&lt;ulink linkID="352115" linkType="Reference"&gt;352115&lt;/ulink&gt;], [&lt;ulink linkID="347997" linkType="Reference"&gt;347997&lt;/ulink&gt;], [&lt;ulink linkID="391719" linkType="Reference"&gt;391719&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;Results from the ATTRACT (Anti-TNF Trial in RA with Concomitant Therapy) trial served as the basis for the European Type II variation application for infliximab with MTX for the reduction of the signs and symptoms of RA. The double-blind, placebo-controlled, randomized clinical trial involved 428 patients with particularly difficult-to-manage forms of the disease. Results after a year indicate that the therapy is generally well tolerated, with no increased incidence of serious adverse events; there was a significant reduction in the signs and symptoms of arthritis (50% versus 20% for placebo) which was observed as early as 2 weeks and was maintained through 54 weeks of treatment [&lt;ulink linkID="356925" linkType="Reference"&gt;356925&lt;/ulink&gt;]. In July 2000, the Arthritis Advisory Committee to the FDA recommended approval of infliximab with MTX for reduction of structural damage in patients with RA. Infliximab is approved for treatment of RA in patients who have an inadequate response to MTX alone [&lt;ulink linkID="374366" linkType="Reference"&gt;374366&lt;/ulink&gt;]. However, the committee also recommended that Centocor Ortho Biotech conduct further studies to evaluate trough levels of the drug and their relationship to dosage, efficacy and safety [&lt;ulink linkID="376471" linkType="Reference"&gt;376471&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Preliminary findings from a prospective 3-year follow-up study of all patients who participating in Centocor Ortho Biotech-sponsored clinical trials for CD and RA showed that infliximab had a favorable safety profile compared with placebo, with no serious adverse effects identified at that time [&lt;ulink linkID="366759" linkType="Reference"&gt;366759&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Psoriatic arthritis&lt;/subtitle&gt;In June 2017, pooled clinical data from a matching-adjusted indirect comparison of pivotal phase III clinical studies (FUTURE 1, FUTURE 2 and IMPACT 2), which evaluated the comparative efficacy of secukinumab and infliximab, in biologic-naive patients with active psoriatic arthritis were presented at the 18th EULAR Annual European Congress of Rheumatology, Madrid, Spain. In FUTURE 1 study, patients received secukinumab (75 or 150 mg) or placebo, and patients in placebo group were re-randomized (1:1) to receive secukinumab (75 or 150 mg) at week 16 or 24 till week 52. In FUTURE 2 study, patients received secukinumab (75, 150 or 300 mg) or placebo, and placebo treated patients were re-randomized (1:1) to receive secukinumab (75 or 150 mg) at week 16 or 24 till week 52. In IMPACT 2 study, patients were randomized (1:1) to receive infliximab (5 mg/kg) or placebo, and non-responders at week 24 from infliximab treated group received up-titration to 10 mg/kg and placebo treated patients also received infliximab (5 or 10 mg/kg). In placebo-adjusted comparisons, at week 14/16, compared to infliximab treatment, higher change from baseline in SF-36 MCS score was observed in secukinumab treatment group (p = 0.063). In non-placebo-adjusted comparisons, at week 24, compared to infliximab, secukinumab treated patients exhibited higher PASI  75 and 90 response (p = 0.090 and 0.084, respectively) [&lt;ulink linkID="1935806" linkType="Reference"&gt;1935806&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2016, clinical data from two clinical studies (FUTURE 2 and IMPACT 2) were presented at the 80th ACR Annual Meeting in Washington DC. In the IMPACT 2 study, patients (n = 100) were randomized (1:1) to receive infliximab (5 mg/kg, iv). Individual patient's data from the pooled &lt;ulink linkID="55275" linkType="Drug"&gt;secukinumab&lt;/ulink&gt; arm of FUTURE 2 study (n = 299) were weighed to match the aggregate patient's baseline of the infliximab arm of the IMPACT 2 study.  At week-6/8, the proportion of patients in the placebo adjusted group who achieved American college of rheumatology (ACR) scores were 41, 54.9 and 43.7% (ACR 20), 20, 38.7 and 22.7% (ACR 50), 12, 4.6 and 5.8% (ACR 70) in infliximab 5 mg/kg, secukinumab 150 mg and secukinumab 300 mg groups, respectively, whereas those achieved in week-14/16 were 47, 63 and 53.3% (ACR 20), 33, 46.2 and 46.5% (ACR 50), 14, 16.4 and 12.8% (ACR 70) in infliximab 5 mg/kg, secukinumab 150 mg and secukinumab 300 mg groups, respectively. In the non-placebo adjusted groups, 54, 79.6 and 74.9% (ACR 20), 41, 57.7 and 44.5% (ACR 50), 27, 36.5 and 24.3% (ACR 70) in infliximab 5 mg/kg, secukinumab 150 mg and secukinumab 300 mg groups achieved ACR responses at week-24, respectively, and the proportion of patients who achieved ACR responses at week-52/54 were 58.9, 88.2 and 84.5% (ACR 20), 36.7, 44 and 74.2% (ACR 50), 22.2, 20 and 34.2% (ACR 70) in infliximab 5 mg/kg, secukinumab 150 mg and secukinumab 300 mg groups, respectively [&lt;ulink linkID="1873874" linkType="Reference"&gt;1873874&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2005, clinical data on infliximab were presented at the 62nd American Academy of Dermatology meeting in New Orleans, LA. In a randomized phase III trial, the effect of the compound on dactylitis and enthesopathy was tested. Patients (n = 200) were enrolled with active, polyarticular PsA: At least five swollen and tender joints, and failure to respond to DMARDs or NSAIDs. Patients were randomized to infliximab 5 mg/kg or placebo, receiving treatment at weeks 0, 2, 6, 14, and 22. The presence and severity of dactylitis for each digit on both the hands and feet (0 for no dactylitis and 3 for severe dactylitis) was measured, with a total potential score between 0 to 60. Enthesopathy in the feet was also evaluated. All patients reported at least one dactylitis digit at baseline. Infliximab patients showed significant improvement in dactylitis severity score compared with placebo, both at 14 and 24. The proportion of infliximab patients showing dactylitis fell significantly compared with the placebo; 18.2% versus 30.9% at week 14 and 11.8% versus 34.0% at week 24. At baseline, 42% of infliximab patients showed symptoms of enthesopathy, and 35% showed symptoms in the placebo group. Significant reduction of enthesopathy among patients in the infliximab group compared with placebo was noted both at weeks 14 and 24; 22.2% and 20.4% in the infliximab group and 33.7% and 37.2% in the placebo group, respectively [&lt;ulink linkID="588896" linkType="Reference"&gt;588896&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2004, clinical data on infliximab were presented at the 68th Annual Scientific Meeting of the American College of Rheumatology in San Antonio, TX. In the phase III IMPACT 2 study, infliximab provided a 70% improvement or greater in symptoms of arthritis in 27% of patients, compared with 2% of patients on placebo at 24 weeks. Treatment with infliximab also resulted in a 90% or greater improvement in PASI score for nearly 40% of patients and a 100% improvement in PASI score for 21% of patients, compared to none of the placebo patients. Improvements in arthritis and psoriasis were seen as early as week 2 and were maintained throughout the study. Infliximab was well tolerated, no deaths or cases of tuberculosis or other opportunistic infections were reported, and significant laboratory abnormalities were unusual [&lt;ulink linkID="588896" linkType="Reference"&gt;588896&lt;/ulink&gt;]. In June 2005, results were presented at the Annual European Congress of Rheumatology in Vienna, Austria. Radiographic analyses demonstrated that infliximab resulted in a mean change of -0.70 from baseline in structural damage as measured using the van der Heijde-Sharp scoring method. Placebo-treated patients experienced an increase of 0.82. At week 14, 58% of infliximab-treated patients achieved the primary efficacy outcome of ACR 20, compared to 11% of patients receiving placebo. Additionally, at week 14, 64% of patients receiving infliximab experienced PASI 75, compared to 2% of patients receiving placebo.  [&lt;ulink linkID="606767" linkType="Reference"&gt;606767&lt;/ulink&gt;]. Disease improvement was noted with or without the concomitant use of MTX [&lt;ulink linkID="680284" linkType="Reference"&gt;680284&lt;/ulink&gt;]. In November 2011, clinical data from a sub-analysis from the IMPACT-2 study were presented at the ACR/ARHP Annual Meeting in Chicago, IL. Patients with persistent disease activity entered early escape at week 16 and all the remaining patients treated with placebo crossed over to infliximab at week 24. A subset of 37 patients with disease activity and mean C-reactive protein of 3.47 mg/dl was included in the sub-analysis. At week 24, the median changes in digital X-ray radiogrammetry-bone mineral density (DXR-BMD) for all patients were -0.38% (n = 37) and -0.04% at week 54 (n = 26). At week 24, less hand bone loss was observed in the infliximab group (-0.24%) than the placebo group (-0.50%), whereas at week 54, a greater difference in DXR-BMD change was observed between the two groups (+0.41 versus 0.51%) [&lt;ulink linkID="1228645" linkType="Reference"&gt;1228645&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2003, a randomized, double-blind, placebo-controlled, parallel assignment, safety and efficacy,  phase III trial (&lt;ulink linkID="4278" linkType="Protocol"&gt;NCT00051623&lt;/ulink&gt;, CR004789) in patients with psoriatic arthritis (n = 200) was initiated. The primary endpoints were the proportion of patients with American College of Rheumatology 20% improvement (ACR 20) response and the change from baseline in total radiographic scores of hands and feet. The trial was completed in July 2003 and infliximab was found to significantly inhibit radiographic progression in patients with psoriatic arthritis as early as 6 months after starting treatment and the beneficial effect continued through one year of infliximab therapy [&lt;ulink linkID="885030" linkType="Reference"&gt;885030&lt;/ulink&gt;], [&lt;ulink linkID="885952" linkType="Reference"&gt;885952&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In the double-blind, placebo-controlled IMPACT study, 104 patients received infliximab 5 mg/kg or placebo. At week 16, 65% of those taking infliximab achieved ARC 20, and 68% of those with evaluable PsA achieved a 76% improvement in PASI score [&lt;ulink linkID="573924" linkType="Reference"&gt;573924&lt;/ulink&gt;]. In June 2005, 2-year data from IMPACT were also presented at the Annual European Congress of Rheumatology in Vienna, Austria. Infliximab resulted in 62% of patients sustaining ARC 20. A total of 64% of infliximab-treated patients with a baseline PASI score of at least 2.5 achieved a  75 responses. Moreover, patients displayed positive responses in measures of dactylitis and enthesopathy [&lt;ulink linkID="607013" linkType="Reference"&gt;607013&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2000, infliximab data were presented at the 10th Inflammation Research Association National Meeting in Hot Springs, VA.  In a 10-week trial in ten patients with PsA, infliximab improved all clinical parameters. At the end of the trial, all patients achieved ACR 50 and seven achieved ACR 70 responses. Improvement was also observed in two sarcoidosis patients following infusion of infliximab; the effect lasted over 10 months [&lt;ulink linkID="384704" linkType="Reference"&gt;384704&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;OTHER STUDIES&lt;/subtitle&gt;In October 2018, clinical data from Institute of Rheumatology, Rheumatoid Arthritis (IORRA) cohort were presented 82nd ACR Annual Meeting in Chicago, IL. Patients (n = 912) who received DMARDs during the observational period were enrolled. The proportion of methotrexate use, and dose was significantly decreased in patients who received entanercept, &lt;ulink linkID="6259" linkType="Drug"&gt;tocilizumab&lt;/ulink&gt; and abatacept and was significantly increased in patients treated with infliximab and adalimumab [&lt;ulink linkID="2084419" linkType="Reference"&gt;2084419&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2016, clinical data were presented from FLOW study, at the 80th ACR Annual Meeting in Washington DC. Psoriatic arthritis patients (n = 44) with inadequate response to conventional therapy were treated with bDMARDs (infliximab, n = 15; adalimumab, n = 17; certolizumab pegol, n = 1; ustekinumab, n = 7; and secukinumab, n = 4).  Decrease of activated Th1 cells was observed, and disease activity score (DAS28) erythrocyte sedimentation rate (ESR) and Psoriasis Area and Severity Index (PASI) at initiation was 3.58 and 27.8, and at month 6 was 2.65 and 10, respectively in ustekinumab responder. Further, decrease of activated Th1 and Th17 cells was observed, and DAS28 (ESR) and PASI at initiation was 5.28 and 3.1, and at month 6 was 1.54 and 1.2, respectively in adalimumab responder [&lt;ulink linkID="1874041" linkType="Reference"&gt;1874041&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Osteoarthritis&lt;/subtitle&gt;In July 2007, a randomized, double-blind, placebo-controlled, parallel-group, phase IV study (&lt;ulink linkID="67324" linkType="Protocol"&gt;NCT01144143&lt;/ulink&gt;; 10702) began in the US to assess the efficacy of intra-articular infliximab compared with methylprednisolone in patients with osteoarthritis of the knee (n = 16). The primary endpoint was reduction in cellular infiltrates in synovial tissue after  4 weeks. The study completed in January 2011  [&lt;ulink linkID="1163688" linkType="Reference"&gt;1163688&lt;/ulink&gt;]. In June 2012, data were presented at EULAR 2012 in Berlin, Germany. A significant improvement in total WOMAC score was seen with treatment, and high baseline levels of synovial cellularity predicted improvement.  The synovial markers, CD68 macrophages and CD54 ICAM-1, were reduced [&lt;ulink linkID="1299787" linkType="Reference"&gt;1299787&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Behcet's disease&lt;/subtitle&gt;In June 2016, clinical data from a prospective, multicenter study (&lt;ulink linkID="84890" linkType="Protocol"&gt;NCT01532570&lt;/ulink&gt;) were presented in 25 patients at the 17th EULAR Annual European Congress of Rheumatology in London, UK. At week-14 and 30, 61% patients were complete responders and at week-54 and final point of therapy (5 mg/kg), 69 and 67% patients were complete responders, respectively. The serious adverse events reported were worsening and cataract [&lt;ulink linkID="1767872" linkType="Reference"&gt;1767872&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In July 2015, an open-label, single-arm, phase III trial (&lt;ulink linkID="235767" linkType="Protocol"&gt;NCT02505568&lt;/ulink&gt;; CR107121; REMICADEBEC3001) began in patients (expected n = 41) with moderate to severe refractory intestinal Behcet's  disease, in South Korea. The trial was expected to complete in August  2018 [&lt;ulink linkID="1709868" linkType="Reference"&gt;1709868&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2012, data were presented from a prospective, non-comparative, interventional study to assess safety and efficacy of a single iv injection of infliximab in patients (n=15) with acute unilateral posterior uveitis in Behcet's disease at EULAR 2012 in Berlin, Germany. Results suggest that intraocularly produced and/or acting TNF is vital in Behcet's disease-associated uveitis, and as such, intravitreal infliximab could be considered when systemic administration is not feasible [&lt;ulink linkID="1299786" linkType="Reference"&gt;1299786&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2012, Mitsubishi Tanabe initiated a phase III trial for a subtype of Behcet's disease in Japan [&lt;ulink linkID="1288966" linkType="Reference"&gt;1288966&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In clinical studies carried out with infliximab in patients with Behcet's disease, a significant decrease in ocular attacks was seen [&lt;ulink linkID="514105" linkType="Reference"&gt;514105&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By September 2000, infliximab was reported to be undergoing investigation for potential treatment of Behcet's disease [&lt;ulink linkID="384704" linkType="Reference"&gt;384704&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Crohn's disease&lt;/subtitle&gt;In April 2012, Mitsubishi Tanabe initiated a phase III trial for pediatric CD in Japan [&lt;ulink linkID="1288966" linkType="Reference"&gt;1288966&lt;/ulink&gt;].  In February 2015, the drug was listed as being under phase III development for pediatric CD in Japan [&lt;ulink linkID="1630728" linkType="Reference"&gt;1630728&lt;/ulink&gt;]. In September 2016, this was still the case [&lt;ulink linkID="1797626" linkType="Reference"&gt;1797626&lt;/ulink&gt;]; however, in November 2016, the indication of pediatric CD was listed as 'deleted' on the company pipeline [&lt;ulink linkID="1868643" linkType="Reference"&gt;1868643&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By July 2004, infliximab was in phase III trials for maintenance treatment of CD in Japan [&lt;ulink linkID="554411" linkType="Reference"&gt;554411&lt;/ulink&gt;]; in November 2005, these trials were ongoing [&lt;ulink linkID="636682" linkType="Reference"&gt;636682&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By August 2001, a 5000 patient registry, TREAT (Therapy Research Evaluation and Assessment Tool), had enrolled 1200 CD patients [&lt;ulink linkID="421209" linkType="Reference"&gt;421209&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2000, studies presented at the Digestive Disease Week (DDW) meeting in Orlando, FL, reported that significant numbers of patients were able to discontinue steroid use following treatment with infliximab. The &lt;ulink linkID="21111" linkType="Company"&gt;Mayo Clinic&lt;/ulink&gt; conducted a study of 100 patients with refractory and/or fistulizing CD. Of those patients who were receiving infliximab, 73% were able to discontinue steroid use. In addition, 53% of infliximab-treated patients showed remission of inflammatory symptoms; 35% showed closed fistulas; 69% showed improvement in both inflammation and fistulizing disease. Patients in the study received from one to seven infusions of infliximab for a total of 242 infusions administered. Median time to response was 7 days, and median duration of response was 10 weeks [&lt;ulink linkID="366808" linkType="Reference"&gt;366808&lt;/ulink&gt;], [&lt;ulink linkID="368225" linkType="Reference"&gt;368225&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The Center Hospitalier in Luxembourg conducted a multicenter expanded access study in which 146 patients were evaluated. Tests were administered upon entry in the study and 8 weeks after the last infusion in 89 patients (59 with refractory disease and 33 with fistulizing disease). The results showed that the clinical response to infliximab was associated with a significant increase in disease-specific quality-of-life in refractory CD as well as in fistulizing disease [&lt;ulink linkID="368225" linkType="Reference"&gt;368225&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The Beth Israel Deaconess Medical Center in Boston studied 100 patients who received a total of 207 infliximab infusions. Baseline, serial disease and perianal fistula activity were assessed prospectively every 2 weeks for 6 months. In this study 40% of patients were able to discontinue steroid therapy [&lt;ulink linkID="366752" linkType="Reference"&gt;366752&lt;/ulink&gt;], [&lt;ulink linkID="368225" linkType="Reference"&gt;368225&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The use of infliximab in children with refractory CD was being investigated in an open-label collaborative study. Preliminary results (29 patients) presented at DDW 2000 showed that about 75% responded to infliximab (one to three doses of 5 mg/kg iv) although responders tended to relapse after 2 to 3 months. All patients with growth failure showed improvement, and 14 of the 17 steroid-dependent patients were able to discontinue steroid therapy. Further studies are required to determine repeated dosing regimens [&lt;ulink linkID="366397" linkType="Reference"&gt;366397&lt;/ulink&gt;]. A 1-year follow up study showed that there was a remarkably prolonged duration of response to infliximab in &lt;br&gt;&lt;/br&gt; with early CD compared to late CD. No complications or adverse events were reported [&lt;ulink linkID="366805" linkType="Reference"&gt;366805&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In a German multicenter study conducted in collaboration with Essex Pharma in 153 patients with refractory CD, response rates to infliximab (5 mg/kg with additional doses in patients with fistulizing disease) were stable and predictable, with 37% remission and 59% improvement after 4 weeks in non-fistulizing patients, and 41% remission and 70% improvement in fistulizing patients [&lt;ulink linkID="366812" linkType="Reference"&gt;366812&lt;/ulink&gt;]. Preliminary results from a Dutch study were also presented at DDW 2000. This multicenter trial recruited 126 patients with active refractory and fistulizing CD and initial results confirmed that the efficacy of infliximab infusion. Seven patients were identified as having metastatic CD - perineal defects arising from granulomatomous inflammation after proctocolectomy. The effectiveness of infliximab in the treatment of this specific condition was being investigated [&lt;ulink linkID="366871" linkType="Reference"&gt;366871&lt;/ulink&gt;], [&lt;ulink linkID="366876" linkType="Reference"&gt;366876&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The Virginia anti-TNF cooperative study (VACS) was set up to assess the effectiveness of infliximab in clinical practice. Preliminary studies presented at DDW in May 2000 found that early experiences with infliximab use were consistent with the findings of clinical trials [&lt;ulink linkID="366748" linkType="Reference"&gt;366748&lt;/ulink&gt;]. A similar study in Minnesota confirmed these findings whilst reporting that subjective improvement in disease condition may occur without meeting objective criteria [&lt;ulink linkID="366806" linkType="Reference"&gt;366806&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;A survey of infliximab use conducted at Mount Sinai Medical Center in New York suggests that the incidence of short term adverse events was lower then previously reported in clinical trials, but an additional complication, complete bowel obstruction, was observed in ten patients, suggesting that infliximab should be used in care in patients with bowel strictures [&lt;ulink linkID="366815" linkType="Reference"&gt;366815&lt;/ulink&gt;], [&lt;ulink linkID="366816" linkType="Reference"&gt;366816&lt;/ulink&gt;]. The same group also observed that patients with fistulizing CD who do not respond to infliximab therapy after a second infusion are unlikely to respond to a third. The study also revealed that one third of responders are predicted to relapse within two months of the last dose [&lt;ulink linkID="366817" linkType="Reference"&gt;366817&lt;/ulink&gt;]. Pretreatment of fistulizing CD patients with 6-mercaptopurine/azathiopurine may be of benefit in conjunction with infliximab [&lt;ulink linkID="367523" linkType="Reference"&gt;367523&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;According to data published in 2000, short-term remission is a feature of infliximab-treated CD but response duration is unpredictable. Immune activation in the mucosa and periphery can however be used to predict clinical relapse [&lt;ulink linkID="366807" linkType="Reference"&gt;366807&lt;/ulink&gt;] and concomitant use of immunomodulatory drugs may limit responsiveness [&lt;ulink linkID="367033" linkType="Reference"&gt;367033&lt;/ulink&gt;]. Several other studies presented at DDW 2000 attempted to determine further predictive factors of response [&lt;ulink linkID="366819" linkType="Reference"&gt;366819&lt;/ulink&gt;], [&lt;ulink linkID="367029" linkType="Reference"&gt;367029&lt;/ulink&gt;], [&lt;ulink linkID="367030" linkType="Reference"&gt;367030&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2014, a single-centre, observational, pilot, retrospective, cohort clinical trial (&lt;ulink linkID="171862" linkType="Protocol"&gt;NCT02057016&lt;/ulink&gt;; LTIT-090114) was initiated in Italy in patients (expected n = 258) with inflammatory bowel disease including CD. At that time, the trial was expected to complete in December 2014. In February 2015, the trial was completed [&lt;ulink linkID="1634184" linkType="Reference"&gt;1634184&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Ankylosing spondylitis&lt;/subtitle&gt;In June 2012, clinical data were presented at EULAR 2012 in Berlin, Germany. The long-term safety and efficacy of infliximab was evaluated in patients (n = 69) with AS over ten years. Of 29 patients who completed the ten-year study, the AS disease activity score  was I.7 and all other parameters, including bath AS disease activity, functional and meterology indexes, remained low. The drug retained efficacy over the ten years and no new safety signals were reported [&lt;ulink linkID="1296320" linkType="Reference"&gt;1296320&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By May 2007, Japanese phase III studies had been initiated [&lt;ulink linkID="810874" linkType="Reference"&gt;810874&lt;/ulink&gt;]; these were ongoing in January 2008 [&lt;ulink linkID="901809" linkType="Reference"&gt;901809&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2003, data from the phase III ASSERT trial were released. The randomized, placebo-controlled, double-blind study enrolled 279 patients. Patients were given infliximab 5 mg/kg infusions at weeks 0, 2 and 6, followed by infusions every 6 weeks. The primary endpoint of the trial was the proportion of patients demonstrating a 20% or greater improvement in signs and symptoms as measured by the AS assessment (ASAS 20) at 24 weeks. Patients were assessed at baseline and at 24 weeks by standard AS performance scores and by magnetic resonance imaging of their joints. In the infliximab group, 61.2% achieved ASAS 20 compared to 19.2% with placebo-treated patients [&lt;ulink linkID="510394" linkType="Reference"&gt;510394&lt;/ulink&gt;]. In June 2004, data were presented data from two sub-analyses of the ASSERT trial, which showed that patients treated with infliximab experienced improved productivity, including a reduction in missed work days, and improved quality of life. In addition, data confirming the safety and efficacy of infliximab over a 3-year period were presented. After 3 years, infliximab-treated patients had a 60% regression of their disease activity compared to baseline, and showed a 24% improvement in spinal mobility. Mean levels of CRP decreased 88.4% compared to baseline and no major changes in mean ESR were observed. The clinical efficacy of infliximab did not decrease and no major side effects occurred during the third year of therapy [&lt;ulink linkID="544254" linkType="Reference"&gt;544254&lt;/ulink&gt;], [&lt;ulink linkID="544256" linkType="Reference"&gt;544256&lt;/ulink&gt;]. In October 2004, additional clinical data from the ASSERT trial were presented at the 68th Annual Scientific Meeting of the American College of Rheumatology in San Antonio, TX. Patients with active AS treated with infliximab experience a decrease in spinal inflammation activity as measured by magnetic resonance imaging, while patients receiving placebo showed no effect [&lt;ulink linkID="565086" linkType="Reference"&gt;565086&lt;/ulink&gt;], [&lt;ulink linkID="565281" linkType="Reference"&gt;565281&lt;/ulink&gt;], [&lt;ulink linkID="566146" linkType="Reference"&gt;566146&lt;/ulink&gt;]. In June 2007, two- year ASSERT data were presented at the annual European League Against Rheumatism conference in Barcelona, Spain, demonstrating that infliximab patients continued to experience improvement in spinal mobility and sustain reductions in spinal inflammation [&lt;ulink linkID="805090" linkType="Reference"&gt;805090&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2000, results of a trial of infliximab in 11 patients with AS were presented at the 10th Inflammation Research Association National Meeting in Hot Springs, VA. Infliximab infusion every 2 weeks led to a 50% improvement in activity, function, pain scores and quality of life in nine patients [&lt;ulink linkID="384704" linkType="Reference"&gt;384704&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Asthma&lt;/subtitle&gt;In April 2006, at the second Asthma and COPD SMi conference in London, UK, Centocor Ortho Biotech stated that it had completed a clinical trial of infliximab in patients with moderate asthma. Results of a randomized, double-blind, placebo-controlled, parallel-group, pilot study of infliximab (5 mg/kg) on the safety, efficacy and biomarkers of inflammation in patients (n = 38) with moderate asthma receiving ICS are expected to be published 'soon'. A double-blind, placebo-controlled study of the tolerability, safety and activity of infliximab (5 mg/kg) in patients (n = 30) with severe asthma has also been run, with patients receiving therapy at weeks 2, 6, 14 and 22 after therapy initiation. Patients underwent a 4-month safety follow-up period [&lt;ulink linkID="665081" linkType="Reference"&gt;665081&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2006, clinical data on infliximab were presented at the second Asthma and COPD SMi conference in London, UK. In a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-finding study,  the safety and efficacy of infliximab (3 and 5 mg/kg) in symptomatic patients (n = 234) with moderate-to-severe COPD was investigated. Infliximab was administered at 2, 6, 12, 18 and 24 weeks after the start of therapy. Safety follow-ups were carried out at weeks 30, 36 and 44. Preliminary results showed that no treatment benefit was observed in any of the primary or secondary endpoints including forced expiratory volume in one second (FEV1) and quality of life. Trends suggested some functional benefit in the cachectic populations [&lt;ulink linkID="665081" linkType="Reference"&gt;665081&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Congestive heart failure&lt;/subtitle&gt;In August 2000, a randomized, double-blind, placebo-controlled, dose-finding,  phase II trial (ATTACH) was initiated in the US to assess infliximab in subjects (expected n = 150) with class III/IV heart failure associated with a radionuclide left ventricular ejection fraction of &amp;lt;/= 35%. The primary endpoint was improvement in clinical status. The trial was completed in April 2001. Results were reported in July 2003, showing neither dose (5 or 10 mg) of infliximab improved clinical status at 14 weeks and the combined risk of death from any cause or hospitalization for heart failure through 28 weeks increased for patients on the 10 mg dose [&lt;ulink linkID="2051301" linkType="Reference"&gt;2051301&lt;/ulink&gt;]. However, in October 2001, due to  negative preliminary   results, the company announced that further development of infliximab for the treatment of CHF had been put on hold. At that time,  the company was to continue following patients who participated in the trial  [&lt;ulink linkID="428095" linkType="Reference"&gt;428095&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Kawasaki disease&lt;/subtitle&gt;In May 2012, a phase III, randomized, parallel-group, open-label study (&lt;ulink linkID="87374" linkType="Protocol"&gt;NCT01596335&lt;/ulink&gt;; TA-650-22) was initiated in Japan, to evaluate the efficacy and safety of infliximab compared with polyethylene glycol-treated human immunoglobulin (VGIH) in patients (estimated n = 100) with Kawasaki disease refractory to initial therapy with iv immunoglobulin (IVIG). Patients were to receive iv infliximab (5 mg/kg body weight administered over at least 2 h) or iv VGIH (2 g/kg body weight administered over at least 20 h). The primary endpoint was the defervescence rate within 48 h post-treatment. At that time, the study was scheduled to complete in August 2014 [&lt;ulink linkID="1308525" linkType="Reference"&gt;1308525&lt;/ulink&gt;]. In October 2014, the trial was ongoing  [&lt;ulink linkID="1308525" linkType="Reference"&gt;1308525&lt;/ulink&gt;]. By May 2015, efficacy and safety of infliximab had been confirmed in patients with Kawasaki disease [&lt;ulink linkID="1660434" linkType="Reference"&gt;1660434&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In April 2004, a randomized, open-label, active-controlled, parallel-group, phase I study (&lt;ulink linkID="43225" linkType="Protocol"&gt;NCT00271570&lt;/ulink&gt;; 041374, 2004-0548) began in the US to assess the safety of infliximab in patients with acute Kawasaki disease who had failed to become afebril after iv gamma globulin therapy with &lt;ulink linkID="46924" linkType="Drug"&gt;Gammagard&lt;/ulink&gt; (n = 24). The primary endpoint was adverse events. The study completed in October 2006 [&lt;ulink linkID="1163663" linkType="Reference"&gt;1163663&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Hepatitis C virus infection&lt;/subtitle&gt;In July 2005, Schering-Plough began a randomized, open-label, active-controlled, parallel-group, phase III trial (&lt;ulink linkID="12631" linkType="Protocol"&gt;NCT00237484&lt;/ulink&gt;; P04257; P04257AM4; PEGADE) began in Canada to assess the safety and efficacy of infliximab induction therapy followed by &lt;ulink linkID="3364" linkType="Drug"&gt;PEGinterferon alfa-2b&lt;/ulink&gt; plus &lt;ulink linkID="5369" linkType="Drug"&gt;ribavirin&lt;/ulink&gt; in treatment-naive patients with HCV genotype 1 infection (n = 96). The primary endpoint was the proportion of patients that achieved sustained virological response (SVR) at 24 weeks post-treatment. The study was due to complete in June 2011 [&lt;ulink linkID="1163901" linkType="Reference"&gt;1163901&lt;/ulink&gt;].  In November 2012, clinical data were presented at the Liver Meeting 2012 in Boston, MA. It was found that a single dose of infliximab pretreatment did not result in improved SVR, rapid or early virologic responses compared with patients who did not receive infliximab [&lt;ulink linkID="1340422" linkType="Reference"&gt;1340422&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Polymyalgia Rheumatica&lt;/subtitle&gt;In June 2007, a randomized, double-blind, phase III trial (&lt;ulink linkID="80364" linkType="Protocol"&gt;NCT01423591&lt;/ulink&gt;; P04578) was 	initiated in patients (n = 23) with refractory polymyalgia rheumatica in Spain. The trial was expected to complete in December 2011; in August 2011, the trial was ongoing but not recruiting participants [&lt;ulink linkID="1458337" linkType="Reference"&gt;1458337&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Inflammatory bowel disease&lt;/subtitle&gt;In October 2008, an interventional, open label single center pilot, study (&lt;ulink linkID="35855" linkType="Protocol"&gt;NCT00791557&lt;/ulink&gt;: 06-07-14) was initiated to assess the efficacy infliximab in adults (expected n = 2) with inflammatory bowel disease who have moderate to severe pyoderma gangrenosum. The study was completed by February 2010 [&lt;ulink linkID="1875179" linkType="Reference"&gt;1875179&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Cancer&lt;/subtitle&gt;In December 2007,  data were presented at the 49th ASH meeting in Atlanta, GA, from a 37-patient, open-label, two-arm, randomized, phase II trial of two doses of infliximab in patients with  low/intermediate-risk myelodysplastic syndrome (MDS). Patients received infliximab at 3 or 5 mg/kg iv on days 1 and 15, thereafter every 4 weeks, for a total of eight courses; 20 patients completed all courses. In the 3 mg/kg arm, there was one complete response and  one  partial. No patients responded in the 5 mg/kg arm. A total of 21 patients had stable disease, 11  had disease progression and 2 were inevaluable. Three patients died due to infections in the 3 mg/kg arm. The investigators suggested that the results warranted investigation of the drug in combination with other agents for MDS [&lt;ulink linkID="857767" linkType="Reference"&gt;857767&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2006, phase I trial data of infliximab in patients with advanced epithelial ovarian cancer and ascites accumulation were presented at the 97th AACR meeting in Washington DC. In this study, 17 patients were enrolled; six patients received 5 mg/kg and 12 received 10 mg/kg. Infliximab was well tolerated with no toxicities reported. Infliximab was detected in both plasma and ascitic fluid. After 24-h treatment, TNF-alpha protein expression decreased in the ascites of all patients and 11 of 17 patients showed decreased percentage of tumor cells in the ascitic fluid, compared to pretreatment levels (median decrease compared to baseline = 59%; 7 to 72%). The proportion of tumor cells continued to decrease at 48 h in 6 of 17 patients (median decrease compared to baseline = 63%; 10 to 67%) [&lt;ulink linkID="657310" linkType="Reference"&gt;657310&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2004, clinical data on infliximab were presented at the 16th EORTC-NCI-AACR meeting in Geneva, Switzerland. A total of 17 patients with advanced cancer were administered infliximab  (5 mg/kg iv) at  intervals of 4 weeks. Six patients reported a clinical benefit and four had a greater than 20% reduction in fatigue severity score. Four patients died during the study, one due to disease progression, one possibly due to adverse effects of treatment and two from causes probably unrelated to treatment. Eight patients died from disease progression after completing the study and five patients remained alive [&lt;ulink linkID="564755" linkType="Reference"&gt;564755&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In August 1999, The Arizona Cancer Center was conducting a phase II trial for multiple myeloma on behalf of Centocor Ortho Biotech [&lt;ulink linkID="338150" linkType="Reference"&gt;338150&lt;/ulink&gt;]. No further development has since been reported for this indication.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Miscellaneous studies&lt;/subtitle&gt;In  May 2017, results from a study that compared the incidence rates of active tuberculosis in patients treated with ustekinumab versus those treated with infliximab or golimumab using data from company-sponsored, randomized phase II and III studies were presented at the DDW 2017 in Chicago, IL. When compared with anti-TNFalpha treatments infliximab, golimumab, overall number of active tuberculosis cases was low in studies that used the anti-IL12/23 agent ustekinumab (0.5 versus 0.03%, respectively). After adjusting for patient-years, incidence rate of active tuberculosis was lower in patients treated with ustekinumab (0.02 per 100 patient-years) versus those who received infliximab or golimumab (0. 28 per 100 patient-years) [&lt;ulink linkID="1924212" linkType="Reference"&gt;1924212&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2016, data from a Swedish national rheumatology quality register which evaluated the uptake and factors associated with use of originator Remicade and its biosimilar CT-P13 (Remsima, Inflectra) in patients with rheumatic disease were presented at the 80th ACR Annual Meeting in Washington DC. A total of 318, 118 and 608 patients received Remicade, Inflectra and Remsima, respectively. With Remicade as first and second biological (n = 216 and 102), median HAQ was 0.9 and 1.0, respectively; and median disease activity score 28 based on erythrocyte sedimentation rate (DAS28-ESR) was 4.0 and 4.3, respectively. As second or third line of treatment, biosimilars were preferred relative to the originator product (odds ratio of 1.69) when compared to other lines of treatment [&lt;ulink linkID="1874166" linkType="Reference"&gt;1874166&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2016, clinical data from a large, prospective, multinational, observational, real-life cohort study (QUO-VADIS) which evaluated the efficacy of golimumab in patients (expected n = 963) with ankylosing spondylitis were presented at the 17th EULAR Annual European Congress of Rheumatology in London, UK. Patients received &amp;gt;/= 1 dose of either golimumab (n = 751) or infliximab (n = 212). Mean duration of stay for acute care was  3.3 versus 4 h; 1.3 versus 1.1 visits for acute care admissions; 4.1 versus 7.3 days for hospitalization; and 2.1 versus 2.2 visits for outpatient/day care in all treated versus golimumab treated patients at 6 months, respectively. Mean change from baseline in work impairment was -20.9 and -24.3 versus -21.8 and -25.4; activity impairment was -22.7 and -25.9 versus -23.2 and -27.6; presenteeism was -21.6 and -23.5 versus -22.7 and -24.7; and absenteeism was -8.5 and -5.7 versus -8.2 versus -8.5  in all treated patients and golimumab only patients at 3 and 6 months, respectively [&lt;ulink linkID="1768101" linkType="Reference"&gt;1768101&lt;/ulink&gt;]. Further data were presented at the same conference. In all treated and in golimumab-only cohort, over 6 months of treatment with golimumab and infliximab showed improvements from baseline in clinical outcome measurements  (mean bath ankylosing spondylitis disease activity index, bath spondylitis functional index, pegylated glutaminase  disease activity, ankylosing disease activity score  disease activity category of inactive (&amp;lt; 1.3), moderate (&amp;gt;/= 1.3 to &amp;lt;/= 2.1), high (&amp;gt;/= 2.1 to &amp;lt;/= 3.5), very high (&amp;gt; 3.5) and missing,  short form-36  physical component summary scores  and mental component summary scores) [&lt;ulink linkID="1768099" linkType="Reference"&gt;1768099&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2016, data from from Corrona registry evaluating low disease activity (LDA) in rheumatoid arthritis patients initiating infliximab with and without dose escalation were presented at the 17th EULAR Annual European Congress of Rheumatology in London, UK. Biologic-naive patients more likely achieved LDA without escalation (66.7%) than patients who escalated but did not achieve LDA (45.8%). Patients receiving less dose escalations were more likely to reach LDA [&lt;ulink linkID="1768020" linkType="Reference"&gt;1768020&lt;/ulink&gt;]. In November 2016, further clinical data were presented at the 80th ACR Annual Meeting in Washington DC. ). Mean CDAI was 19.6 and 16.6 at time of initiation and at first dose escalation, respectively. In patients with three dose escalations (n = 30), a progressive decrease in mean CDAI from initiation until the second dose escalation was observed and the mean CDAI remained at a plateau. The decrease in mean CDAI was less and the overall level of disease was higher in patients with four dose escalations. Trends in health assessment questionnaire were found to be flat across three dose escalations [&lt;ulink linkID="1873901" linkType="Reference"&gt;1873901&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2016, data from a questionnaire based study which evaluated the patients' experience or satisfaction with iv administered biologic therapy in 100 patients with inflammatory arthritis were presented at the 17th EULAR Annual European Congress of Rheumatology in London, UK. Patients received infliximab (71%), rituximab (12%), tocilizumab (10%), abatacept (6%) or golimumab (1%) with a mean duration of  4.07 years. After receiving the therapy, patients' satisfaction of “extremely favorable” rating was increased from 33 to 71% and this “extremely favorable” was evident in patients with or without previous sc biologic therapy [&lt;ulink linkID="1768033" linkType="Reference"&gt;1768033&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2015, clinical data were presented  a global, randomized, double-blind, placebo-controlled, parallel-group study (PREVENT) at the Digestive Disease Week 2015 in Washington DC.									Patients (n = 297) were equally randomized to receive infliximab (5 mg/kg; n = 147) or placebo (n = 150) at week 0 then q8w thereafter through week 200. The proportion of patients with clinical recurrence and endoscopic recurrence prior to or at week 76 were lower for infliximab compared with placebo, although the difference was not statistically significant [&lt;ulink linkID="1660298" linkType="Reference"&gt;1660298&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2015, clinical data were presented from 85 pubertal adolescents with Crohn's disease who were naïve to infliximab at the 97th Annual Meeting and Exposition of the Endocrine Society in San Diego, CA.  In patients treated with infliximab, testosterone and estradiol levels were increased from 0 to 10 weeks while measures of systemic inflammation were decreased [&lt;ulink linkID="1638076" linkType="Reference"&gt;1638076&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2014,  data  from a 12-month clinical study  in 66 pediatric patients with crohn's disease were presented at the 16th ICE/96th ENDO Joint conference in Chicago, IL.		From baseline to 10 weeks, the serum IGF-1 levels and IGF-1 z-scores were increased, even though one-year IGF-1 z-scores were not significantly different from that of baseline. Peripheral quantitative CT z-scores of bone density and structure were increased with infliximab therapy. In the first 10 weeks, changes in IGF-1 z-scores were associated with increases in trabecular density, cortical thickness  and muscle area [&lt;ulink linkID="1571359" linkType="Reference"&gt;1571359&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2014, data were presented from a clinical trial at the 72nd AAD Annual Meeting in Denver, CO. A total of 61 patients were included in the study. Overall, 62, 31 and 7% of patients had psoriasis, psoriatic arthritis and both. The proportions of patients with live birth, elective abortion and spontaneous abortion were 72.1, 19.7 and 8.2%, respectively [&lt;ulink linkID="1537102" linkType="Reference"&gt;1537102&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In May 2013, data were presented from a prospective observational registry (DEVELOP; included patients from 86 centers in North America and Europe) in inflammatory bowel disease patients at Digestive Disease Week 2013 in Orlando, FL. Of the 4343 patients enrolled, 2586 patients exposed to anti-TNF biologics including 2503 patients  received infliximab (4347 patient years (PY)) and 1757 patients received only non-biologic therapies (3369 PY). Differences in serious infections for immunomodulator exposure within 31 days were not observed [&lt;ulink linkID="1418266" linkType="Reference"&gt;1418266&lt;/ulink&gt;]; later that month, further data  were presented at the  same conference. Malignancies were not reported among 1130 patients who were not exposed to immunomodulators. Patients treated with infliximab showed no significant increase in risk of malignancies [&lt;ulink linkID="1418679" linkType="Reference"&gt;1418679&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2012, results were presented from a retrospective analysis of pediatric Takayasu's Arteritis patients (n=23) treated with infliximab and cyclophosphamide in the US and Brazil  at EULAR 2012 in Berlin, Germany. At 6, 12, 24, and 48 months, no differences were observed between inflammatory markers or angiographic progression in both treatment groups. No serious adverse events were seen with infliximab and sepsis was seen in one patient on cyclophosphamide. Data suggested that INF was not inferior in treatment to CYC, although patient numbers were not large enough for statistical significance [&lt;ulink linkID="1299788" linkType="Reference"&gt;1299788&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2012, clinical data from a retrospective case-control study of 52 patients with inflammatory bowel disease treated with infliximab  maintenance therapy were presented at DDW 2012, in San Diego, CA. Antibodies to infliximab (ATI) were developed after a median of 16 weeks initiation of infliximab and after a median of 5 infusions. ATIs disappeared in 14 patients whereas in 38 patients ATIs persisted. Compared to patients with transient ATIs, patients with sustained ATIs had a two-fold higher risk to suffer an acute infusion reaction. Following dose optimization ATIs were not observed in 57% patients and in the other 43% patients, ATIs disappeared rapidly [&lt;ulink linkID="1292160" linkType="Reference"&gt;1292160&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In June 2001, trials were reported to be ongoing in graft-versus-host disease [&lt;ulink linkID="412607" linkType="Reference"&gt;412607&lt;/ulink&gt;]; however, no development has been reported for graft-versus-host disease since then [&lt;ulink linkID="519679" linkType="Reference"&gt;519679&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By September 2000, infliximab was also thought to have potential use in inflammatory bowel disease-associated arthritis, atherosclerosis and uveitis [&lt;ulink linkID="384704" linkType="Reference"&gt;384704&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In September 2000, positive results were also presented from a 41 year-old female patient with autoimmune hepatitis; hepatic enzymes and erythrocyte sedimentation rate were normalized after three infusions. Improvement were also seen in 15 of 16 patients with ulcerative colitis, and of seven patients hospitalized awaiting colectomy, six avoided surgery as a result of infliximab treatment. A 75% response was seen in acute disease and a 95% response in chronic disease. In another study, infliximab promoted a sustained improvement and 35% increase in FEV1 [&lt;ulink linkID="384704" linkType="Reference"&gt;384704&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;In March 2010, the EMA's PDCO approved a pediatric investigation plan for infliximab in immunology, rheumatology, transplantation, dermatology, gastroenterology and hepatology [&lt;ulink linkID="1086478" linkType="Reference"&gt;1086478&lt;/ulink&gt;]. In September 2011, the PDCO adopted a positive opinion on a compliance check regarding the pediatric investigation plan [&lt;ulink linkID="1224391" linkType="Reference"&gt;1224391&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;Infliximab's mode of action in the treatment of CD is not completely understood and may involve interaction with immune cells. According to studies presented at DDW in May 2000 infliximab has an antiproliferative effect on mucosal lymphocytes [&lt;ulink linkID="366474" linkType="Reference"&gt;366474&lt;/ulink&gt;] and may interact with monocytes or macrophages, but it does not have a direct anti-T-cell effect [&lt;ulink linkID="366367" linkType="Reference"&gt;366367&lt;/ulink&gt;], [&lt;ulink linkID="367057" linkType="Reference"&gt;367057&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><ExpertReview>&lt;para&gt;&lt;subtitle&gt;Dr David Chantry, ICOS Corporation, Bothell, WA, USA&lt;/subtitle&gt;&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;20 January 2000 &lt;/subtitle&gt;&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Synthesis and SAR&lt;/subtitle&gt;Tumor necrosis factor (TNF) has been well-established as a mediator of inflammation. &lt;ulink linkType="Drug" linkID="6850"&gt;Infliximab&lt;/ulink&gt; (cA2/CenTNF) is a chimeric human/mouse monoclonal antibody which binds to and neutralizes the biological activity of TNF. It consists of the constant regions of human (Hu) IgG1, fused to the Fv region of a high affinity neutralizing murine anti-HuTNF antibody [&lt;ulink linkType="reference" linkID="237564"&gt;237564&lt;/ulink&gt;]. The antibody is purified from culture supernatants of a mouse myeloma cell line transfected with the cDNA encoding cA2 [&lt;ulink linkType="reference" linkID="237564"&gt;237564&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Pharmacology&lt;/subtitle&gt;&lt;ulink linkType="Drug" linkID="6850"&gt;Infliximab&lt;/ulink&gt; recognizes human TNF but not lymphotoxin (TNFbeta) [&lt;ulink linkType="reference" linkID="237564"&gt;237564&lt;/ulink&gt;], and neutralizes the biological activity of TNF in a range of in vitro assays, including cell cytotoxicity, mitogenesis, cytokine release and induction of adhesion molecules [&lt;ulink linkType="reference" linkID="237564"&gt;237564&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="237559"&gt;237559&lt;/ulink&gt;]. Transgenic mice, which constitutively express high levels of human TNF, were used to demonstrate the in vivo efficacy of &lt;ulink linkType="Drug" linkID="6850"&gt;infliximab&lt;/ulink&gt; [&lt;ulink linkType="reference" linkID="237559"&gt;237559&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="224224"&gt;224224&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In addition to neutralizing the biological action of TNF, &lt;ulink linkType="Drug" linkID="6850"&gt;infliximab&lt;/ulink&gt; retains the ability to activate complement and is therefore capable of killing cells which express TNF in a membrane-associated form [&lt;ulink linkType="reference" linkID="237558"&gt;237558&lt;/ulink&gt;]. It has been suggested that this may be relevant to its in vivo mechanism of action [&lt;ulink linkType="reference" linkID="237558"&gt;237558&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;An alternative strategy to neutralize TNF has been via the production of recombinant soluble derivatives of the two TNF receptors, p55 (Tenefuse, Ro-45-2081), under development by Hoffman-La Roche, and p75 (Enbrel, TNR001), under development by Immunex. In contrast to &lt;ulink linkType="Drug" linkID="6850"&gt;infliximab&lt;/ulink&gt;, these soluble receptor constructs neutralize both TNF and lymphotoxin [&lt;ulink linkType="reference" linkID="221744"&gt;221744&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="221746"&gt;221746&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Metabolism&lt;/subtitle&gt;&lt;ulink linkType="Drug" linkID="6850"&gt;Infliximab&lt;/ulink&gt; is administered iv. Therapeutic benefit has been reported in both rheumatoid arthritis (RA) and Crohn's disease, at doses of 1 to 20 mg/kg. It is expected that dosing will remain within this range. In patients with Crohn's disease, following a single dose of &lt;ulink linkType="Drug" linkID="6850"&gt;infliximab&lt;/ulink&gt; (5 to 20 mg/kg), free serum &lt;ulink linkType="Drug" linkID="6850"&gt;infliximab&lt;/ulink&gt; could be detected for up to 12 weeks [&lt;ulink linkType="reference" linkID="169204"&gt;169204&lt;/ulink&gt;]. In a study of six patients with HIV who received two infusions of &lt;ulink linkType="Drug" linkID="6850"&gt;infliximab&lt;/ulink&gt; (10 mg/kg, 10 days apart) the serum half-life of the antibody was determined to be 257 +/- 70 h [&lt;ulink linkType="reference" linkID="237591"&gt;237591&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Toxicity&lt;/subtitle&gt;&lt;ulink linkType="Drug" linkID="6850"&gt;Infliximab&lt;/ulink&gt; is generally well tolerated; adverse events associated with treatment are described below.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Clinical Development&lt;/subtitle&gt;&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;RA&lt;/subtitle&gt;In a phase I/II trial 20 Patients with active RA were treated with a single dose of &lt;ulink linkType="Drug" linkID="6850"&gt;infliximab&lt;/ulink&gt; (10 mg/kg). &lt;ulink linkType="Drug" linkID="6850"&gt;Infliximab&lt;/ulink&gt; was generally well tolerated and significant improvements were observed in the Ritchie articular index (p &amp;lt; 0.001), the swollen joint count (p &amp;lt; 0.001) and in the levels of C-reactive protein (CRP) (p &amp;lt; 0.001) [&lt;ulink linkType="reference" linkID="167721"&gt;167721&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In a second study, seven patients with active RA were enrolled in an open-label trial. Patients received up to four cycles of treatment; 20 mg/kg (cycle 1) and 10 mg/kg (cycles 2 to 4). Improvements in clinical and laboratory measures of disease activity were observed following each administration (median improvements in swollen joint count and CRP levels exceeded 80%) [&lt;ulink linkType="reference" linkID="167654"&gt;167654&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Crohn's disease&lt;/subtitle&gt;In an open-label study, five patients with active, steroid-resistant, Crohn's disease (Crohn's disease activity index (CDAI) &gt;150) were treated with a single dose of &lt;ulink linkType="Drug" linkID="6850"&gt;infliximab&lt;/ulink&gt;. The treatment was well tolerated and the CDAI normalized within 4 weeks of treatment and remained stable for up to 8 weeks following cessation of treatment [&lt;ulink linkType="reference" linkID="169204"&gt;169204&lt;/ulink&gt;]. In a separate open-label study, ten patients with active Crohn's disease received a single dose of &lt;ulink linkType="Drug" linkID="6850"&gt;infliximab&lt;/ulink&gt;. Of the patients treated, eight showed a normalization of CDAI scores and healing of ulcerations (demonstrated by colonoscopy). The average duration of response was 4 weeks and the treatment was well tolerated [&lt;ulink linkType="reference" linkID="237688"&gt;237688&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;HIV&lt;/subtitle&gt;Six patients with CD4 counts &amp;lt; 200/mm3 were treated with two infusions of &lt;ulink linkType="Drug" linkID="6850"&gt;infliximab&lt;/ulink&gt; (10 mg/kg), with a 14 day interval between infusions. &lt;ulink linkType="Drug" linkID="6850"&gt;Infliximab&lt;/ulink&gt; was generally well tolerated. The serum half-life of the antibody was 257 +/- 70 h, and no change in CD4 cell counts or plasma HIV RNA levels were observed [&lt;ulink linkType="reference" linkID="237591"&gt;237591&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;RA&lt;/subtitle&gt;73 Patients with active RA were enrolled in a four-center, randomized, placebo-controlled, double-blind trial. Patients received &lt;ulink linkType="Drug" linkID="6850"&gt;infliximab&lt;/ulink&gt; (1 or 10 mg/kg), or placebo, in a single infusion. Analysis of six clinical laboratory parameters of disease activity showed that 2/24 patients in the placebo group had a positive response compared to 11/25 in the 1 mg/kg group (p &amp;lt; 0.0083) and 19/25 in the 10 mg/kg treatment group (p &amp;lt; 0.001) [&lt;ulink linkType="reference" linkID="167650"&gt;167650&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Crohn's disease&lt;/subtitle&gt;Several phase II clinical trials have now been completed. In an initial placebo-controlled double-blind trial, 108 patients received a single infusion of placebo or &lt;ulink linkType="Drug" linkID="6850"&gt;infliximab&lt;/ulink&gt; (5, 10 or 20 mg/kg). Of the patients treated with &lt;ulink linkType="Drug" linkID="6850"&gt;infliximab&lt;/ulink&gt;, 65% achieved a clinical response (p &amp;lt; 0.001), and 33% went into remission within 4 weeks of treatment (p &amp;lt; 0.006) [&lt;ulink linkType="reference" linkID="245966"&gt;245966&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In a follow-up study, repeated administration of &lt;ulink linkType="Drug" linkID="6850"&gt;infliximab&lt;/ulink&gt; was maintained patients in remission. 73 Patients who showed a positive response to a single infusion of &lt;ulink linkType="Drug" linkID="6850"&gt;infliximab&lt;/ulink&gt;, at 8 weeks following treatment, were randomized and at 12 weeks, received four additional infusions of &lt;ulink linkType="Drug" linkID="6850"&gt;infliximab&lt;/ulink&gt; (or placebo) at 8-week intervals. Of the patients who continued to receive &lt;ulink linkType="Drug" linkID="6850"&gt;infliximab&lt;/ulink&gt;, 60% remained in remission. Interestingly, 19% of the placebo group remained in remission, 48 weeks after a single infusion of the antibody [&lt;ulink linkType="reference" linkID="245966"&gt;245966&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In a separate trial, &lt;ulink linkType="Drug" linkID="6850"&gt;infliximab&lt;/ulink&gt; was effective in the treatment of enterocutaneous fistulae (a severe complication of Crohn's disease). 94 Patients were given three &lt;ulink linkType="Drug" linkID="6850"&gt;infliximab&lt;/ulink&gt; infusions, 2 and 4 weeks apart. Of these patients, two thirds showed at least 50% closing of the fistulae (p &amp;lt; 0.002) [&lt;ulink linkType="reference" linkID="245966"&gt;245966&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;HIV&lt;/subtitle&gt;The &lt;ulink linkType="Company" linkID="20520"&gt;National Institute of Allergy and Infectious Diseases&lt;/ulink&gt; is currently conducting a phase II trial of &lt;ulink linkType="Drug" linkID="6850"&gt;infliximab&lt;/ulink&gt; in conjunction with interleukin (IL)-2 treatment [&lt;ulink linkType="reference" linkID="188753"&gt;188753&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;RA&lt;/subtitle&gt;A large-scale multicenter, phase III trial, termed ATTRACT (Anti-TNF in RA with Concomitant Therapy) included 428 patients at 34 sites in US and Europe [&lt;ulink linkType="reference" linkID="304364"&gt;304364&lt;/ulink&gt;]. This double-blind, placebo-controlled, randomized trial was designed to evaluate the safety and efficacy of &lt;ulink linkType="Drug" linkID="6850"&gt;infliximab&lt;/ulink&gt; in combination with methotrexate in patients with active arthritis. &lt;ulink linkType="Drug" linkID="6850"&gt;Infliximab&lt;/ulink&gt; (3 mg/kg iv) or placebo was administered at 0, 2 and 6 weeks, and every 8 weeks thereafter. All patients received methotrexate. Following 30 weeks of treatment 50% of patients receiving &lt;ulink linkType="Drug" linkID="6850"&gt;infliximab&lt;/ulink&gt; showed a reduction in disease severity, as measured by the ACR 20 (a standard rheumatological assessment of disease activity), compared to 20% in the placebo group. Furthermore, analysis of radiographic data at the one-year time point indicated that &lt;ulink linkType="Drug" linkID="6850"&gt;infliximab&lt;/ulink&gt; treatment was arresting the ongoing joint damage. This finding led to the safety monitoring committee recommending that the trial be unblinded to allow patients receiving placebo to receive &lt;ulink linkType="Drug" linkID="6850"&gt;infliximab&lt;/ulink&gt;. &lt;ulink linkType="Company" linkID="26997"&gt;Centocor&lt;/ulink&gt; filed an additional BLA for &lt;ulink linkType="Drug" linkID="6850"&gt;infliximab&lt;/ulink&gt; for the treatment of RA [&lt;ulink linkType="reference" linkID="343887"&gt;343887&lt;/ulink&gt;] and following review, received approval in late 1999.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Crohn's disease&lt;/subtitle&gt;A randomized, multicenter, double-blind, placebo-controlled study was carried out in 94 adult patients who had abdominal or perianal fistulas as a complication of Crohn's disease. Patients were treated with &lt;ulink linkType="Drug" linkID="6850"&gt;infliximab&lt;/ulink&gt; (5 or 10 mg/kg iv) or placebo at 0, 2 and 6 weeks. Of the patients who received 5 and 10 mg/kg, 68 and 56%, respectively, achieved the primary end point (a 50% reduction in the number of draining fistulas) compared to 15% in the placebo group (p &amp;lt; 0.002 and p &amp;lt; 0.02, respectively). The median length of time for which fistulas remained closed was three months.&lt;/para&gt;&lt;para&gt;In a separate phase III trial, 108 patients with moderate-to-severe Crohn's disease were treated with &lt;ulink linkType="Drug" linkID="6850"&gt;infliximab&lt;/ulink&gt; (5 mg/kg) or placebo as a single iv infusion. Of the patients receiving &lt;ulink linkType="Drug" linkID="6850"&gt;infliximab&lt;/ulink&gt;, 82% showed a significant (p &amp;lt; 0.001) improvement in their disease severity as measured by the CDAI at four weeks and 48% achieved remission (p &amp;lt; 0.001). Following four additional infusions, given 8 weeks apart, &lt;ulink linkType="Drug" linkID="6850"&gt;infliximab&lt;/ulink&gt; maintained the initial treatment response and a greater number of &lt;ulink linkType="Drug" linkID="6850"&gt;infliximab&lt;/ulink&gt;-treated patients achieved remission [&lt;ulink linkType="reference" linkID="325711"&gt;325711&lt;/ulink&gt;]. These two studies formed the basis for &lt;ulink linkType="Company" linkID="26997"&gt;Centocor&lt;/ulink&gt; to file a BLA for &lt;ulink linkType="Drug" linkID="6850"&gt;infliximab&lt;/ulink&gt; for the treatment of Crohn's disease.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Side Effects and Contraindications&lt;/subtitle&gt;A range of minor side effects have been reported, including fever, malaise, headaches, nausea, peripheral edema, upper respiratory tract infections and abdominal pain [&lt;ulink linkType="reference" linkID="167650"&gt;167650&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="167654"&gt;167654&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="328734"&gt;328734&lt;/ulink&gt;]. In clinical trials of &lt;ulink linkType="Drug" linkID="6850"&gt;infliximab&lt;/ulink&gt; in psoriasis patients, approximately 5% of patients discontinued treatment, most commonly due to these side effects. The development of autoantibodies, which has been reported for a subset of patients taking &lt;ulink linkType="Drug" linkID="6850"&gt;infliximab&lt;/ulink&gt;, does not lead to the development of the clinical signs of systemic lupus erythematosus [&lt;ulink linkType="reference" linkID="167654"&gt;167654&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Current Opinion&lt;/subtitle&gt;The identification of TNF as a major mediator of inflammation and the subsequent clinical development of TNF antagonists for the treatment of Crohn's disease and RA represents a significant achievement in the area of inflammation research. Initial concerns that anti-TNF therapy may severely compromise the host response to infection appear not to have been borne out in the majority of patients taking &lt;ulink linkType="Drug" linkID="6850"&gt;infliximab&lt;/ulink&gt;. Although in the setting of Crohn's disease, other less severe side effects have caused up to 5% of patients to discontinue treatment with &lt;ulink linkType="Drug" linkID="6850"&gt;infliximab&lt;/ulink&gt;.&lt;/para&gt;&lt;para&gt;The major issue facing the developers of &lt;ulink linkType="Drug" linkID="6850"&gt;infliximab&lt;/ulink&gt; is one of cost. While initial sales of &lt;ulink linkType="Drug" linkID="6850"&gt;infliximab&lt;/ulink&gt; have been robust, the broader inflammation market remains highly segmented and includes many relatively inexpensive therapeutics. It remains to be seen to what extent the impressive clinical efficacy shown by TNF antagonists in the clinic so far, will serve to offset their relatively high cost. &lt;/para&gt;&lt;para&gt;While there is considerable effort focused on the development of orally available, small-molecule inhibitors of TNF, this has not yet translated into clinical success. It is likely that protein-based therapies will remain the only route available for the antagonism of TNF for the foreseeable future. In this context, &lt;ulink linkType="Drug" linkID="6850"&gt;infliximab&lt;/ulink&gt; will continue to compete with the soluble form of the TNF receptor, Enbrel, which is currently approved for RA, and with antibodies to TNF which are currently in development by other companies, including D2E7 (Knoll AG) and &lt;ulink linkType="Drug" linkID="2731"&gt;CDP-571&lt;/ulink&gt; (&lt;ulink linkType="Company" linkID="29901"&gt;Celltech Chiroscience&lt;/ulink&gt; plc), assuming that these drugs successfully negotiate the regulatory hurdles. Nevertheless it would appear that &lt;ulink linkType="Drug" linkID="6850"&gt;infliximab&lt;/ulink&gt; and Enbrel, which are already approved products, will be at an advantage over these other TNF antagonists which are at an earlier stage of clinical development.&lt;/para&gt;</ExpertReview><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1062953">Janssen Biologics BV</Company><Country id="CY">Cyprus</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="84">Crohns disease</Indication><Source id="1501609" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1062953">Janssen Biologics BV</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1781">Psoriatic arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2003-01-01T00:00:00.000Z</StatusDate><Source id="1414388" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17608">Xian-Janssen Pharmaceutical Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="398">Ankylosing spondylitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2007-09-01T00:00:00.000Z</StatusDate><Source id="1268046" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17608">Xian-Janssen Pharmaceutical Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="84">Crohns disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2007-09-01T00:00:00.000Z</StatusDate><Source id="1268046" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19711">Schering-Plough Corp</Company><Country id="GB">UK</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="281">Psoriasis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2005-12-01T00:00:00.000Z</StatusDate><Source id="642831" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="26997">Janssen Biotech Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="337">Ulcerative colitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2006-01-24T00:00:00.000Z</StatusDate><Source id="647339" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="TR">Turkey</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2017-02-28T00:00:00.000Z</StatusDate><Source id="1904530" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="TR">Turkey</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1781">Psoriatic arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2017-02-28T00:00:00.000Z</StatusDate><Source id="1904530" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1035060">Mitsubishi Tanabe Pharma Corp</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="780">Kawasaki disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2015-12-21T00:00:00.000Z</StatusDate><Source id="1722916" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="281">Psoriasis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2009-11-04T00:00:00.000Z</StatusDate><Source id="1054580" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="26997">Janssen Biotech Inc</Company><Country id="NO">Norway</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1781">Psoriatic arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2004-10-21T00:00:00.000Z</StatusDate><Source id="1458649" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17608">Xian-Janssen Pharmaceutical Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="281">Psoriasis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2013-12-31T00:00:00.000Z</StatusDate><Source id="2066111" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1062953">Janssen Biologics BV</Company><Country id="CY">Cyprus</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="281">Psoriasis</Indication><Source id="1501609" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1062953">Janssen Biologics BV</Company><Country id="IS">Iceland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><Source id="1450511" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1062953">Janssen Biologics BV</Company><Country id="ES">Spain</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="84">Crohns disease</Indication><Source id="1362545" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1062953">Janssen Biologics BV</Company><Country id="ES">Spain</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="281">Psoriasis</Indication><Source id="1362545" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1062953">Janssen Biologics BV</Company><Country id="ES">Spain</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="398">Ankylosing spondylitis</Indication><Source id="1362545" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1062953">Janssen Biologics BV</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="84">Crohns disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2003-01-01T00:00:00.000Z</StatusDate><Source id="1414388" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1062953">Janssen Biologics BV</Company><Country id="DK">Denmark</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="84">Crohns disease</Indication><Source id="1427364" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="26997">Janssen Biotech Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="337">Ulcerative colitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2014-01-21T00:00:00.000Z</StatusDate><Source id="1517902" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="26997">Janssen Biotech Inc</Company><Country id="NO">Norway</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2004-10-21T00:00:00.000Z</StatusDate><Source id="1458649" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="26997">Janssen Biotech Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="84">Crohns disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1998-10-13T00:00:00.000Z</StatusDate><Source id="301111" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1062953">Janssen Biologics BV</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="281">Psoriasis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2003-01-01T00:00:00.000Z</StatusDate><Source id="1414388" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="26997">Janssen Biotech Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2018-01-09T00:00:00.000Z</StatusDate><Source id="2124671" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1062953">Janssen Biologics BV</Company><Country id="GR">Greece</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="84">Crohns disease</Indication><Source id="1438015" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="26997">Janssen Biotech Inc</Company><Country id="NO">Norway</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="337">Ulcerative colitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2004-10-21T00:00:00.000Z</StatusDate><Source id="1458649" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1035060">Mitsubishi Tanabe Pharma Corp</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="768">Behcets disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2009-08-11T00:00:00.000Z</StatusDate><Source id="1047222" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1062953">Janssen Biologics BV</Company><Country id="FR">France</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2000-01-03T00:00:00.000Z</StatusDate><Source id="1351880" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="26997">Janssen Biotech Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1781">Psoriatic arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2005-10-18T00:00:00.000Z</StatusDate><Source id="629282" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17332">Johnson &amp; Johnson</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="337">Ulcerative colitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2000-12-28T00:00:00.000Z</StatusDate><Source id="1737842" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1062953">Janssen Biologics BV</Company><Country id="SK">Slovakia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><Source id="1466334" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1781">Psoriatic arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2009-11-04T00:00:00.000Z</StatusDate><Source id="1054580" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="337">Ulcerative colitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2009-11-04T00:00:00.000Z</StatusDate><Source id="1054580" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1035060">Mitsubishi Tanabe Pharma Corp</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2007-10-01T00:00:00.000Z</StatusDate><Source id="836299" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1035060">Mitsubishi Tanabe Pharma Corp</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="398">Ankylosing spondylitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2010-04-30T00:00:00.000Z</StatusDate><Source id="1098694" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1062953">Janssen Biologics BV</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="337">Ulcerative colitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2003-01-01T00:00:00.000Z</StatusDate><Source id="1414388" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1062953">Janssen Biologics BV</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2003-01-01T00:00:00.000Z</StatusDate><Source id="1414388" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="26997">Janssen Biotech Inc</Company><Country id="NO">Norway</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="398">Ankylosing spondylitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2004-10-21T00:00:00.000Z</StatusDate><Source id="1458649" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="26997">Janssen Biotech Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="281">Psoriasis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2006-09-27T00:00:00.000Z</StatusDate><Source id="694230" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="26997">Janssen Biotech Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="337">Ulcerative colitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2018-01-09T00:00:00.000Z</StatusDate><Source id="2124671" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1062953">Janssen Biologics BV</Company><Country id="CY">Cyprus</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><Source id="1501609" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1062953">Janssen Biologics BV</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="398">Ankylosing spondylitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2003-01-01T00:00:00.000Z</StatusDate><Source id="1414388" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1062953">Janssen Biologics BV</Company><Country id="PT">Portugal</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="84">Crohns disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2008-09-01T00:00:00.000Z</StatusDate><Source id="1387614" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="26997">Janssen Biotech Inc</Company><Country id="NO">Norway</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="84">Crohns disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2004-10-21T00:00:00.000Z</StatusDate><Source id="1458649" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="26997">Janssen Biotech Inc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-07-01T00:00:00.000Z</StatusDate><Source id="1184372" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="26997">Janssen Biotech Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2003-08-05T00:00:00.000Z</StatusDate><Source id="500103" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1062953">Janssen Biologics BV</Company><Country id="FR">France</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="84">Crohns disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2000-01-03T00:00:00.000Z</StatusDate><Source id="1351880" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1062953">Janssen Biologics BV</Company><Country id="DK">Denmark</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><Source id="1427364" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="26997">Janssen Biotech Inc</Company><Country id="NO">Norway</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="281">Psoriasis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2004-10-21T00:00:00.000Z</StatusDate><Source id="1458649" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17608">Xian-Janssen Pharmaceutical Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2007-09-01T00:00:00.000Z</StatusDate><Source id="1268046" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="84">Crohns disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2017-02-28T00:00:00.000Z</StatusDate><Source id="1904530" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="26997">Janssen Biotech Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1781">Psoriatic arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2018-01-09T00:00:00.000Z</StatusDate><Source id="2124671" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="26997">Janssen Biotech Inc</Company><Country id="XE">South America</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="337">Ulcerative colitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2014-01-21T00:00:00.000Z</StatusDate><Source id="1517902" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1035060">Mitsubishi Tanabe Pharma Corp</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="84">Crohns disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2007-10-01T00:00:00.000Z</StatusDate><Source id="836299" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1062953">Janssen Biologics BV</Company><Country id="ES">Spain</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><Source id="1362545" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1062953">Janssen Biologics BV</Company><Country id="ES">Spain</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1781">Psoriatic arthritis</Indication><Source id="1362545" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="26997">Janssen Biotech Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="398">Ankylosing spondylitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2005-04-19T00:00:00.000Z</StatusDate><Source id="596330" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1035060">Mitsubishi Tanabe Pharma Corp</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="281">Psoriasis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2010-01-20T00:00:00.000Z</StatusDate><Source id="1069817" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="26997">Janssen Biotech Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="398">Ankylosing spondylitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2018-01-09T00:00:00.000Z</StatusDate><Source id="2124671" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="337">Ulcerative colitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2017-02-28T00:00:00.000Z</StatusDate><Source id="1904530" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="TR">Turkey</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="84">Crohns disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2017-02-28T00:00:00.000Z</StatusDate><Source id="1904530" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="TR">Turkey</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="337">Ulcerative colitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2017-02-28T00:00:00.000Z</StatusDate><Source id="1904530" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1062953">Janssen Biologics BV</Company><Country id="IS">Iceland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="84">Crohns disease</Indication><Source id="1450511" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2017-02-28T00:00:00.000Z</StatusDate><Source id="1904530" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1781">Psoriatic arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2017-02-28T00:00:00.000Z</StatusDate><Source id="1904530" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="26997">Janssen Biotech Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="84">Crohns disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2018-01-09T00:00:00.000Z</StatusDate><Source id="2124671" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="84">Crohns disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2009-11-04T00:00:00.000Z</StatusDate><Source id="1054580" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1062953">Janssen Biologics BV</Company><Country id="ES">Spain</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="337">Ulcerative colitis</Indication><Source id="1362545" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1062953">Janssen Biologics BV</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="84">Crohns disease</Indication><Source id="1437445" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1035060">Mitsubishi Tanabe Pharma Corp</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="337">Ulcerative colitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2010-06-18T00:00:00.000Z</StatusDate><Source id="1121601" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1062953">Janssen Biologics BV</Company><Country id="GR">Greece</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><Source id="1438015" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2009-11-04T00:00:00.000Z</StatusDate><Source id="1054580" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="26997">Janssen Biotech Inc</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="337">Ulcerative colitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2015-09-30T00:00:00.000Z</StatusDate><Source id="1732119" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17608">Xian-Janssen Pharmaceutical Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="337">Ulcerative colitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2019-01-09T00:00:00.000Z</StatusDate><Source id="2110322" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="26997">Janssen Biotech Inc</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="84">Crohns disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2015-09-30T00:00:00.000Z</StatusDate><Source id="1732119" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="26997">Janssen Biotech Inc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="768">Behcets disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2015-07-31T00:00:00.000Z</StatusDate><Source id="1709868" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17332">Johnson &amp; Johnson</Company><Country id="XE">South America</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="84">Crohns disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-07-01T00:00:00.000Z</StatusDate><Source id="1267460" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17332">Johnson &amp; Johnson</Company><Country id="XE">South America</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="337">Ulcerative colitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-07-01T00:00:00.000Z</StatusDate><Source id="1267460" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17332">Johnson &amp; Johnson</Company><Country id="X0">Africa</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1781">Psoriatic arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-07-01T00:00:00.000Z</StatusDate><Source id="1267460" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17332">Johnson &amp; Johnson</Company><Country id="X0">Africa</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="84">Crohns disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-07-01T00:00:00.000Z</StatusDate><Source id="1267460" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17332">Johnson &amp; Johnson</Company><Country id="XJ">Middle East</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="84">Crohns disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-07-01T00:00:00.000Z</StatusDate><Source id="1267460" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17332">Johnson &amp; Johnson</Company><Country id="XE">South America</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="398">Ankylosing spondylitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-07-01T00:00:00.000Z</StatusDate><Source id="1267460" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17332">Johnson &amp; Johnson</Company><Country id="XF">Central America</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="398">Ankylosing spondylitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-07-01T00:00:00.000Z</StatusDate><Source id="1267460" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17332">Johnson &amp; Johnson</Company><Country id="XF">Central America</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-07-01T00:00:00.000Z</StatusDate><Source id="1267460" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17332">Johnson &amp; Johnson</Company><Country id="XJ">Middle East</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="337">Ulcerative colitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-07-01T00:00:00.000Z</StatusDate><Source id="1267460" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17332">Johnson &amp; Johnson</Company><Country id="X0">Africa</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-07-01T00:00:00.000Z</StatusDate><Source id="1267460" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17332">Johnson &amp; Johnson</Company><Country id="XF">Central America</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1781">Psoriatic arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-07-01T00:00:00.000Z</StatusDate><Source id="1267460" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17332">Johnson &amp; Johnson</Company><Country id="XJ">Middle East</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="398">Ankylosing spondylitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-07-01T00:00:00.000Z</StatusDate><Source id="1267460" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17332">Johnson &amp; Johnson</Company><Country id="X0">Africa</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="398">Ankylosing spondylitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-07-01T00:00:00.000Z</StatusDate><Source id="1267460" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17332">Johnson &amp; Johnson</Company><Country id="X0">Africa</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="337">Ulcerative colitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-07-01T00:00:00.000Z</StatusDate><Source id="1267460" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17332">Johnson &amp; Johnson</Company><Country id="XE">South America</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-07-01T00:00:00.000Z</StatusDate><Source id="1267460" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17332">Johnson &amp; Johnson</Company><Country id="XF">Central America</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="84">Crohns disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-07-01T00:00:00.000Z</StatusDate><Source id="1267460" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17332">Johnson &amp; Johnson</Company><Country id="XF">Central America</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="337">Ulcerative colitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-07-01T00:00:00.000Z</StatusDate><Source id="1267460" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17332">Johnson &amp; Johnson</Company><Country id="XJ">Middle East</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-07-01T00:00:00.000Z</StatusDate><Source id="1267460" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17332">Johnson &amp; Johnson</Company><Country id="XE">South America</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1781">Psoriatic arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-07-01T00:00:00.000Z</StatusDate><Source id="1267460" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17332">Johnson &amp; Johnson</Company><Country id="XJ">Middle East</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1781">Psoriatic arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-07-01T00:00:00.000Z</StatusDate><Source id="1267460" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="XF">Central America</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="337">Ulcerative colitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-07-01T00:00:00.000Z</StatusDate><Source id="1267460" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="XJ">Middle East</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="84">Crohns disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-07-01T00:00:00.000Z</StatusDate><Source id="1267460" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="XE">South America</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="398">Ankylosing spondylitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-07-01T00:00:00.000Z</StatusDate><Source id="1267460" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="XE">South America</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="1781">Psoriatic arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-07-01T00:00:00.000Z</StatusDate><Source id="1267460" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="X2">Asia</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="84">Crohns disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-07-01T00:00:00.000Z</StatusDate><Source id="1267460" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="X2">Asia</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-07-01T00:00:00.000Z</StatusDate><Source id="1267460" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="XF">Central America</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="398">Ankylosing spondylitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-07-01T00:00:00.000Z</StatusDate><Source id="1267460" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="XF">Central America</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="1781">Psoriatic arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-07-01T00:00:00.000Z</StatusDate><Source id="1267460" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="X0">Africa</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="84">Crohns disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-07-01T00:00:00.000Z</StatusDate><Source id="1267460" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="X2">Asia</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="337">Ulcerative colitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-07-01T00:00:00.000Z</StatusDate><Source id="1267460" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="XJ">Middle East</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-07-01T00:00:00.000Z</StatusDate><Source id="1267460" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="XF">Central America</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="84">Crohns disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-07-01T00:00:00.000Z</StatusDate><Source id="1267460" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-04-15T00:00:00.000Z</StatusDate><Source id="1184372" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="153">Hepatitis C virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-04-15T00:00:00.000Z</StatusDate><Source id="1184372" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="1781">Psoriatic arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-04-15T00:00:00.000Z</StatusDate><Source id="1184372" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="X0">Africa</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-07-01T00:00:00.000Z</StatusDate><Source id="1267460" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="X0">Africa</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="1781">Psoriatic arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-07-01T00:00:00.000Z</StatusDate><Source id="1267460" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="XJ">Middle East</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="1781">Psoriatic arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-07-01T00:00:00.000Z</StatusDate><Source id="1267460" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="X2">Asia</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="398">Ankylosing spondylitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-07-01T00:00:00.000Z</StatusDate><Source id="1267460" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="XJ">Middle East</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="398">Ankylosing spondylitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-07-01T00:00:00.000Z</StatusDate><Source id="1267460" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="XE">South America</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-07-01T00:00:00.000Z</StatusDate><Source id="1267460" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="XE">South America</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="84">Crohns disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-07-01T00:00:00.000Z</StatusDate><Source id="1267460" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-04-15T00:00:00.000Z</StatusDate><Source id="1184372" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="XF">Central America</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-07-01T00:00:00.000Z</StatusDate><Source id="1267460" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="XJ">Middle East</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="337">Ulcerative colitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-07-01T00:00:00.000Z</StatusDate><Source id="1267460" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="XE">South America</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="337">Ulcerative colitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-07-01T00:00:00.000Z</StatusDate><Source id="1267460" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="X2">Asia</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="1781">Psoriatic arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-07-01T00:00:00.000Z</StatusDate><Source id="1267460" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="X0">Africa</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="398">Ankylosing spondylitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-07-01T00:00:00.000Z</StatusDate><Source id="1267460" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="X0">Africa</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="337">Ulcerative colitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-07-01T00:00:00.000Z</StatusDate><Source id="1267460" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1035060">Mitsubishi Tanabe Pharma Corp</Company><Country id="ID">Indonesia</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2013-01-21T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="26997">Janssen Biotech Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2009-06-08T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="26997">Janssen Biotech Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="245">Osteoarthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2013-12-08T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="26997">Janssen Biotech Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="780">Kawasaki disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2005-10-30T00:00:00.000Z</StatusDate><Source id="1163663" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="26997">Janssen Biotech Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="616">Graft versus host disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2002-12-31T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="26997">Janssen Biotech Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="768">Behcets disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2005-01-25T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="26997">Janssen Biotech Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1185">Chronic obstructive pulmonary disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2014-02-21T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="26997">Janssen Biotech Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="31">Asthma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2008-01-22T00:00:00.000Z</StatusDate><Source id="869409" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19711">Schering-Plough Corp</Company><Country id="ES">Spain</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="2887">Polymyalgia rheumatica</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2013-02-28T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="26997">Janssen Biotech Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1828">Multiple myeloma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-02-28T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="26997">Janssen Biotech Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="153">Hepatitis C virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2012-11-11T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1035060">Mitsubishi Tanabe Pharma Corp</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2013-01-21T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1035060">Mitsubishi Tanabe Pharma Corp</Company><Country id="JP">Japan</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="425">Cachexia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2015-11-30T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1035060">Mitsubishi Tanabe Pharma Corp</Company><Country id="JP">Japan</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1036">Sarcoidosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2015-11-30T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="26997">Janssen Biotech Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="55">Cardiac failure</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2003-04-22T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20315">Tanabe Seiyaku Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="84">Crohns disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2007-10-01T00:00:00.000Z</StatusDate><Source id="836299" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20315">Tanabe Seiyaku Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2007-10-01T00:00:00.000Z</StatusDate><Source id="836299" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="153">Hepatitis C virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2009-11-04T00:00:00.000Z</StatusDate><Source id="1054580" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2009-11-04T00:00:00.000Z</StatusDate><Source id="1054580" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1781">Psoriatic arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2009-11-04T00:00:00.000Z</StatusDate><Source id="1054580" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2009-11-04T00:00:00.000Z</StatusDate><Source id="1054580" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1062953">Janssen Biologics BV</Company><Country id="FR">France</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1999-08-13T00:00:00.000Z</StatusDate><Source id="1351880" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1062953">Janssen Biologics BV</Company><Country id="FR">France</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="84">Crohns disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1999-08-13T00:00:00.000Z</StatusDate><Source id="1351880" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19711">Schering-Plough Corp</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="84">Crohns disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1999-08-23T00:00:00.000Z</StatusDate><Source id="336911" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1062953">Janssen Biologics BV</Company><Country id="ES">Spain</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1781">Psoriatic arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1999-09-01T00:00:00.000Z</StatusDate><Source id="1362545" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1062953">Janssen Biologics BV</Company><Country id="ES">Spain</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="281">Psoriasis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1999-09-01T00:00:00.000Z</StatusDate><Source id="1362545" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1062953">Janssen Biologics BV</Company><Country id="ES">Spain</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1999-09-01T00:00:00.000Z</StatusDate><Source id="1362545" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1062953">Janssen Biologics BV</Company><Country id="ES">Spain</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="337">Ulcerative colitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1999-09-01T00:00:00.000Z</StatusDate><Source id="1362545" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1062953">Janssen Biologics BV</Company><Country id="ES">Spain</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="398">Ankylosing spondylitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1999-09-01T00:00:00.000Z</StatusDate><Source id="1362545" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1062953">Janssen Biologics BV</Company><Country id="ES">Spain</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="84">Crohns disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1999-09-01T00:00:00.000Z</StatusDate><Source id="1362545" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1062953">Janssen Biologics BV</Company><Country id="DK">Denmark</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="84">Crohns disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1999-08-13T00:00:00.000Z</StatusDate><Source id="1427364" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1062953">Janssen Biologics BV</Company><Country id="DK">Denmark</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1999-08-13T00:00:00.000Z</StatusDate><Source id="1427364" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1062953">Janssen Biologics BV</Company><Country id="IS">Iceland</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2000-10-19T00:00:00.000Z</StatusDate><Source id="1451739" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1062953">Janssen Biologics BV</Company><Country id="IS">Iceland</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="84">Crohns disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2000-10-19T00:00:00.000Z</StatusDate><Source id="1451739" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1062953">Janssen Biologics BV</Company><Country id="SK">Slovakia</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1999-08-13T00:00:00.000Z</StatusDate><Source id="1466864" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26997">Janssen Biotech Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="337">Ulcerative colitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-09-01T00:00:00.000Z</StatusDate><Source id="1225323" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17608">Xian-Janssen Pharmaceutical Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="337">Ulcerative colitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2012-03-26T00:00:00.000Z</StatusDate><Source id="1646944" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17608">Xian-Janssen Pharmaceutical Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="281">Psoriasis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2013-05-23T00:00:00.000Z</StatusDate><Source id="1440862" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1035060">Mitsubishi Tanabe Pharma Corp</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="780">Kawasaki disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2012-05-09T00:00:00.000Z</StatusDate><Source id="1308525" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1035060">Mitsubishi Tanabe Pharma Corp</Company><Country id="JP">Japan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="398">Ankylosing spondylitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2010-04-30T00:00:00.000Z</StatusDate><Source id="1098694" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1035060">Mitsubishi Tanabe Pharma Corp</Company><Country id="JP">Japan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="337">Ulcerative colitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2010-06-18T00:00:00.000Z</StatusDate><Source id="1121601" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1035060">Mitsubishi Tanabe Pharma Corp</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1036">Sarcoidosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2005-08-22T00:00:00.000Z</StatusDate><Source id="619481" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1035060">Mitsubishi Tanabe Pharma Corp</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="425">Cachexia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2005-08-22T00:00:00.000Z</StatusDate><Source id="619481" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1035060">Mitsubishi Tanabe Pharma Corp</Company><Country id="JP">Japan</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="780">Kawasaki disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2015-05-15T00:00:00.000Z</StatusDate><Source id="1660434" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1035060">Mitsubishi Tanabe Pharma Corp</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="84">Crohns disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2013-09-30T00:00:00.000Z</StatusDate><Source id="1658315" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1035060">Mitsubishi Tanabe Pharma Corp</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="337">Ulcerative colitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2013-09-30T00:00:00.000Z</StatusDate><Source id="1658315" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17332">Johnson &amp; Johnson</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="337">Ulcerative colitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2000-12-28T00:00:00.000Z</StatusDate><Source id="1737842" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26997">Janssen Biotech Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="153">Hepatitis C virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-07-01T00:00:00.000Z</StatusDate><Source id="1184372" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="337">Ulcerative colitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2009-11-04T00:00:00.000Z</StatusDate><Source id="1054580" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1035060">Mitsubishi Tanabe Pharma Corp</Company><Country id="JP">Japan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="281">Psoriasis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2010-01-20T00:00:00.000Z</StatusDate><Source id="1069817" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1035060">Mitsubishi Tanabe Pharma Corp</Company><Country id="JP">Japan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="780">Kawasaki disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2015-12-21T00:00:00.000Z</StatusDate><Source id="1722916" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1035060">Mitsubishi Tanabe Pharma Corp</Company><Country id="ID">Indonesia</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-07-21T00:00:00.000Z</StatusDate><Source id="1209304" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1035060">Mitsubishi Tanabe Pharma Corp</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-07-21T00:00:00.000Z</StatusDate><Source id="1209304" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26997">Janssen Biotech Inc</Company><Country id="US">US</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="245">Osteoarthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2007-07-31T00:00:00.000Z</StatusDate><Source id="1163688" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19711">Schering-Plough Corp</Company><Country id="ES">Spain</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2887">Polymyalgia rheumatica</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2007-06-30T00:00:00.000Z</StatusDate><Source id="1458337" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26997">Janssen Biotech Inc</Company><Country id="US">US</Country><DevelopmentStatus id="S" sortOrder="6">Suspended</DevelopmentStatus><Indication id="55">Cardiac failure</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-10-01T00:00:00.000Z</StatusDate><Source id="428095" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17608">Xian-Janssen Pharmaceutical Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="281">Psoriasis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2013-10-17T00:00:00.000Z</StatusDate><Source id="1615066" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20315">Tanabe Seiyaku Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2003-07-17T00:00:00.000Z</StatusDate><Source id="501309" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20315">Tanabe Seiyaku Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-06-30T00:00:00.000Z</StatusDate><Source id="492580" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17608">Xian-Janssen Pharmaceutical Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="337">Ulcerative colitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2014-11-15T00:00:00.000Z</StatusDate><Source id="1615054" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20315">Tanabe Seiyaku Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2000-08-01T00:00:00.000Z</StatusDate><Source id="391719" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20315">Tanabe Seiyaku Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="84">Crohns disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1999-09-01T00:00:00.000Z</StatusDate><Source id="347997" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20315">Tanabe Seiyaku Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="84">Crohns disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1998-03-26T00:00:00.000Z</StatusDate><Source id="282255" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20315">Tanabe Seiyaku Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1998-03-19T00:00:00.000Z</StatusDate></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26997">Janssen Biotech Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="337">Ulcerative colitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2012-12-17T00:00:00.000Z</StatusDate><Source id="1354304" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26997">Janssen Biotech Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1781">Psoriatic arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-07-01T00:00:00.000Z</StatusDate><Source id="1184372" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26997">Janssen Biotech Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2011-07-01T00:00:00.000Z</StatusDate><Source id="1184372" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26997">Janssen Biotech Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="84">Crohns disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2018-01-09T00:00:00.000Z</StatusDate><Source id="2124671" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26997">Janssen Biotech Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="398">Ankylosing spondylitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2018-01-09T00:00:00.000Z</StatusDate><Source id="2124671" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19711">Schering-Plough Corp</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="398">Ankylosing spondylitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2003-05-21T00:00:00.000Z</StatusDate><Source id="533721" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26997">Janssen Biotech Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1781">Psoriatic arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2003-07-17T00:00:00.000Z</StatusDate><Source id="500260" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26997">Janssen Biotech Inc</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="398">Ankylosing spondylitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2004-02-29T00:00:00.000Z</StatusDate><Source id="533368" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26997">Janssen Biotech Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="768">Behcets disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2003-05-15T00:00:00.000Z</StatusDate><Source id="492580" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26997">Janssen Biotech Inc</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="398">Ankylosing spondylitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2004-12-20T00:00:00.000Z</StatusDate><Source id="577869" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26997">Janssen Biotech Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="337">Ulcerative colitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2003-07-17T00:00:00.000Z</StatusDate><Source id="500260" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26997">Janssen Biotech Inc</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="1781">Psoriatic arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2004-12-01T00:00:00.000Z</StatusDate><Source id="573924" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26997">Janssen Biotech Inc</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="337">Ulcerative colitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2005-04-19T00:00:00.000Z</StatusDate><Source id="596330" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26997">Janssen Biotech Inc</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1781">Psoriatic arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2005-05-17T00:00:00.000Z</StatusDate><Source id="601834" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26997">Janssen Biotech Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="281">Psoriasis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2000-10-04T00:00:00.000Z</StatusDate><Source id="384704" type="CONFERENCE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26997">Janssen Biotech Inc</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="337">Ulcerative colitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2005-09-16T00:00:00.000Z</StatusDate><Source id="623536" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19711">Schering-Plough Corp</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="337">Ulcerative colitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2006-01-27T00:00:00.000Z</StatusDate><Source id="647468" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26997">Janssen Biotech Inc</Company><Country id="US">US</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="616">Graft versus host disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-06-14T00:00:00.000Z</StatusDate><Source id="412607" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26997">Janssen Biotech Inc</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="281">Psoriasis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2005-09-30T00:00:00.000Z</StatusDate><Source id="629052" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20315">Tanabe Seiyaku Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="768">Behcets disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2003-01-28T00:00:00.000Z</StatusDate><Source id="514105" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26997">Janssen Biotech Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="55">Cardiac failure</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2000-08-31T00:00:00.000Z</StatusDate><Source id="2051301" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26997">Janssen Biotech Inc</Company><Country id="US">US</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="768">Behcets disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2000-10-04T00:00:00.000Z</StatusDate><Source id="384704" type="CONFERENCE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26997">Janssen Biotech Inc</Company><Country id="US">US</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="398">Ankylosing spondylitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2000-10-04T00:00:00.000Z</StatusDate><Source id="384704" type="CONFERENCE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26997">Janssen Biotech Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="337">Ulcerative colitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2000-10-04T00:00:00.000Z</StatusDate><Source id="384704" type="CONFERENCE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26997">Janssen Biotech Inc</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1999-11-11T00:00:00.000Z</StatusDate><Source id="347168" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26997">Janssen Biotech Inc</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="84">Crohns disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1998-08-01T00:00:00.000Z</StatusDate><Source id="295779" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26997">Janssen Biotech Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1828">Multiple myeloma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1999-08-27T00:00:00.000Z</StatusDate><Source id="338150" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26997">Janssen Biotech Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="337">Ulcerative colitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1999-08-27T00:00:00.000Z</StatusDate><Source id="338150" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26997">Janssen Biotech Inc</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1999-08-02T00:00:00.000Z</StatusDate><Source id="334836" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26997">Janssen Biotech Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="84">Crohns disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1997-09-03T00:00:00.000Z</StatusDate><Source id="257039" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26997">Janssen Biotech Inc</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="84">Crohns disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1997-12-30T00:00:00.000Z</StatusDate><Source id="273271" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26997">Janssen Biotech Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><Source id="245966" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26997">Janssen Biotech Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="84">Crohns disease</Indication><Source id="190567" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26997">Janssen Biotech Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><Source id="190567" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20315">Tanabe Seiyaku Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="84">Crohns disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2005-05-12T00:00:00.000Z</StatusDate><Source id="601716" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20315">Tanabe Seiyaku Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="768">Behcets disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2007-01-26T00:00:00.000Z</StatusDate><Source id="760918" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20315">Tanabe Seiyaku Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="398">Ankylosing spondylitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2007-05-09T00:00:00.000Z</StatusDate><Source id="810874" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20315">Tanabe Seiyaku Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="337">Ulcerative colitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2006-12-18T00:00:00.000Z</StatusDate><Source id="755838" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20315">Tanabe Seiyaku Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="281">Psoriasis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2006-12-18T00:00:00.000Z</StatusDate><Source id="755838" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19711">Schering-Plough Corp</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="398">Ankylosing spondylitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2004-07-21T00:00:00.000Z</StatusDate><Source id="550199" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19711">Schering-Plough Corp</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="281">Psoriasis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2005-10-06T00:00:00.000Z</StatusDate><Source id="627104" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19711">Schering-Plough Corp</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1781">Psoriatic arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2004-10-14T00:00:00.000Z</StatusDate><Source id="564519" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19711">Schering-Plough Corp</Company><Country id="DE">Germany</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1781">Psoriatic arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2006-04-27T00:00:00.000Z</StatusDate><Source id="657893" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26997">Janssen Biotech Inc</Company><Country id="US">US</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="31">Asthma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2006-04-27T00:00:00.000Z</StatusDate><Source id="665081" type="CONFERENCE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26997">Janssen Biotech Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1185">Chronic obstructive pulmonary disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2006-04-27T00:00:00.000Z</StatusDate><Source id="665081" type="CONFERENCE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1035060">Mitsubishi Tanabe Pharma Corp</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="398">Ankylosing spondylitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2007-10-01T00:00:00.000Z</StatusDate><Source id="836299" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1035060">Mitsubishi Tanabe Pharma Corp</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="281">Psoriasis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2007-10-01T00:00:00.000Z</StatusDate><Source id="836299" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19711">Schering-Plough Corp</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2005-08-30T00:00:00.000Z</StatusDate><Source id="962951" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1035060">Mitsubishi Tanabe Pharma Corp</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="337">Ulcerative colitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2007-11-01T00:00:00.000Z</StatusDate><Source id="853099" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1035060">Mitsubishi Tanabe Pharma Corp</Company><Country id="JP">Japan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="768">Behcets disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2007-10-01T00:00:00.000Z</StatusDate><Source id="836299" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1035060">Mitsubishi Tanabe Pharma Corp</Company><Country id="JP">Japan</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="281">Psoriasis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2008-02-29T00:00:00.000Z</StatusDate><Source id="957748" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1035060">Mitsubishi Tanabe Pharma Corp</Company><Country id="JP">Japan</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="398">Ankylosing spondylitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2008-09-30T00:00:00.000Z</StatusDate><Source id="957748" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1035060">Mitsubishi Tanabe Pharma Corp</Company><Country id="JP">Japan</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="337">Ulcerative colitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2009-06-30T00:00:00.000Z</StatusDate><Source id="1029779" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26997">Janssen Biotech Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="780">Kawasaki disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2004-04-30T00:00:00.000Z</StatusDate><Source id="1163663" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19711">Schering-Plough Corp</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2000-07-26T00:00:00.000Z</StatusDate><Source id="376121" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19711">Schering-Plough Corp</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="84">Crohns disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2000-10-10T00:00:00.000Z</StatusDate><Source id="385255" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19711">Schering-Plough Corp</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1781">Psoriatic arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2004-12-31T00:00:00.000Z</StatusDate><Source id="657689" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19711">Schering-Plough Corp</Company><Country id="AU">Australia</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2006-03-23T00:00:00.000Z</StatusDate><Source id="657452" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19711">Schering-Plough Corp</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2000-06-29T00:00:00.000Z</StatusDate><Source id="372577" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19711">Schering-Plough Corp</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="281">Psoriasis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2005-12-01T00:00:00.000Z</StatusDate><Source id="642831" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19711">Schering-Plough Corp</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="337">Ulcerative colitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2006-03-09T00:00:00.000Z</StatusDate><Source id="654634" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19711">Schering-Plough Corp</Company><Country id="AU">Australia</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1781">Psoriatic arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2006-03-23T00:00:00.000Z</StatusDate><Source id="657452" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20315">Tanabe Seiyaku Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2003-07-25T00:00:00.000Z</StatusDate><Source id="500704" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20315">Tanabe Seiyaku Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="84">Crohns disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2002-05-31T00:00:00.000Z</StatusDate><Source id="485413" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26997">Janssen Biotech Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2004-09-28T00:00:00.000Z</StatusDate><Source id="596330" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19711">Schering-Plough Corp</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="153">Hepatitis C virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2005-07-31T00:00:00.000Z</StatusDate><Source id="1163901" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19711">Schering-Plough Corp</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2000-02-11T00:00:00.000Z</StatusDate><Source id="344434" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26997">Janssen Biotech Inc</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="281">Psoriasis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2006-09-27T00:00:00.000Z</StatusDate><Source id="694230" type="PR"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="5">Accelerated Approval</RegulatoryDesignation><OwnerCompany id="26997">Janssen Biotech Inc</OwnerCompany><Country id="US">US</Country><Indication id="84">Crohns disease</Indication><AwardedIndication>Treatment of moderately to severely active Crohn’s disease for the reduction of the signs and symptoms, in patients who have an inadequate response to conventional therapies and treatment of patients with fistulizing Crohn’s disease for the reduction in the number of draining enterocutaneous fistulas</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1998-08-24T00:00:00.000Z</MileStoneDate><Source id="301111" type="PR"></Source></Row><Row><RegulatoryDesignation id="5">Accelerated Approval</RegulatoryDesignation><OwnerCompany id="26997">Janssen Biotech Inc</OwnerCompany><Country id="US">US</Country><Indication id="84">Crohns disease</Indication><AwardedIndication>Treatment of moderately to severely active Crohn’s disease for the reduction of the signs and symptoms, in patients who have an inadequate response to conventional therapies and treatment of patients with fistulizing Crohn’s disease for the reduction in the number of draining enterocutaneous fistulas</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="3">Filed</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1997-12-30T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation><OwnerCompany id="26997">Janssen Biotech Inc</OwnerCompany><Country id="US">US</Country><Indication id="337">Ulcerative colitis</Indication><AwardedIndication>Treatment of active Ulcerative colitis (UC)</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2004-12-16T00:00:00.000Z</MileStoneDate><Source id="576598" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1035060">Mitsubishi Tanabe Pharma Corp</OwnerCompany><Country id="JP">Japan</Country><Indication id="768">Behcets disease</Indication><AwardedIndication>Particular type of Behcet's disease (Intestinal Behcet’s disease, Neuro-Behcet’s disease, Vasculo-Behcet’s disease)</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2012-09-13T00:00:00.000Z</MileStoneDate><Source id="1330320" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1035060">Mitsubishi Tanabe Pharma Corp</OwnerCompany><Country id="JP">Japan</Country><Indication id="780">Kawasaki disease</Indication><AwardedIndication>Refractory Kawasaki disease</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2012-09-13T00:00:00.000Z</MileStoneDate><Source id="1330320" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1035060">Mitsubishi Tanabe Pharma Corp</OwnerCompany><Country id="JP">Japan</Country><Indication id="398">Ankylosing spondylitis</Indication><AwardedIndication>Ankylosing spondylitis</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2008-06-06T00:00:00.000Z</MileStoneDate><Source id="957748" type="CORPORATE"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="18077">Merck &amp; Co Inc</OwnerCompany><Country id="AU">Australia</Country><Indication id="291">Rheumatoid arthritis</Indication><AwardedIndication>For reducing the signs and symptoms in patients with moderately to severely active polyarticular-course juvenile rheumatoid arthritis (JRA) who have had an inadequate response to methotrexate.</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2005-10-12T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="26997">Janssen Biotech Inc</OwnerCompany><Country id="US">US</Country><Indication id="337">Ulcerative colitis</Indication><AwardedIndication>Treatment of pediatric (0 to 16 years of age) ulcerative colitis</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2003-11-12T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="26997">Janssen Biotech Inc</OwnerCompany><Country id="US">US</Country><Indication id="84">Crohns disease</Indication><AwardedIndication>Treatment of pediatric (0 to 16 years of age) Crohn's Disease</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2003-11-12T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="26997">Janssen Biotech Inc</OwnerCompany><Country id="US">US</Country><Indication id="1036">Sarcoidosis</Indication><AwardedIndication>Treatment of chronic sarcoidosis</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2003-05-21T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1035060">Mitsubishi Tanabe Pharma Corp</OwnerCompany><Country id="JP">Japan</Country><Indication id="768">Behcets disease</Indication><AwardedIndication>Treatment of intractable retinal uveitis due to Behçet's disease</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2002-03-15T00:00:00.000Z</MileStoneDate><Source id="492580" type="CORPORATE"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="26997">Janssen Biotech Inc</OwnerCompany><Country id="US">US</Country><Indication id="84">Crohns disease</Indication><AwardedIndication>Treatment of Crohn's disease</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1995-11-14T00:00:00.000Z</MileStoneDate></Row></RegulatoryDesignationStatus><Targets><Target id="PTGT-03212"><Name>Tumor necrosis factor ligand</Name><SwissprotNumbers></SwissprotNumbers></Target><Target id="PTGT-07179"><Name>TNF alpha ligand</Name><SwissprotNumbers><Swissprot>O35734</Swissprot><Swissprot>O77510</Swissprot><Swissprot>O77764</Swissprot><Swissprot>P01375</Swissprot><Swissprot>P04924</Swissprot><Swissprot>P06804</Swissprot><Swissprot>P13296</Swissprot><Swissprot>P16599</Swissprot><Swissprot>P19101</Swissprot><Swissprot>P23383</Swissprot><Swissprot>P23563</Swissprot><Swissprot>P29553</Swissprot><Swissprot>P33620</Swissprot><Swissprot>P36939</Swissprot><Swissprot>P48094</Swissprot><Swissprot>P51435</Swissprot><Swissprot>P51742</Swissprot><Swissprot>P51743</Swissprot><Swissprot>P59684</Swissprot><Swissprot>P59693</Swissprot><Swissprot>P59694</Swissprot><Swissprot>P59695</Swissprot><Swissprot>P79337</Swissprot><Swissprot>P79374</Swissprot><Swissprot>Q06599</Swissprot><Swissprot>Q19LH4</Swissprot><Swissprot>Q1G1A2</Swissprot><Swissprot>Q1WM27</Swissprot><Swissprot>Q2MH05</Swissprot><Swissprot>Q539C2</Swissprot><Swissprot>Q75N23</Swissprot><Swissprot>Q8HZD9</Swissprot><Swissprot>Q8JFG3</Swissprot><Swissprot>Q8MKG8</Swissprot><Swissprot>Q8WNR1</Swissprot><Swissprot>Q9BEA1</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1022450">Mitsubishi Chemical Holdings Corp</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1042344">American Cancer Society</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="17332">Johnson &amp; Johnson</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="18077">Merck &amp; Co Inc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="20646">New York University</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="24839">Harvard Medical School</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="DOL1000090">Royalty Pharma</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="13">Drug - Funding</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>2</CountActive><CountInactive>0</CountInactive><CountTotal>2</CountTotal></Type><Type><Type sortOrder="5">Drug - Commercialization License</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><Deals><Deal id="108141" title="Schering-Plough to market Centocor's infliximab and develop Centocor's golimumab worldwide excluding North, Central and South America, Japan and other Asia Pacific territories, the Middle East and Africa "></Deal><Deal id="118463" title="Mitsubishi Tanabe to develop Centocor's infliximab in Japan "></Deal><Deal id="135483" title="Royalty Pharma to acquire New York University's Remicade royalty"></Deal><Deal id="246919" title="ACS to award Dana-Farber funding to support the studies on ipilimumab-induced colitis treatment"></Deal></Deals><PatentFamilies><PatentFamily id="105753" number="WO-2005117966" title="Method to reduce hepatotoxicity of Fas-mediated apoptosis-inducing agents"></PatentFamily><PatentFamily id="1068579" number="US-20060051353" title="Methods and compositions to evaluate antibody treatment response"></PatentFamily><PatentFamily id="1084167" number="WO-2009126682" title="Use of a combination of olopatadine and cilomilast to treat non-infectious rhinitis and allergic conjunctivitis"></PatentFamily><PatentFamily id="1087528" number="WO-2005011689" title="Trans-capsular administration of high specificity cytokine inhibitors into orthopedic joints"></PatentFamily><PatentFamily id="1088991" number="WO-2004082635" title="Methods and compositions related to joint inflammation diseases"></PatentFamily><PatentFamily id="1089613" number="WO-2005117969" title="Solution phase biopanning method using engineered decoy proteins "></PatentFamily><PatentFamily id="1099528" number="WO-2004098598" title="Composition comprising roflumilast and a TNFα antagonist"></PatentFamily><PatentFamily id="1118191" number="WO-2005118646" title="Epitope directed selection of antibodies to murine tissue factor "></PatentFamily><PatentFamily id="1174641" number="WO-2005110452" title="Multiple-variable dose regimen for treating TNFα-related disorders"></PatentFamily><PatentFamily id="1235940" number="WO-2008127975" title="Use of an inhibitor of TNFa plus an antihistamine to treat allergic rhinitis and allergic conjunctivitis"></PatentFamily><PatentFamily id="1289165" number="WO-2004060920" title="Complexes of protein crystals and ionic polymers"></PatentFamily><PatentFamily id="1290200" number="WO-2005092366" title="Treatment of neurological conditions using complement C5a receptor modulators"></PatentFamily><PatentFamily id="1293789" number="WO-2008028044" title="Markers and methods for assessing and treating ulcerative colitis and related disorders using 66 gene panel"></PatentFamily><PatentFamily id="1294459" number="WO-2008137383" title="Markers and methods for assessing and treating ulcerative colitis and related disorders using a 19 gene panel"></PatentFamily><PatentFamily id="1294491" number="WO-2008142405" title="Method for predicting the response of a patient to treatment with an anti-TNFα antibody"></PatentFamily><PatentFamily id="1306844" number="WO-2010009377" title="Methods and compositions for pharmacogenetic analysis of anti-inflammatory drugs in the treatment of rheumatoid arthritis and other inflammatory diseases"></PatentFamily><PatentFamily id="1312830" number="WO-2009117791" title="Mucosal gene signatures"></PatentFamily><PatentFamily id="1329218" number="WO-2009147362" title="Method of rheumatoid arthritis treatment"></PatentFamily><PatentFamily id="1329534" number="WO-2009132863" title="Knock-in mouse for modelling blockade of human TNF-alpha"></PatentFamily><PatentFamily id="1362824" number="WO-2004035080" title="Treatment of hypersensitivity conditions"></PatentFamily><PatentFamily id="1379556" number="US-20090142769" title="Methods for determining anti-TNF therapeutic response"></PatentFamily><PatentFamily id="1413902" number="WO-2011056590" title="Assays for the detection of anti-TNF drugs and autoantibodies"></PatentFamily><PatentFamily id="1439102" number="US-20060094645" title="Method for defining and treating chemically-induced immune disorders using tumor necrosis factor (TNF-alpha), interleukin-1 (IL-1), and interleulin-6R (IL-6R) antagonists"></PatentFamily><PatentFamily id="1441433" number="WO-2007123976" title="Antibody profiling for determination of patient responsiveness"></PatentFamily><PatentFamily id="1456913" number="WO-2009052140" title="Use of tnf receptor antagonists for treating dry eye"></PatentFamily><PatentFamily id="1470705" number="WO-2006017574" title="Improving treatments"></PatentFamily><PatentFamily id="1474914" number="WO-2007137275" title="Stimulators of osteoblastogenesis and applications of the same"></PatentFamily><PatentFamily id="149741" number="WO-2012054532" title="Methods for determining anti-drug antibody isotypes"></PatentFamily><PatentFamily id="1509425" number="WO-00172298" title="Treatments for immune-mediated ear disorders"></PatentFamily><PatentFamily id="1511781" number="WO-2005067454" title="Combination therapy for treating hepatitis C virus infection"></PatentFamily><PatentFamily id="1512834" number="WO-2006050050" title="Chemically defined media compositions"></PatentFamily><PatentFamily id="1512933" number="US-20050255104" title="Methods of treating psoriasis using anti-TNF receptor fusion proteins"></PatentFamily><PatentFamily id="1515305" number="WO-2007135568" title="A method for predicting responsiveness to TNFα blocking agents"></PatentFamily><PatentFamily id="151620" number="WO-2010042634" title="Use of IL-20 antagonists for treating rheumatoid arthritis and osteoporosis"></PatentFamily><PatentFamily id="1549929" number="WO-03084386" title="Methods for ultrasonic imaging and treating diseased tissues"></PatentFamily><PatentFamily id="1558327" number="WO-2011015916" title="Vectors and compounds for expression of recombinant infliximab"></PatentFamily><PatentFamily id="1594715" number="WO-2009047001" title="Non-thiopurine methyltransferase related effects in 6-mercaptopurine therapy"></PatentFamily><PatentFamily id="1622320" number="WO-09408619" title="Treatment of autoimmune and inflammatory disorders."></PatentFamily><PatentFamily id="1632220" number="WO-2010025340" title="Markers and methods for assessing and treating ulcerative colitis and related disorders using a 20 gene panel"></PatentFamily><PatentFamily id="1641118" number="EP-00173494" title="Chimeric receptors by DNA splicing and expression"></PatentFamily><PatentFamily id="1706421" number="WO-2011015919" title="Highly efficient process of purification and production of recombinant infliximab"></PatentFamily><PatentFamily id="172112" number="WO-00018409" title="Use of certain drugs for treating nerve root injury"></PatentFamily><PatentFamily id="1751115" number="WO-2010038840" title="Method for predicting pharmacological efficacy of anti-TNFα antibody preparation on rheumatoid arthritis, and pharmacological efficacy prediction apparatus"></PatentFamily><PatentFamily id="179617" number="WO-2005067477" title="Anti-human lymphotoxin alpha antibodies, compositions, methods and uses"></PatentFamily><PatentFamily id="1841448" number="WO-03105989" title="Use of a clathrate modifier to promote passage of proteins during nanofiltration"></PatentFamily><PatentFamily id="184199" number="WO-2008147938" title="WNT5A as an inflammatory disease marker"></PatentFamily><PatentFamily id="1842565" number="WO-2006009764" title="Controlled release formulations of enzymes, microorganisms, and antibodies with mucoadhesive polymers"></PatentFamily><PatentFamily id="1860743" number="WO-2011095636" title="Method for detecting anti-drug antibodies"></PatentFamily><PatentFamily id="1957508" number="WO-2006122187" title="Treating and evaluating inflammatory disorders"></PatentFamily><PatentFamily id="19823" number="WO-09805357" title="Anti-TNF antibodies and methotrexate in the treatment of autoimmune disease."></PatentFamily><PatentFamily id="1982721" number="WO-2008048986" title="Gene array technique for predicting response in inflammatory bowel diseases"></PatentFamily><PatentFamily id="1995547" number="EP-00125023" title="Recombinant immunoglobulin preparations"></PatentFamily><PatentFamily id="201468" number="WO-2007117685" title="Conjugates of an anti-TNF-alpha antibody"></PatentFamily><PatentFamily id="2027815" number="WO-00158469" title="Methods for treating glaucoma"></PatentFamily><PatentFamily id="2028783" number="WO-2004014387" title="Combination therapy with p38 MAP kinase inhibitors and their pharmaceutical compositions"></PatentFamily><PatentFamily id="2031207" number="US-07517963" title="Tumour necrosis factor binding ligands"></PatentFamily><PatentFamily id="2061721" number="WO-2009011782" title="Methods and compositions for pulmonary administration of a tnfa inhibitor"></PatentFamily><PatentFamily id="2108356" number="WO-2008137828" title="Matrix marker model and methods for assessing and treating arthritis and related disorders"></PatentFamily><PatentFamily id="2132626" number="WO-2010060999" title="Predicting clinical response to treatment with a soluble TNF-antagonist, or TNF, or a TNF receptor agonist"></PatentFamily><PatentFamily id="2153004" number="WO-2009070442" title="Enhanced Fc receptor-mediated tumor necrosis factor superfamily mRNA expression in peripheral blood leukocytes in patients with rheumatoid arthritis"></PatentFamily><PatentFamily id="2175979" number="US-06881407" title="Method for treating hepatitis"></PatentFamily><PatentFamily id="2200001" number="WO-2005070052" title="Use of photodynamic therapy to enhance treatment with immuno-modulating agents"></PatentFamily><PatentFamily id="2219036" number="WO-2011112669" title="Non-aqueous high concentration reduced viscosity suspension formulations"></PatentFamily><PatentFamily id="2220960" number="WO-2009073575" title="Methods for treating induced cellular proliferative disorders"></PatentFamily><PatentFamily id="2228651" number="WO-2012085228" title="Method to optimize the treatment of patients with biological drugs"></PatentFamily><PatentFamily id="2229273" number="WO-2010081173" title="Modified antibody compositions, methods of making and using thereof"></PatentFamily><PatentFamily id="2252405" number="WO-2006004958" title="Detection or measurement of antibodies to antigenic proteins in biological tissues or samples"></PatentFamily><PatentFamily id="2271670" number="WO-2008124937" title="Alleles and polymorphisms predictive of responsiveness to biologic therapy in psoriasis"></PatentFamily><PatentFamily id="2272153" number="WO-00137874" title="Therapy of psoriasis"></PatentFamily><PatentFamily id="2305282" number="WO-2010103350" title="A method for predicting the responsiveness to an anti-TNFα antibody treatment"></PatentFamily><PatentFamily id="2324733" number="WO-2011147763" title="Biomarkers"></PatentFamily><PatentFamily id="2326307" number="WO-2005115456" title="Methods of modulating the reproductive endocrine system by modulation of TNFαactivity"></PatentFamily><PatentFamily id="2329082" number="WO-2007089303" title="Methods and compositions for diagnosing ankylosing spondylitis using biomarkers"></PatentFamily><PatentFamily id="233501" number="RU-02454730" title="Method of treating diverticulosis in experiment"></PatentFamily><PatentFamily id="2345377" number="WO-2007056540" title="TNF-alpha blocker treatment for enterocolitis associated with immunostimulatory therapeutic antibody therapy"></PatentFamily><PatentFamily id="2360524" number="WO-2004105798" title="A pharmaceutical composition comprising a p2x7"></PatentFamily><PatentFamily id="2371471" number="EA-00016240" title="Method for forecasting effectiveness of treating psoriasis patients by infliximab"></PatentFamily><PatentFamily id="2374501" number="WO-2010062960" title="Methods of determining responsiveness to anti-TNFα therapy in inflammatory bowel disease"></PatentFamily><PatentFamily id="2376813" number="WO-2012101183" title="Genes and genes combinations based on gene MKNK1 predictive of early response or non response of subjects suffering from inflammatory disease to cytokine targeting drugs (CyTD) or anti-inflammatory biological drugs"></PatentFamily><PatentFamily id="2399536" number="WO-2012154987" title="Methods of disease activity profiling for personalized therapy management"></PatentFamily><PatentFamily id="2399829" number="WO-2012154253" title="Assays for detecting autoantibodies to anti-TNFα drugs"></PatentFamily><PatentFamily id="2447273" number="WO-2013006810" title="Assays for detecting neutralizing autoantibodies to biologic therapy with TNF alpha"></PatentFamily><PatentFamily id="2466593" number="WO-2014096873" title="Biomarkers in inflammatory bowel disease"></PatentFamily><PatentFamily id="2469910" number="US-20130040835" title="Genes predictive of anti-TNF response in inflammatory diseases"></PatentFamily><PatentFamily id="2474173" number="WO-2004037205" title="Low dose methods for treating disorders in which TNFα activity is detrimental."></PatentFamily><PatentFamily id="2475081" number="WO-2007120626" title="Uses and compositions for treatment of ankylosing spondylitis"></PatentFamily><PatentFamily id="2475136" number="WO-2008005315" title="Automatic injection device"></PatentFamily><PatentFamily id="2478596" number="WO-00149321" title="TNF inhibitors for the treatment of neurological, retinal and muscular disorders"></PatentFamily><PatentFamily id="2519336" number="WO-2013063510" title="Protein formulations containing amino acids"></PatentFamily><PatentFamily id="2541782" number="WO-2013080050" title="Methods and compositions for determining responsiveness to treatment with a TNF-alpha inhibitor"></PatentFamily><PatentFamily id="2549420" number="WO-2013087911" title="Compounds and methods for treating inflammatory diseases"></PatentFamily><PatentFamily id="2563389" number="WO-2013105013" title="Mutant antibodies and conjugation thereof"></PatentFamily><PatentFamily id="2580195" number="US-20130216530" title="Methods for optimizing biological response modifier therapy using therapeutic drug monitoring of immunosuppressants"></PatentFamily><PatentFamily id="2622568" number="WO-2013162456" title="Method for detecting concentration of antibody or fusion protein"></PatentFamily><PatentFamily id="2627066" number="US-20130295685" title="Mobility shift assays for detecting anti-tnf alpha drugs and autoantibodies"></PatentFamily><PatentFamily id="2636545" number="WO-2013173410" title="Affinity peptides toward infliximab"></PatentFamily><PatentFamily id="2650850" number="WO-2013181694" title="Compositions and methods for treating crohn's disease and related conditions and infections"></PatentFamily><PatentFamily id="2655523" number="WO-2013186632" title="Conjugates of biologically active molecules to functionalized polymers"></PatentFamily><PatentFamily id="2655924" number="WO-2013186230" title="Pharmaceutical formulation for a therapeutic antibody"></PatentFamily><PatentFamily id="2679503" number="WO-2014023816" title="Method for lowering the viscosity of high-concentration protein solutions"></PatentFamily><PatentFamily id="2683038" number="WO-2014026905" title="Complex-specific antibodies and antibody fragments and its use"></PatentFamily><PatentFamily id="2687868" number="WO-2014029890" title="Method for predicting responsiveness to TNF antibody therapy"></PatentFamily><PatentFamily id="2688066" number="WO-2014031676" title="Process for manufacturing drug delivery formulations"></PatentFamily><PatentFamily id="2696457" number="WO-2014037680" title="High concentration aqueous protein solution having reduced viscosity"></PatentFamily><PatentFamily id="2706258" number="WO-2014045081" title="Stable pharmaceutical composition, comprising an aqueous solution of an antibody-derived therapeutically active protein"></PatentFamily><PatentFamily id="2713715" number="EP-02716768" title="Cell-based assay for assessing TNF-α inhibitors"></PatentFamily><PatentFamily id="2717440" number="WO-2014058389" title="Optimised heavy chain and light chain signal peptides for the production of recombinant antibody therapeutics"></PatentFamily><PatentFamily id="2719353" number="WO-2014060785" title="Diagnostic method for predicting response to TNFα inhibitor"></PatentFamily><PatentFamily id="2752463" number="WO-2014083520" title="Assays for detecting neutralizing autoantibodies to biologic therapy"></PatentFamily><PatentFamily id="2756147" number="WO-2014093297" title="Cathelicidin as novel inflammatory bowel disease marker and therapy for colitis-associated intestinal fibrosis"></PatentFamily><PatentFamily id="2780791" number="WO-2014117250" title="Biomarkers for inflammatory bowel disease with ankylosing spondylitis"></PatentFamily><PatentFamily id="2791128" number="WO-2014134570" title="Compositions and methods for autoimmune disease"></PatentFamily><PatentFamily id="279393" number="WO-00248715" title="Inflammatory markers as tools in the detection and prevention of diabetes mellitus and as tools to aid in the selection of agents to be used for the prevention and treatment of diabetes"></PatentFamily><PatentFamily id="2802205" number="WO-2014149935" title="Manufacturing methods to control C-terminal lysine, galactose and sialic acid content in recombinant proteins"></PatentFamily><PatentFamily id="2804971" number="WO-2014151200" title="Compositions useful for the treatment of gastrointestinal disorders"></PatentFamily><PatentFamily id="2817723" number="WO-2014171032" title="Pharmaceutical formulation and method for manufacturing same"></PatentFamily><PatentFamily id="2823088" number="WO-2014175164" title="Fd chain gene or L chain gene each capable of increasing secretion amount of Fab-type antibody"></PatentFamily><PatentFamily id="2825039" number="WO-2014177746" title="Prognosis of response to treatment with anti-TNF-alpha in patients with rheumatoid arthritis"></PatentFamily><PatentFamily id="2905586" number="WO-2015038777" title="Liquid protein formulations containing water soluble organic dyes"></PatentFamily><PatentFamily id="2960998" number="WO-2015091438" title="Analysis of antibodies"></PatentFamily><PatentFamily id="2977258" number="WO-2015110989" title="Biomarker panel for assessment of mucosal healing"></PatentFamily><PatentFamily id="3045576" number="WO-2015154052" title="Isotyping immunoglobulins using accurate molecular mass"></PatentFamily><PatentFamily id="3058405" number="WO-2015162251" title="Tumor necrosis factor alpha antagonists for treating viral infections"></PatentFamily><PatentFamily id="3063126" number="WO-2015166461" title="Methods of selecting treatment regimen using TNFα and anti-TNFα drug levels"></PatentFamily><PatentFamily id="3067619" number="WO-2015173259" title="New method for treating melanoma"></PatentFamily><PatentFamily id="3071205" number="WO-2015177368" title="Circulating miRNAs as biomarkers of therapy effectiveness in rheumatoid arthritis patients treated with anti-TNFα"></PatentFamily><PatentFamily id="3091707" number="WO-2015191423" title="Biomarkers and methods for assessing response to inflammatory disease therapy"></PatentFamily><PatentFamily id="3092044" number="WO-2015191783" title="Biomarkers for inflammatory disease and methods of using same"></PatentFamily><PatentFamily id="3106793" number="WO-2016005748" title="Treatment of lysosomal disorders (anti-TNF therapy)"></PatentFamily><PatentFamily id="3115948" number="WO-2016010002" title="Method for identifying epitope of protein"></PatentFamily><PatentFamily id="3123325" number="WO-2016016871" title="Methods of predicting response to treatment with anti-TNFα biological inhibitors"></PatentFamily><PatentFamily id="3123336" number="WO-2016015779" title="Method to predict the lack of response to anti-TNF α therapies"></PatentFamily><PatentFamily id="3123558" number="WO-2016018978" title="Quantifying monoclonal antibody therapeutics by LC-MS/MS"></PatentFamily><PatentFamily id="3129870" number="WO-2016020790" title="Lateral flow immunoassays for the detection of antibodies against biological drugs"></PatentFamily><PatentFamily id="3131696" number="WO-2016024254" title="Therapy selection for psoriasis and psoriatic arthritis"></PatentFamily><PatentFamily id="3134985" number="WO-2017093750" title="Methods for predicting response to anti-TNF therapy"></PatentFamily><PatentFamily id="3150956" number="WO-2016042436" title="Method and kit for the predictive prognosis of responsiveness to treatments of autoimmune diseases"></PatentFamily><PatentFamily id="3161605" number="US-20160097777" title="Immunological method"></PatentFamily><PatentFamily id="3171003" number="US-20160106846" title="Polymers for delivery of therapeutic proteins"></PatentFamily><PatentFamily id="3173563" number="WO-2016063204" title="Methods for prediction of anti-TNF alpha drug levels and autoantibody formation"></PatentFamily><PatentFamily id="3174040" number="WO-2016063223" title="Methods for predicting clinical outcomes in subjects afflicted with ulcerative colitis"></PatentFamily><PatentFamily id="3186844" number="WO-2016073488" title="Targeted delivery platform for delivery of therapeutics"></PatentFamily><PatentFamily id="3201821" number="WO-2016089946" title="Methods and compositions for controlling antibody aggregation"></PatentFamily><PatentFamily id="3203650" number="WO-2016092045" title="Methods and kits for predicting medically refractory acute severe colitis"></PatentFamily><PatentFamily id="3204279" number="WO-2016094309" title="Inhibition of TNF signaling in cancer immunotherapy"></PatentFamily><PatentFamily id="3227309" number="WO-2016109631" title="Molecular isotopic engineering"></PatentFamily><PatentFamily id="3236452" number="WO-2016110595" title="A universal assay for determining the quantity of tnfα inhibitory drugs and their corresponding anti-drug-antibodies"></PatentFamily><PatentFamily id="3262277" number="WO-2016120625" title="Biomarker"></PatentFamily><PatentFamily id="3316468" number="WO-2014134657" title="A cell expression system"></PatentFamily><PatentFamily id="3353497" number="WO-2016140921" title="Method of treating a localized fibrotic disorder using an IL-33 antagonist"></PatentFamily><PatentFamily id="3373968" number="WO-2015184002" title="Anti-HER2 glycoantibodies and uses thereof"></PatentFamily><PatentFamily id="3408477" number="WO-2016164665" title="Systems and methods for patient-specific dosing"></PatentFamily><PatentFamily id="34137" number="WO-2007056539" title="Prophylaxis and treatment of enterocolitis associated with anti-CTLA-4 antibody therapy"></PatentFamily><PatentFamily id="3427498" number="WO-2016170513" title="Risk locus for psoriatic arthritis"></PatentFamily><PatentFamily id="3433338" number="WO-2016172769" title="Compositions and methods for administering antibodies"></PatentFamily><PatentFamily id="3440545" number="WO-2016179469" title="Methods and compositions for diagnosing and treating inflammatory bowel disease"></PatentFamily><PatentFamily id="3482286" number="WO-2016205570" title="Vectors for use in an inducible coexpression system"></PatentFamily><PatentFamily id="3522481" number="WO-2017012568" title="PH-sensitive linkers for delivering a therapeutic agent"></PatentFamily><PatentFamily id="3523307" number="CN-106290885" title="A serum infliximab ELISA detection kit and detection method"></PatentFamily><PatentFamily id="357694" number="WO-2007124414" title="CXCL13 antagonists and their use for the treatment of inflammatory diseases"></PatentFamily><PatentFamily id="3587214" number="WO-2017053686" title="Drug delivery system and methods of use"></PatentFamily><PatentFamily id="3594877" number="WO-2017058999" title="Biomarkers and methods for assessing response to inflammatory disease therapy withdrawal"></PatentFamily><PatentFamily id="3594976" number="WO-2017059276" title="Therapeutic and diagnostic methods for autoimmune diseases and/or inflammation"></PatentFamily><PatentFamily id="3614544" number="US-09636412" title="Conjugates of an anti-tnf-alpha antibody"></PatentFamily><PatentFamily id="3617877" number="US-20170121774" title="Methods and compositions for assessing predicting responsiveness to a TNF inhibitor"></PatentFamily><PatentFamily id="3625481" number="WO-2017077080" title="A method for quantifying anti-TNF antibodies"></PatentFamily><PatentFamily id="3625482" number="WO-2017077081" title="A method for quantifying therapeutic antibodies"></PatentFamily><PatentFamily id="3726214" number="WO-2017123672" title="Combination treatment for inflammatory diseases"></PatentFamily><PatentFamily id="3738606" number="WO-2017187656" title="Assay method for anti-drug antibodies"></PatentFamily><PatentFamily id="3745223" number="WO-2017132557" title="Prediction of therapeutic response in inflammatory conditions"></PatentFamily><PatentFamily id="3745252" number="WO-2017132625" title="System and method for injection component preparation"></PatentFamily><PatentFamily id="3749911" number="WO-2017136511" title="Assessment of intestinal barrier function to improve treatment of inflammatory bowel disease"></PatentFamily><PatentFamily id="3779694" number="WO-2017149065" title="Improved fermentation process"></PatentFamily><PatentFamily id="380917" number="TW-201210613" title="Use of il-20 antagonists for preventing rheumatoid arthritis and osteoporosis"></PatentFamily><PatentFamily id="3809497" number="US-09903866" title="Portable devices for detection of antibodies against therapeutic drugs"></PatentFamily><PatentFamily id="3814628" number="WO-2017175228" title="Infiltrating immune cell proportions predict anti-TNF response in colon biopsies"></PatentFamily><PatentFamily id="3821404" number="WO-2017181038" title="Serum biomarkers for predicting and evaluating response to TNF inhibitor therapy in rheumatoid arthritis patients"></PatentFamily><PatentFamily id="3829210" number="WO-2017189679" title="Cell culture medium"></PatentFamily><PatentFamily id="3835149" number="WO-2017189751" title="Target-binding activated split reporter systems for analyte detection and related components and methods"></PatentFamily><PatentFamily id="387120" number="EP-00131740" title="Undenatured Virus-Free Biologically Active Protein Derivatives"></PatentFamily><PatentFamily id="3887224" number="WO-2017216206" title="Methods for predicting acute severe colitis treatment response"></PatentFamily><PatentFamily id="3887926" number="EP-03257866" title="Modified anti-TNF antibody and use thereof in the treatment of IBD"></PatentFamily><PatentFamily id="3906153" number="WO-2019097251" title="Novel compositions"></PatentFamily><PatentFamily id="3938787" number="WO-2018019881" title="Bioadhesive platform to perform bioactive treatment"></PatentFamily><PatentFamily id="3938843" number="WO-2018020060" title="Method for predicting the clinical response to a treatment with anti-inflammatory agents"></PatentFamily><PatentFamily id="4003603" number="WO-2016031250" title="Method for treating psoriasis patient which received anti-TNF-α antibody therapy"></PatentFamily><PatentFamily id="4040899" number="US-20180117157" title="Stable pharmaceutical composition, comprising an aqueous solution of an antibody-derived therapeutically active protein"></PatentFamily><PatentFamily id="4081361" number="WO-2018102591" title="Biomarker test and method for assessing mucosal healing in response to treatment of ulcerative colitis"></PatentFamily><PatentFamily id="4137785" number="WO-2018140121" title="Anti-TNF antibodies, compositions, and methods for the treatment of active psoriatic arthritis"></PatentFamily><PatentFamily id="4200789" number="WO-2018170099" title="Control of total afucosylated glycoforms of antibodies produced in cell culture"></PatentFamily><PatentFamily id="4206064" number="WO-2018183173" title="Anti il-36r antibodies combination therapy"></PatentFamily><PatentFamily id="4221172" number="WO-2018184540" title="Infliximab composition containing histidine buffer system"></PatentFamily><PatentFamily id="4221173" number="WO-2018184541" title="Lyophilized preparation of infliximab monoclonal antibody"></PatentFamily><PatentFamily id="4221327" number="WO-2018185244" title="C4BP-based compounds for treating immunological diseases"></PatentFamily><PatentFamily id="4221919" number="WO-2018187792" title="Treatment of inflammatory bowel diseases with 2'-fucosyllactose compounds"></PatentFamily><PatentFamily id="4292397" number="WO-2018219559" title="Topical treatment of inflammatory bowel disease using antibodies and fragments thereof"></PatentFamily><PatentFamily id="4292660" number="WO-2018220588" title="Methods for assessing mucosal healing in crohn's disease patients"></PatentFamily><PatentFamily id="4292903" number="WO-2018222022" title="Single nucleotide polymorphic marker composition for predicting response to anti-TNF preparation, and method using same to predict response to anti-TNF preparation"></PatentFamily><PatentFamily id="4313306" number="WO-2018231151" title="Methods and kits for evaluating clinical outcomes of autoimmune disease"></PatentFamily><PatentFamily id="4313583" number="WO-2018232265" title="Universal self-regulating mammalian cell line platform for the production of biologics"></PatentFamily><PatentFamily id="4352648" number="WO-2019012531" title="Assays for assessing neutralizing antibodies levels in subjects treated with a biological drug and uses thereof in personalized medicine"></PatentFamily><PatentFamily id="4362534" number="WO-2019015767" title="Drug mixing device"></PatentFamily><PatentFamily id="4362535" number="WO-2019015768" title="Drug mixing device"></PatentFamily><PatentFamily id="4362536" number="WO-2019015769" title="Drug mixing device"></PatentFamily><PatentFamily id="4362537" number="WO-2019015770" title="Drug mixing device"></PatentFamily><PatentFamily id="4362538" number="WO-2019015771" title="Drug mixing device"></PatentFamily><PatentFamily id="4362539" number="WO-2019015772" title="Drug mixing device"></PatentFamily><PatentFamily id="4362540" number="WO-2019015773" title="Drug mixing device"></PatentFamily><PatentFamily id="4362541" number="WO-2019015774" title="Drug mixing device"></PatentFamily><PatentFamily id="4362542" number="WO-2019015775" title="Drug mixing device"></PatentFamily><PatentFamily id="4363081" number="WO-2019018394" title="Treating rheumatoid arthritis"></PatentFamily><PatentFamily id="4363149" number="WO-2019018571" title="Methods and uses of inflammatory bowel disease biomarkers"></PatentFamily><PatentFamily id="4388254" number="WO-2019025624" title="Biomarkers for assessing the response status for treatment of inflammatory condition or disease affecting the digestive tract such as inflammatory bowel disease in human patients"></PatentFamily><PatentFamily id="4388256" number="WO-2019025630" title="Microfluidic systems with capillary pumps"></PatentFamily><PatentFamily id="4434411" number="WO-2019055357" title="Process for lyophilized pharmaceutical formulation of a therapeutic protein"></PatentFamily><PatentFamily id="4443430" number="WO-2019060330" title="Methods for predicting response to treatment"></PatentFamily><PatentFamily id="4495773" number="WO-2019087200" title="Prognostic methods for anti-TNFα treatment"></PatentFamily><PatentFamily id="4537897" number="WO-2019108756" title="Interaction of fibroblasts and immune cells for activation and uses thereof"></PatentFamily><PatentFamily id="4561900" number="WO-2019122253" title="Liquid delivery composition"></PatentFamily><PatentFamily id="4561903" number="WO-2019122258" title="Solid delivery composition"></PatentFamily><PatentFamily id="504468" number="WO-2008054532" title="Compositions and methods for treating anthrax lethality"></PatentFamily><PatentFamily id="591705" number="WO-2009006301" title="Protein stabilization"></PatentFamily><PatentFamily id="59365" number="WO-2011057035" title="Agent and methods for reducing inflammatory markers"></PatentFamily><PatentFamily id="596297" number="WO-2009097095" title="Methods for treating hematopoietic malignancies"></PatentFamily><PatentFamily id="623255" number="WO-2005020924" title="A rapid way to obtain high expression clones of mammalian cells using a methylcellulose and immunoprecipitation screening method"></PatentFamily><PatentFamily id="63281" number="WO-2009003905" title="Prognostic method for the determination of the suitability of biopharmaceutical treatment"></PatentFamily><PatentFamily id="648034" number="WO-09102078" title="Tumor necrosis factor binding ligands"></PatentFamily><PatentFamily id="656161" number="WO-2005038056" title="Combination therapy for the treatment of viral diseases"></PatentFamily><PatentFamily id="664155" number="WO-2008028031" title="Markers and methods for assessing and treating ulcerative colitis and related disorders using a 43 gene panel"></PatentFamily><PatentFamily id="670371" number="WO-2010141483" title="Potentiation of autoimmune and inflammatory disease treatments by immune regulatory oligonucleotide (IRO) antagonists of TLR7 and TLR9"></PatentFamily><PatentFamily id="673572" number="WO-2012061620" title="Methods for treating, diagnosing, and monitoring rheumatoid arthritis"></PatentFamily><PatentFamily id="714288" number="JP-2009225713" title="The effectiveness determination method of an infliximab"></PatentFamily><PatentFamily id="718736" number="WO-02066603" title="Chemically Defined Medium For Cultured Mammalian Cells"></PatentFamily><PatentFamily id="728457" number="KR-2004032377" title="Therapeutic composition for herniation of intervertebral disk"></PatentFamily><PatentFamily id="733577" number="WO-2004098578" title="Composition comprising a PDE4 inhibitor and a TNFα antagonist"></PatentFamily><PatentFamily id="748526" number="WO-2012054997" title="Method for labelling with radionuclides murine or human, monoclonal or polyclonal anti-tumour necrosis factor antibodies associated with diseases with physiopathogenesis involving tumor necrosis factor; reagent for &lt;i&gt;in vivo&lt;/i&gt; and/or &lt;i&gt;in vitro&lt;/i&gt; diagnosis on the basis of murine or human, monoclonal or polyclonal anti-tumor necrosis factor antibodies linked to radionuclides; methods for diagnosing &lt;i&gt;in vitro&lt;/i&gt; and/or &lt;i&gt;in vivo&lt;/i&gt; diseases with physiopathogenesis involving the tumour necrosis factor, using the thus obtained reagent, and kit containing said reagent for diagnosing diseases with physiopathogenesis involving the tumour necrosis factor"></PatentFamily><PatentFamily id="77554" number="WO-2009033282" title="Mitogen-activated protein kinase kinase kinase 14 (MAP3K14) polymorphisms as indicators of subject outcome in critically ill subjects"></PatentFamily><PatentFamily id="787597" number="WO-2009128931" title="In vitro estimation of in vivo half-life binding proteins"></PatentFamily><PatentFamily id="789733" number="WO-2005004881" title="Use of ribofuranose derivatives against inflammatory bowel diseases"></PatentFamily><PatentFamily id="815037" number="WO-2010044952" title="Biomarkers for anti-TNF treatment in ulcerative colitis and related disorders"></PatentFamily><PatentFamily id="815668" number="JP-2011004743" title="Method to discriminate|determine the effectiveness of the infliximab drug efficacy in a rheumatoid-arthritis patient"></PatentFamily><PatentFamily id="829568" number="WO-09216553" title="Monoclonal and chimeric antibodies specific for human tumor necrosis factor."></PatentFamily><PatentFamily id="842602" number="JP-07080914" title="Antigen Against Human Tumor Necrosis Factor"></PatentFamily><PatentFamily id="844746" number="WO-2005000227" title="Methods of treating TNF-mediated disorders"></PatentFamily><PatentFamily id="849750" number="WO-2008154543" title="Methods for treating juvenile idiopathic arthritis"></PatentFamily><PatentFamily id="863028" number="WO-2010082497" title="Method for measuring systemic concentration of protein-containing medicament"></PatentFamily><PatentFamily id="868633" number="WO-00050079" title="Tumor necrosis factor antagonists for the treatment of neurological disorders"></PatentFamily><PatentFamily id="887596" number="WO-2008036658" title="Method and system for controlled infusion of therapeutic substances"></PatentFamily><PatentFamily id="892571" number="WO-2010034864" title="In vitro method and kit for prognosis or prediction of response by patients with rheumatoid arthritis to treatment with TNF-α factor blocking agents"></PatentFamily><PatentFamily id="895071" number="US-20120088678" title="Method for prediction of response to rheumatoid arthritis therapeutics"></PatentFamily><PatentFamily id="918342" number="WO-2004035078" title="Treatment of inflammatory bowel disease"></PatentFamily><PatentFamily id="919249" number="EP-01550454" title="Extracorporeal photopheresis in combination with anti-tnf treatment"></PatentFamily><PatentFamily id="949451" number="US-20030228642" title="Crohn's disease treatment and efficacy prediction methods"></PatentFamily><PatentFamily id="960370" number="WO-2011117366" title="Genes and genes combinations predictive of early response or non response of subjects suffering from inflammatory disease to cytokine targeting drugs (CyTD)"></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="1">Analyte</Type><Count>9</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="10">Process</Type><Count>14</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>4</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="2">Drug Target</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>44</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="4">Delivery device</Type><Count>12</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>38</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="8">General interest</Type><Count>100</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>42</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Avesthagen Ltd" id="1002448"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Hospital Vall D'Hebron" id="1003065"></CompanyLink><CountAsOwner>7</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>7</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Universidad De Cordoba" id="1003165"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Universitat de Barcelona" id="1003992"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="MV Lomonosov Moscow State University" id="1004069"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Biogen Inc" id="1005244"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Atonomics Aps" id="1005833"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Institut Claudius Regaud" id="1006181"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="DNA Chip Research" id="1006354"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Agency For Science Technology &amp; Research" id="1006569"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Chi-Mei Medical Center Of Taiwan" id="1007394"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Deutsches Rheuma-Forschungs Zentrum Berlin" id="1007591"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="National Cheng Kung University" id="1010719"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Exagen Diagnostics Inc" id="1010913"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Northern Illinois University" id="1011021"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Progenika Biopharma SA" id="1011936"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="ATUM" id="1012382"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Ulvac Inc" id="1013304"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Ulsan" id="1017944"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Symyx Technologies Inc" id="1017945"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="The University of Arkansas System" id="1018113"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="TACT IP LLC" id="1018689"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Zhejiang Hisun Pharmaceutical Co Ltd" id="1019688"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Universidad De Cantabria" id="1020210"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sirius Genomics Inc" id="1020511"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="TcLand SA" id="1021074"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Advanced Medical Technologies Ag" id="1022172"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Nodality Inc" id="1022251"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Mitsubishi Chemical Holdings Corp" id="1022450"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Asahi Kasei Corp" id="1022453"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Universitatsklinikum Erlangen" id="1025042"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Technion - Israel Institute of Technology" id="1030571"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Adocia SAS" id="1031509"></CompanyLink><CountAsOwner>4</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Singapore Health Services Pte Ltd" id="1032650"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Spinalcyte Llc" id="1034084"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="The Methodist Hospital Research Institute" id="1036527"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Hungarian Academy Of Sciences TKI" id="1037104"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Rowan University" id="1037651"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Kirin Holdings Co Ltd" id="1037687"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Maas Medical Llc" id="1038383"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Germans Trias i Pujol Hospital" id="1039086"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Hospital Clinic of Barcelona" id="1039423"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Centre Hospitalier Universitaire de Toulouse" id="1041394"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Eagle Pharmaceuticals Inc" id="1041920"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="CHU de Bordeaux" id="1042190"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Copenhagen Hospital Corp" id="1042412"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Newlab" id="1042979"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Biomonitor A/S" id="1044763"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="CytomX Therapeutics Inc" id="1045603"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Asan Foundation" id="1049605"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Seattle Children's Hospital" id="1049938"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sutter Health" id="1050283"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Pfenex Inc" id="1051271"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Servicio Andaluz De Salud" id="1058089"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="OSE Immunotherapeutics" id="1059851"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="O-Ray Pharma Inc" id="1061149"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Kaytee Bio Co &amp; Ltd" id="1062688"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Generalitat de Cataluna" id="1062777"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Gold Nanotech Inc" id="1062909"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Spherium Biomed" id="1065377"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Promise Advanced Proteomics" id="1069083"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Federal State Institution &quot;State Scientific Centre for Dermatovenerology&quot; Federal Agency for Provision of High Technology" id="1069989"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Mathilda and Terrence Kennedy Institute of Rheumatology Trust" id="1070928"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="AbbVie Inc" id="1072507"></CompanyLink><CountAsOwner>13</CountAsOwner><CountAsThirdParty>2</CountAsThirdParty><CountTotal>13</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Norut AS" id="1078670"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Instituto de Investigación Hospital Universitario La Paz" id="1079538"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Tanvex Biopharma USA Inc" id="1082261"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Mallinckrodt plc" id="1085756"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="QuiaPEG Pharmaceuticals Ab" id="1091242"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Ud-Genomed Medical Genomic Technologies Kft" id="1091885"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Absci Llc" id="1093072"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="House Ear Clinic Inc" id="1093667"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Jesse Brown VA Medical Center" id="1093961"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Aquilon Cyl Sanidad Animal" id="1094678"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="In.Medica" id="1094990"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Servicio Cántabro De Salud" id="1096345"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sunyette Pty Ltd" id="1100238"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Fundación Para La Investigación Biomédica De Córdoba" id="1104007"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Credence Medsystems Inc" id="1104471"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Celltrion Healthcare Co Ltd" id="1105372"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>7</CountAsThirdParty><CountTotal>7</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Figene Llc" id="1106798"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Excelse Bio" id="1109149"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Fundacion Instituto de Investigacion Marques de Valdecilla, IDIVAL" id="1113123"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Nippon Kotai Kenkyusho KK" id="1119971"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Rambam Med-Tech Ltd" id="1124061"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Myosotis" id="1125487"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Blueprint Bio Inc" id="1125924"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Nature's Fingerprint Authentication" id="1126541"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Neuclone Biologics Pty Ltd" id="1128970"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Inflammatix Inc" id="1129965"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Projections Research Inc" id="1137772"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Worcester State University" id="1139378"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Intract Pharma Ltd" id="1144222"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Captain James A. Lovell Federal Health Care Center" id="1151145"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Maximus Diagnostic Technologies LLC" id="1152092"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Arkansas Children's Hospital" id="1155293"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="CIBER (Consorcio Centro de Investigación Biomédica en Red, MP)" id="1159711"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Kepler Diagnostics Inc" id="1165787"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="CannBioRx Life Sciences Corp" id="1186560"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Abbott Laboratories" id="13601"></CompanyLink><CountAsOwner>4</CountAsOwner><CountAsThirdParty>3</CountAsThirdParty><CountTotal>7</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Biotest AG" id="13737"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Amano Enzyme Inc" id="14097"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Amgen Inc" id="14109"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>2</CountAsThirdParty><CountTotal>5</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="AstraZeneca plc" id="14190"></CompanyLink><CountAsOwner>4</CountAsOwner><CountAsThirdParty>3</CountAsThirdParty><CountTotal>5</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="BASF SE" id="14356"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Battelle" id="14405"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Baxter International Inc" id="14437"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Bayer AG" id="14455"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Boehringer Ingelheim International GmbH" id="14881"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Tsukuba" id="14929"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Bristol-Myers Squibb Co" id="15065"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Cedars-Sinai Medical Center" id="15328"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Cold Spring Harbor Laboratory" id="15518"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="CSL Ltd" id="15563"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Eisai Co Ltd" id="15872"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Universite Paul-Sabatier - Toulouse III" id="15917"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Grifols SA" id="16581"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Idera Pharmaceuticals Inc" id="17006"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Bausch Health Companies Inc" id="17058"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Nektar Therapeutics" id="17221"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="INSERM" id="17229"></CompanyLink><CountAsOwner>5</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>6</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Johnson &amp; Johnson" id="17332"></CompanyLink><CountAsOwner>37</CountAsOwner><CountAsThirdParty>2</CountAsThirdParty><CountTotal>39</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Kaneka Corp" id="17639"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sanford-Burnham Medical Research Institute" id="17746"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Eli Lilly &amp; Co" id="17810"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Merck &amp; Co Inc" id="18077"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>2</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Massachusetts Institute of Technology" id="18225"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Mylan NV" id="18439"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Myriad Genetics Inc" id="18440"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Nestle SA" id="18477"></CompanyLink><CountAsOwner>12</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>12</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Octapharma AG" id="18638"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Pfizer Inc" id="18767"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>8</CountAsThirdParty><CountTotal>9</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Phadia AB" id="18967"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="PDL BioPharma Inc" id="19162"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Roche Holding AG" id="19446"></CompanyLink><CountAsOwner>6</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>7</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Servier" id="19863"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Takeda Pharmaceutical Co Ltd" id="20300"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Teva Pharmaceutical Industries Ltd" id="20348"></CompanyLink><CountAsOwner>5</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>5</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="UCB SA" id="20452"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>2</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="US Government" id="20516"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Alberta" id="20525"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Arizona" id="20527"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of British Columbia" id="20532"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of California" id="20547"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>3</CountAsThirdParty><CountTotal>6</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Cambridge" id="20550"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="City of Hope" id="20558"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Columbia University" id="20559"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Harvard University" id="20584"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Illinois" id="20592"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>2</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of London" id="20607"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>2</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Mount Sinai School of Medicine" id="20631"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="New York University" id="20646"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Queensland" id="20665"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Rochester" id="20669"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Southern California" id="20673"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Stanford University" id="20679"></CompanyLink><CountAsOwner>4</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Utah" id="20690"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Virginia" id="20695"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Washington" id="20701"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Altus Pharmaceuticals Inc" id="20740"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Wakunaga Pharmaceutical Co Ltd" id="20786"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="XOMA Corp" id="20954"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Zeria Pharmaceutical Co Ltd" id="21023"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="New York Blood Center" id="21035"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Scripps Research Institute" id="21102"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Karolinska Institutet" id="21110"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Mayo Clinic Foundation" id="21111"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="New York Society for the Ruptured and Crippled Maintaining and Hospital for Special Surgery" id="21128"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Individual" id="21144"></CompanyLink><CountAsOwner>38</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>38</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Amsterdam" id="21182"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Rutgers University" id="21239"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="The University of Liverpool" id="21242"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Japan Immunoresearch Laboratories Co Ltd" id="21363"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="MorphoSys AG" id="21404"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Oxford" id="22182"></CompanyLink><CountAsOwner>4</CountAsOwner><CountAsThirdParty>2</CountAsThirdParty><CountTotal>5</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Lonza Group AG" id="22690"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Oregon Health Sciences University" id="22708"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Katholieke Universiteit Leuven" id="23009"></CompanyLink><CountAsOwner>4</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Novartis AG" id="23137"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>2</CountAsThirdParty><CountTotal>5</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Texas A&amp;M University System" id="23290"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Imperial College London" id="23577"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Vrije Universiteit van Amsterdam" id="23905"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Assistance Publique Hopitaux de Paris" id="23948"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Universita degli Studi di Roma La Sapienza" id="24408"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Harvard Medical School" id="24839"></CompanyLink><CountAsOwner>4</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>5</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Athens" id="25031"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="National Taiwan University" id="25104"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Cincinnati Children's Hospital Medical Center" id="25631"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Zurich" id="25713"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Synergy Pharmaceuticals Inc" id="25766"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Universite Denis Diderot" id="25808"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Synthon BV" id="26145"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Guy's &amp; St Thomas' Hospital NHS Trust" id="26229"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="A+ Science Invest AB" id="26278"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Bonn" id="26805"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Interleukin Genetics Inc" id="26936"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sanquin Blood Supply Foundation" id="27531"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sun Pharmaceutical Industries Ltd" id="27561"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Samsung Electronics Co Ltd" id="28039"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>3</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Onxeo SA" id="28048"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="GlaxoSmithKline plc" id="28355"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Academia Sinica" id="28429"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="The University Health Network" id="28443"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Institute for Neurological Research" id="28538"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>2</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Natco Pharma Ltd" id="28692"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Universidade Federal do Rio de Janeiro" id="28727"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="National Tsing Hua University" id="29247"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="DynPort Vaccine Company LLC" id="29621"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Momenta Pharmaceuticals Inc" id="29796"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Glycominds Ltd" id="29798"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Universite de Bordeaux" id="29872"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Androclus Therapeutics" id="30549"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Universite Paris XIII" id="30632"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Cosmo Pharmaceuticals SpA" id="30714"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of South Australia" id="30796"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="VU University Medical Center" id="30810"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Hitachi Ltd" id="30875"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Gyros Protein Technologies AB" id="31742"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="General Electric Co" id="CM27927"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Universite de Nantes" id="CM28241"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Tromso" id="DOL1000157"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Centre for Digestive Diseases" id="DOL1000282"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="European Security Partnership" id="DOL1000355"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Debrecen" id="DOL1000728"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>Y</hasSWOTs></ns2:com.thomsonreuters.ls.service.contract.opportunitymonitor.v1.DrugRecordOutput>